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The dissertation is about the design, synthesis and biological applications of polypeptoids 
and boron dipyrromethenes (BODIPYs). The dissertation is divided into seven chapters reporting 
various aspects of the background to my field of study and the results obtained during my PhD 
program.  
Chapter 1 is a concise overview of the fundamental concepts of polypeptoids and hydrogels, as 
well as their recent developments on synthetic strategies, property investigations, and biological 
applications in different fields.  
Chapter 2 presents the design, synthesis and potential application as tissue engineering scaffold of 
thermoreversible ABC polypeptoid hydrogels. A series of ABC copolypeptoids were synthesized 
and their gelation behavior were investigated in water and biological media. The potential use of 
the hydrogel as tissue engineering scaffold to induce chondrogenesis of human stem cells was also 
investigated.  
Chapter 3 describes the synthesis and characterization of a series of highly water soluble 
PEGylated polypeptoids bearing oligomeric ethylene glycol side chains. Their potential use as 
antifouling material was investigated.  
Chapter 4 reports the solution self-assembly of coil-crystalline diblock copolypeptoids (PNMG-b-
PNDG). The relationship between polymer compositions and micelle morphologies was 
investigated.  
Chapter 5 is a brief introduction of BNCT and a concise overview of BODIPYs on their synthetic 
methodologies, functionalization strategies, and potential applications.  
Chapter 6 describes the design, synthesis and in vitro biological studies of a series of carborane-
containing BODIPYs. Their ability to cross the BBB was investigated.  
xxiii 
Chapter 7 reports the design and synthesis of a series of push-pull BODIPYs. Their spectroscopic 
and electrochemical properties were investigated by UV-Vis and fluorescence spectroscopy, cyclic 
voltammetry and DFT calculation.  
 
1 
 : INTRODUCTION TO POLYPEPTOIDS AND HYDROGELS 
1.1 Introduction to polypeptoids 
Polypeptoids, composed of N-substituted polyglycine backbones, are structural mimics of 
polypeptides (Figure 1.1). The polypeptoids are highly structural tunable by tailoring the side chain 
groups, enabling manipulation over their hydrophilicity and lipophilicity balance (HLB), 
conformation1-12, charge characteristics,13-14 thermal and crystallization properties.15 In contrast to 
polypeptides, polypeptoids with the nitrogen being substituted, lack hydrogen bonding interactions 
and chiral centers along the backbones. Thus, the conformation (e.g., random coils, helix1-4, 11-12 
and -sheets5-10) of polypeptoids is strongly dependent on the backbone rigidity, steric, chirality, 
and electrostatic characteristics of the side chains, in contrast to the polypeptides whose secondary 
structure is stabilized by hydrogen bonding. The polypeptoids are thermally processable similar to 
conventional thermoplastics due to the absence of hydrogen bonding on their backbones, whereas 
polypeptides undergo thermal degradation before they can be melt-processed due to the extensive 
hydrogen bonding interactions.15 In addition, studies of polypeptoids showed their enhanced 
proteolytic stability relative to polypeptides16-17, good cytocompatibility18-19 and degradability 
under oxidative conditions that mimics tissue inflammation20. These combined attributes render 
polypeptoids an attractive material for biomedical and biotechnological applications. Recent 
development in the organo-mediated controlled polymerization has enabled access to a variety of 
well-defined polypeptoid homo and block copolymers. The synthetic methods, structural-property 
relationship of polypeptoids as well as their potential applications in different fields such as in 




Figure 1.1. Structure of polypeptoids and polypeptides. 
1.2 Synthesis of R-NCAs and polypeptoids  
1.2.1 Synthesis of N-substituted N-carboxyanhydride (R-NCA) monomers 
A library of N-substituted N-carboxyanhydride (R-NCA) monomers bearing various side 
chain structures (e.g., R= methyl, ethyl, allyl etc., Figure 1.2) have been synthesized using two 
general routes from the N-substituted glycine precursors which are obtained from the reaction 
between primary amine and glyoxylic acid or between ethyl bromoacetate and primary amine 
(Scheme 1.1). 15, 29-32 The precursor (1) is treated with di-tert-butyl dicarbonate or chloroformate 
to obtain the corresponding alkoxycarbonyl protected N-substituted glycine (2) followed by 
cyclization to afford the R-NCAs using activating electrophiles (e.g., PCl3, PBr3, SOCl2 and 
AcCl/Ac2O).   
 
Figure 1.2. Representative chemical structures of N-substituted NCA (R-NCA) monomers. 
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Scheme 1.1. Synthetic procedures of R-NCAs. 
 
1.2.2 Ring-opening polymerizations of R-NCAs using primary amine initiators 
Primary amines are good nucleophiles for the controlled ring-opening polymerization 
(ROP) of R-NCAs to produce polypeptoids bearing amide end group and secondary amino living 
chain ends by releasing CO2 during polymerizations (Scheme 1.2).
15 The nucleophilic ROP 
mechanism has been extensively studied for the primary amine-initiated ROPs of amino acid-
derived NCAs.33 The primary amine-initiated ROPs have been widely investigated on a variety of 
R-NCAs. The N-methyl-N-carboxyanhyride (Me-NCA) was shown to polymerize in a controlled 
manner without chain transfer or termination events after more than 10 iterative polymerization 
steps (a.k.a., living polymerization) using benzyl amine as the initiator.34 The produced 
polysarcosine (PNMG) analyzed by SEC chromatography, NMR and MALDI-TOF spectroscopy 
exhibited narrow Poisson distribution (PDI<1.1-1.3) and controllable molecular weight by simply 
changing the initial monomer to initiator feed ratios. The living chain end of PNMG was further 
supported by the chain extension experiment with different monomers (e.g., Et-NCA, Pr-NCA, 
Bu-NCA and Pe-NCA). The living polymerization character of other monomers (e.g., Et-NCA, 
Pr-NCA, Bu-NCA) was also reported.29-30 The polymerization behavior of R-NCAs is highly 
related to their side chain structures. It was shown that iPr-NCA could not (or very slowly) be 
polymerized in benzylnitrile at room temperature under reduced pressure probably due to the steric 
hindrance of the relatively bulky propagating species that decrease the statistical probability of the 
nucleophilic attack at the C5 position of the monomer.30 Polymerization of monomer in neat above 
4 
its melting temperature was attempt, however, the low MW polymer (16 mer) exhibited broad 
distribution (PDI=1.53). As to N-allyl NCA (Al-NCA)35 and N-2-phenylethyl NCA (2PE-NCA)12, 
the chain lengths of the resulting polypeptoids were limited (DPn<100) probably due to the 
formation of the corresponding 2,5-diketopiperazine from the intramolecular transamidation that 
was kinetically competitive relative to the chain propagation.  
Scheme 1.2. Mechanism of the primary amine-initiated ROP of R-NCA. 
 
1.2.3 Ring-opening polymerizations of R-NCA using alcohol initiators and 1,1,3,3-
tetramethylguanidine 
 
Recently, it was reported that N-butyl N-carboxyanhydride (Bu-NCA) can be polymerized 
in low dielectric THF using benzyl alcohol initiator and catalytic amount of 1,1,3,3,-
tetramethylguanidine (TMG) promoter to produce poly (N-butyl glycine) (PNBG) with controlled 
molecular weight and narrow molecular weight distribution (PDI=1.04-1.08) by adjusting the 
initial monomer to initiator ratios.36 The alcohol alone, however, does not initiate the 
polymerization of Bu-NCA under the same condition. The proposed mechanism was that the TMG 
formed a hydrogen bonding complex with the alcohol, which enhanced the nucleophilicity of the 
alcohols to facilitate the nucleophilic attack of the alcohol to the monomer (Scheme 1.3). The 
polymerization activities and Mn control are strongly dependent on the steric and electronic 
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properties of the alcohols. Primary alcohols (e.g., methanol, ethanol, 2-methoxyethanol, propanol 
and benzyl alcohol) with the presence of TMG promoter can polymerize the Bu-NCA with good 
to moderate control over Mn and PDI. The resulting PNBG polymers were mainly end-capped with 
the alcohol initiators, as evidenced by MALDI-TOF spectroscopic analysis. In contrast, the use of 
more sterically hindered secondary alcohol (e.g., isopropyl alcohol) with the presence of TMG 
produced PNBG polymers whose Mn were much higher than the theoretically predicated values. 
Interestingly, no polymerization was observed at different monomer to initiator ratios when using 
the even more sterically hindered tert-butyl alcohol. The polymerization using more electron 
deficient alcohols with lower pKa s (e.g., 2,2,2-trifluoroethanol and phenol) were also investigated. 
It turned out that using 2,2,2-trifluoroethanol in conjugation with TMG lead to PNBG polymers 
of much higher Mns relative to the theoretical values, whereas using phenol with TMG yielded no 
polymerization regardless of the initial monomer to alcohol ratios. The significant deviation of 
Mns from the theoretical values suggested that the initiation was much slower relative to the 
propagation due to significantly reduced nucleophilicity of the alcohol moiety in the hydrogen 
bonding complexes. The control of polymerization over Mns was also strongly dependent on the 
solvent used. In contrast to the polymerization in THF and toluene, polymerization in more polar 
solvent (e.g., CH2Cl2 and DMF) was much less controllable showing comparable Mns regardless 
of the initial monomer to alcohol ratios.  
1.2.4 Synthesis of cyclic polypeptoids 
Cyclic polypeptoids [i.e., poly(N-butyl glycine)] were synthesized using N-heterocyclic 
carbenes (NHCs)-mediated zwitterionic ring-opening polymerization (ZROP) of Bu-NCA.31, 37 The 
polymer MW and ring size can be easily tuned by controlling the initial monomer to NHC ratios in 
low dielectric solvents such as THF and toluene. The polymerization was mediated by a zwitterionic 
propagating intermediate with two proximate oppositely charged chain ends through electrostatic inte- 
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Scheme 1.3. Mechanism of ROH-initiated ROP with TMG promoter. 
 
raction (Figure 1.3). The polymerization in high dielectric solvents (e.g., DMF, DMSO) only produced 
low MW mixtures of linear and cyclic polymers regardless of the initial monomer to initiator ratios, 
due to the competitive intramolecular transamidation relative to chain propagation. The polymerization 
in toluene showed a pseudo-first order kinetics and the polymerization rate was dependent on the steric 
characteristic of the NHC used. A variety of cyclic polypeptoids with varied side chains were 
synthesized by NHC-mediated ZROP of R-NCAs Me-NCA, Et-NCA, Pg-NCA, Bu-NCA, De-NCA, 
2EH-NCA and 2PE-NCA.11-12 PEG-grafted cyclic random copolypeptoids (PNBG-r-PNPgG) was also 
reported, which appear as toroid structures in AFM, supporting the cyclic architecture of the 
polypepotid backbone.38 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU), a bicyclic amidine, was also 
shown to mediated ZROP s of Bu-NCA in a controlled manner similar to NHCs (Figure 1.3).39 The 
DBU exhibited enhanced moisture/air stability and availability compared to NHC.  
1.3 Physicochemical properties of polypeptoids 
1.3.1 Thermal properties of polypeptoids 
The side chain structures of polypeptoids greatly affect their thermal properties. 
Polypeptoids bearing 2 carbon aliphatic side chains were shown to be amorphous, whereas 
polypeptoids bearing longer linear aliphatic side chains (C3-C14) are highly crystalline.40 The cyc- 
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Figure 1.3. NHC- and DBU-mediated ZROPs of Bu-NCA to afford cyclic PNBGs. 
lic and linear polypeptoids bearing linear aliphatic side chains (C4-C14) all exhibited two melting 
points (Tm1 and Tm2) attributed to the side chain and main chain crystallization.41  The 
crystallizations of main chain and side chain were strongly coupled: increasing side chain length 
increased the side chain melting temperature while decreasing the main chain melting temperature 
(Figure 1.4). The side chain and main chain crystallization of polypeptoid with branched aliphatic 
side chain (2-ethylhexyl) was shown to be greatly suppressed. The cyclic polypeptoids exhibited 
higher main chain melting points compared to the linear analog while the polymer architecture 
does not appreciably affect the side chain melting points. The polymer crystallization was also 
affected by the thermal history of the polymer.  
1.3.2 Thermoresponsive properties of polypeptoids 
The hydrophilicity and lipophilicity balance (HLB) of polypeptoids can be readily tailored 
by controlling the structure of side chains. Amphiphilic polymer solutions, including polypeptoids, 
often undergo dehydration and subsequent hydrophobic collapse at elevated temperature, the so- 
called reversible temperature-induced cloud point transition.42 It was found that poly (N-alkyl 
glycine) with C3 carbon side chains (C3 = n-propyl, allyl, propargyl, and isopropyl) exhibited 
thermoresponsive behavior in water and their cloud temperatures (Tcps) were dependent on the str- 
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Figure 1.4. DSC thermograms of cyclic (left) and linear poly (N-n-alkyl glycine)s (right) during 
the second heating cycle (n in the plot designates the number of carbons on the n-alkyl side chains). 
Reproduced from Ref.40 with permission from American Chemical Society. 
 
uctural and electronic properties of the side chain, the backbone length, as well as the solution 
concentration, whereas poly (N-propargyl glycine) was not soluble in water.30 The Tcps were found 
to increase in the order C3 = n-propyl (15-25 oC) < allyl (27-54 oC) < isopropyl (47-58 oC). The 
Tcps were also shown to be concentration-dependent: decrease with increasing solution 
concentration. Long-term annealing of the aqueous solution of poly (N-(n-propyl) glycine) and 
poly (N-allyl glycine) at above their cloud point temperatures lead to the formation of crystalline 
microparticles and rose bud type morphology driven by the crystallization of the polymer 
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coacervates. The crystallization mechanism and detailed information of the crystalline structure 
has not been reported yet.  
Another way to tune the cloud point transition temperature is to incorporate both 
hydrophobic and hydrophilic segments through copolymerization strategy. NHC-mediated or 
primary amine-initiated copolymerization of Et-NCA and Bu-NCA produced linear or cyclic 
random copolymers, PNBG-r-PNEG, which were thermally responsive in water (Figure 1.5).43 
The cloud point temperature (Tcp) in aqueous solution can be readily tailed in the range 20-60
oC 
by controlling the solution concentration, polymer composition, salt added, and polymer 
architecture (cyclic vs linear). The Tcp was systematically shifted to higher temperature with the 
increase of NEG content in the copolymer, indicating the critical role of hydrophobic effect in the 
thermoresponsive behavior. The molecular weight of the copolymer with constant composition 
was shown to have negligible effect on the Tcp. Interestingly, the cyclic copolyepeptoids exhibited 
4-6 oC lower Tcps than the linear analogs with identical composition, which is tentatively attributed 
to the less entropic loss of the cyclic copolymers during the solution phase transition associated 
with its more compact conformation. The decreased Tcps with increasing concentration of the 
copolymer solutions indicated that intermolecular aggregation rather than intramolecular coil-to-
globule transition was mainly responsible for the reversible phase transition. The Tcp depression 
caused by the addition of various salts is in agreement with the trend of Hofmeister series with 
Na2SO4 decreasing the Td most, followed by NaCl and NaI.  
Bottlebrush copolypeptoids prepared by grafting-through method via the ROMP of 
norbornenyl-terminated PNEG-r-PNBG macromonomers underwent thermoresponsive phase 
transition in aqueous solution similar to the linear macromonomers (Figure 1.6).44 In contrast to 
the linear macromonomers, the bottlebrush copolypeptoids underwent cloud point transition that  
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Figure 1.5. Plots of cloud point temperature (Tcp) versus the molar fraction of NEG segment in the 
cyclic and linear P(NEG-r-NBG) random copolymers bearing different end groups and their 
respective linearly fit curves [cyclic NHC-P(NEG-r-NBG) (●, —), linear Bu-P(NEG-r-NBG) (▲
,—) and linear Bn-P(NEG-r-NBG) (■ , —). Reproduced from Ref.43 with permission from 
American Chemical Society. 
is strongly dependent on the thermal history of the aqueous solutions. Freshly prepared aqueous 
solutions of the bottlebrush copolypeptoids exhibited no notable phase transition, whereas the 
solutions underwent sharp and reversible cloud point transition after thermally annealing at high 
temperature. Interestingly, the aqueous solutions of the bottlebrush copolypeptoids showed normal 
cloud point transition similar to the linear macromonomer which was independent of the thermal 
history upon addition of inorganic salt. It was suggested that the conformational reorganization of 
the bottlebrush copolypeptoids was facilitated upon thermal annealing and addition of salt to favor 
the hydrophobic collapse and intermolecular aggregation, resulting in a thermoresponsive phase 
transition.  
1.3.3 Solution self-assembly of amphiphilic polypeptoid copolymers  
Self-assembly of PNMG-b-poly (N-alkyl glycine). Self-assembly of block copolymers 
have been a long-standing interests both in the fundamental investigation and application 
perspective. Self-assembly based on many amphiphilic and double hydrophilic hetero-block and 
graft copolymers, including PNMG-b-polypeptides, PNMG-b-poly (L-lactide) (AB, A2B, A3B ar- 
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Figure 1.6. Polypeptoid bottlebrush copolymers comprised of linear P(NEG-r-NBG) side chains 
exhibited cloud point transitions that are dependent on the thermal history. Reproduced from 
Ref.44 with permission from Royal Society of Chemistry. 
 
chitectural types), PEG-b-PNMG and PNMG-b-Cn=12-18, in solution have been studied.
15, 26 The 
recent report on aggregation behavior of block copolypeptoids, composed of hydrophilic PNMG 
(DP ~ 50) and poly (N-alkyl glycine) with C2-C5 aliphatic side chains, studied the effect of 
hydrophobicity and chain length of the solvophobic poly (N-alkyl glycine) on their critical micelle 
concentration (CMC) and the size of aggregates formed in aqueous solution.45 Micellation was 
observed for the copolypeptoids containing C3-C5 aliphatic side chains with CMC value ranging 
from 0.6 × 10-6 to 0.1 × 10-3 M. The tendency to form micelles increased with increasing 
hydrophobicity of the side chains in the solvophobic block (C5>C4>C3). It was also found that 
increasing the chain length of hydrophobic block resulted in the formation of larger aggregates. 
The aggregate size and distribution were also strongly dependent on the temperature and solvent 
with smaller aggregate size in buffer (pH=7.4) than in water.  
Redox-responsive polypeptoid micelles. Recently, a redox-sensitive micelle based on 
poly (N-ethyl glycine)-b-poly [(N-propargyl glycine)-r-(N-decyl glycine)] (EPgD) synthesized by 
sequential ROPs of the corresponding monomers using benzyl amine as the initiator, was reported 
(Figure 1.7).19 The copolypeptoids underwent micellation in aqueous solution with CMC in the 
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0.075-0.12 mg/mL range at room temperature. Similarly to previously reported studies, the CMC 
value was gradually decreased with the increase of the hydrophobic segments. The selected 
copolypeptoid (E204Pg13D15) formed well-defined spherical micelles in aqueous solution which 
was further crosslinked in the micellar core with two different crosslinkers using copper-mediated 
alkyne-azido cyclo-addition CuAAC chemistry. The core-crosslinked micelles (CCLMs) bearing 
a disulfide linkage were cleavable in the presence of reducing agents (e.g., dithiothreitol, DTT), 
whereas the other micelles permanently crosslinked with 1,4-diazidobutane were not.  The CCLMs 
showed a mono-modal size distribution and a decreased hydrodynamic diameter (d = 42.4 ± 0.8 
nm) in comparison to the non-crosslinked micelles (NCLMs) (d = 60.1 ± 0.9 nm), as evidenced by 
dynamic light scattering (DLS) analysis. As expected, the NCLMs disassembled in DMF, a non-
selective solvent for all the blocks, with an increase of the hydrodynamic size, broadening of size 
distribution (PDI = 0.41) and the appearance of unimers in the DLS analysis. In contrast, the 
CCLMs maintained the micellar structure with narrow size distribution (d = 59.2 ± 1.6 nm, PDI = 
0.19) in DMF due to the covalent crosslinking in the micellar core. Spherical micelles with some 
short cylinders were observed from TEM analysis of dried CCLMs and NCLMs staining with 
uranyl acetate with average diameter of the CCLMs (21.1 ± 2.3 nm) comparable to that of the 
NCLMs (22.8 ± 2.9 nm), suggesting no appreciable change of the micellar morphology after 
covalent core-crosslinking. Fluorescent dye (1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) or 
hydrophobic anticancer drug doxorubicin (DOX) was further encapsulated into CCLMs and their 
releasing behavior were monitored. For the CCLMs with DOX encapsulated, a maximal 23% drug 
loading capacity and a 37% drug loading efficiency was achieved and the DOX was released in a 
time-dependent manner associated with the disassembly of the CCLMs upon in contact with DTT. 
In contrast, minimal releasing of DOX was observed even after 30 h without the presence of DTT, 
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suggesting that the time-dependent DOX release was based on the cleavage of the disulfide 
crosslinkers in the micellar core and the subsequent micelle disassembly. The redox-responsive 
property make the CCLMs to be a potential smart drug delivery vehicle.  
 
Figure 1.7. Synthesis of redox-responsive and core-cleavable micelles based on amphiphilic block 
copolypeptoids PNEG-b-P(NPgG-r-NDG) and their potential use for DOX encapsulation. Reproduced 
from Ref. 19 with permission from American Chemical Society.  
 
Temperature-responsive polypeptoid micelles. Amphiphilic coil-crystalline cyclic diblock 
copolyeptoids (c-PNMG-b-PNDG) and their linear analogue (l-PNMG-b-PNDG) were synthesized by 
NHC-mediated and BnNH2-initiated ROP of the corresponding monomers, respectively, and their self-
assembly in methanol at low concentration (1mg/mL) was investigated.46 Both the cyclic and linear 
PNMG-b-PNDG were shown to self-assemble into cylindrical micelles with PNDG as the core and 
PNMG as the shell in uniform diameter in methanol at room temperature over the course of several 
days after annealing at 70oC (above the first melting temperature of PNDG) (Figure 1.8). The kinetic 
study of micellation for both cyclic and linear block copolypeptoids in methanol monitored by cryo-
TEM at different time intervals revealed the initial formation of amorphous spherical micelles followed 
by subsequent reorganization into micrometer-long crystalline cylindrical micelles, suggesting that the 
crystallization of the PNDG hydrophobic core was the driven force for the cylindrical micelle 
formation. In addition, the spherical-to-cylindrical morphological transition occurred more rapidly for 
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the linear copolypeptoid than for the cyclic analogue, which was probably due to the retarded 
crystallization of PNDG core for the cyclic analogue associated with the conformational constraint.   
 
Figure 1.8. Synthesis of c-PNMG105-b-PNDG10 block copolypeptoid and its Cryo-TEM images in 
dilute methanol solutions after 1 h (spherical micelles) and 15 d (cylindrical micelles). Reproduced 
from Ref. 46 with permission from American Chemical Society.  
 
At higher concentrations in methanol (5-10 wt%), both cyclic and linear diblock copolyeptoids 
(PNMG-b-PNDG) were shown to form free-standing gels consisting of entangled fibrils at room 
temperature. The gelation is thermoreversible that reverse back to isotropic solution upon heating to 
70oC, which results in the morphological change of crystalline cylindrical micelles to amporphous 
spherical micelles or non-associated polymers induced by the melting of the PNDG crystalline 
domains, as evidenced by both temperature-dependent 1H NMR and DLS analysis. The cyclic polymer 
gels exhibited higher sol-to-gel transition temperatures and higher gel stiffness compared to the linear 
analogs, suggesting enhanced crystallinity in the fibrilar network in the formers relative to the latters.  
1.4 Biologically relevant properties 
1.4.1 Cytotoxicity of polypeptoids 
It is important to investigate the cytotoxicity of polypeptoids before being further used in 
biomedical and biotechnological fields. The cytotoxicity assessment of polysarcosine and its 
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copolymers as well as other water soluble polypeptoids in different cell lines have been reported. 
Random copolypeptoid of cyclic P(NEG74-r-NBG15) exhibited minimal cytotoxicity (cell viability > 
90 %) towards human embryonic lung fibroblasts (HEL229) up to 5.0 mg/mL concentration after 
incubation in PBS buffer at 37oC for 24 h, as evidenced by CellTiter-Blue® assay.43  
The cytotoxicity of the random copolymer of PNMG-r-PNEG with different compositions 
synthesized from primary amine initiated copolymerization of the corresponding NTA monomers (Me-
NTA and Bu-NTA) was also evaluated in human heptoblastoma cells (HepG2) using the MTT cell 
viability asssay.47 It was found that the relative cell viability was dependent on the polymer 
composition and concentration. All the polymers investigated showed increased cytotoxicity towards 
HepG2 cells with increasing polymer concentration from 0.05 to 3.0 mg/mL. P(Sar48-r-NBG26) with 
relative lower PNBG content displayed higher cell viability (>75%) at the whole concentration range 
investigated (0.05-3 mg/mL) comparable to that of PNMG, whereas P(Sar47-r-NBG30) and P(Sar42-r-
NBG36) with relative higher PNBG content exhibited a significant increase of cytotoxicity at 3.0 
mg/mL concentration, presumably due to the partial precipitation of these polymers at this 
concentration associated with their onset cloud point being close to the incubation temperature. 
The homopolymer PNMG (Mn =2.1 kDa, PDI=1.31), diblock and triblock copolypeptoids 
(PNMG-b-PNprG, PNMG-b-PNpenG, PNMG-b-PNprG-b-PNMG) with MW in the range 3.6-9.6 kDa 
all exhibited minimal cytotoxicity (cell viability > 90 %) toward HepG2 cells up to 10 mg/mL polymer 
concentration, as evidenced by WST-1 assay.45  
The above mentioned core-crosslinked micelles (CCLMs) composed of hydrophobic 
[P(NPgG-r-NDG)] core and hydrophilic (PNEG) corona with redox-responsive disulfide crosslinkers 
or non-redox responsive permanent crosslinkers all exhibited minimal cytotoxicity (cell viability > 95 
%) towards HepG2 cells up to 1.0 mg/mL concentration upon incubation in MEMS medium for 48 h, 
as evidenced by MTT assay. Both the redox-reponsive and non-redox responsive CCLMs loaded with 
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the anticancer drug (DOX) displayed time and dosage dependent cytotoxicity towards HepG2 cells.  
The DOX-loaded redox-responsive CCLMs showed higher cytotoxicity relative to the permanently 
crosslinked CCLMs through the whole DOX dosage and time investigated, suggesting more efficient 
release of DOX and more cell death associated with the cleavage of the disulfide crosslinkers of the 
former under reductive environment in HepG2 cells. The DOX dosage- and time-dependent 
cytotoxicity of the permanently crosslinked CCLMs, in a relatively lower level, was presumably due 
to the degradation of polymers in the cellular environment.  
1.4.2 Degradation of polypeptoids 
Hydrolytic degradation. Polypeptoids, with a tertiary amide linkage on the backbone, are 
potentially degradable through hydrolysis. polysarcosine-b-poly(L-proline) copolymer was shown to 
degrade into the corresponding amino acids under highly acidic conditions (6 N HCl, 120 °C, 24 h).48 
Since the hydrolysis of polypeptoids occurred under such a harsh condition, perhaps the hydrolytic 
degradation of polypeptoids in the cellular environment is minimal and slow.  
Enzymatic degradation. The incorporation of tertiary amide bonds is known to enhance 
protease resistance in peptidomimetic therapeutics.26 Currently there is no systematic investigation 
on the enzymatic degradation of high MW polypeptoids. Many studies on peptoid oligomers 
showed their enhanced protease resistance compared to peptide analogs. In sharp contrast to the 
peptide analogs that are readily protease degradable, the sequence-specific peptoid oligomers 
exhibited no protease degradation with the presence of proteases including carboxypeptidase A, 
papain, pepsin, trypsin, elastase, and chymotrypsin.16-17 A reasonable hypothesis was made that proline 
imminopeptidase may also cleave the N-sarcosine terminus26, according to the reported observation 
that the digestion of the copolymer comprised of  L-proline and sarcosine with proline 
imminopeptidase produced 4.4 times higher free L-proline that of theroretically predicted49. Thus, the 
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enzymatic degradation of (poly) peptoids should not be completely ruled out and more investigations 
need to be carried out.  
Oxidative degradation. It is important and necessary to study the degradation behavior under 
oxidative conditions as increased local concentration of various reactive oxygenated species (ROS) are 
generated by oxidative stress in various diseased states under cellular environment.15 A comparative 
investigation on the oxidative degradation of PNEG, PEG and poly (2-oxazoline) (Pox) was conducted 
with the presence of ROS (e.g., HOO∙, HO∙) generated from the H2O2/Cu
2+ source.20 It was found that 
all polymers investigated were degradable at 50 mM H2O2 and Cu
2+, with PEG being significantly 
more stable than the PNEG and POx. Faster degradation rate was observed at higher H2O2 
concentration. It was also shown that high MW polymer exhibited faster degradation in terms of 
percentage molecular weight reduction over time in comparison to the corresponding low MW 
polymer, suggesting chain scission as a main mode of degradation.  
1.5 Hydrogels in tissue engineering 
Hydrogels are three-dimensional (3 D) hydrophilic polymeric networks that can absorb and 
retain a considerable amount of water.50 Hydrogels have received continued interest for 
encapsulating cells and most recently hydrogels have become especially attractive to be used as 
tissue engineering scaffolds for repairing and regenerating a variety of tissues due to their highly 
water-swelled 3 D environment that are similar to soft tissues and allow diffusion of nutrients, 
metabolites and growth factors through the elastic networks.50-55  
A major goal of hydrogels in tissue engineering technology is the development of injectable 
hydrogels. In this case, the hydrogel precursors, bioactive agents and/or drugs are mixed in 
aqueous solutions and immediately form hydrogels upon injection into targeted sites of body using 
syringe administration. The injectable hydrogels allow an effective and homogeneous 
encapsulation of drugs/cells for both in in vitro and in vivo studies. Moreover, the high moldability 
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of injectable hydrogels can adapt to the defect shape of tissues. In addition, it provides a convenient 
and minimally invasive method for in vivo surgical operation, causing smaller scar size, less pain 
and faster recovery for patients.55-56 The immediate in situ gel formation is resulted from ether 
physical crosslinking in response to environmental stimuli such as pH value, temperature, ionic 
concentration, or chemical crosslinking through chemical reactions such as Michael addition, 
Schiff base, disulfide bond formation, etc. In contrast to the chemically crosslinked hydrogels 
which usually undergo significant volume changes during phase transition, the physically 
crosslinked hydrogels usually exhibit sol-gel transitions without marked volume changes. Besides, 
the crosslinking agents and/or photo irradiation used, as well as the heat released in chemically 
crosslinked hydrogels may damage the encapsulated cells and surrounding tissues. Therefore, 
injectable physical hydrogels have received considerable interests in the recent years for tissue 
engineering applications.  
Another important design criterion of injectable hydrogels is their biocompatibility and 
biodegradability.55 The hydrogels should be made of biocompatible materials that are degraded 
into biocompatible products in body. It is desirable that the degradation rate of hydrogels matches 
the rate of tissue formation to give enough space for cell activity, oxygen and nutrients migration 
as well as for the new tissue formed. Meanwhile, the hydrogels should still maintain a relatively 
stable environment with sufficient strength that match the tissue.  
The injectable hydrogels used in tissue engineering should display the following 
characteristics: 1) nontoxic to the cells encapsulated and the surrounding tissue, 2) hydrolytically 
and/or enzymatically degradable, 3) controlled degradation rate that matches with that of the tissue 
formation, 4) controlled mechanical strength to create and maintain a space for tissue development, 
5) provide biological cues (e.g., cell adhesion) to facilitate tissue regeneration.52-53 6), low viscosity 
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before gelation for easy encapsulation of cells and drugs, 7) mild while rapid gelation to avoid 
toxicity and tissue damage, A variety of hydrogels, both naturally occurring hydrogels and 
synthetic hydrogels, have been developed and investigated as potential tissue engineering 
scaffolds. No one material will satisfy all the design criteria, but a wide range of hydrogels will 
provide possible uses in different tissue engineering applications. 
1.6 Naturally occurring hydrogels 
Naturally occurring hydrogels are made from natural polymer-based materials, such as 
proteins (e.g., collagen, gelatin and fibrin), and polysaccharides (e.g., alginate, chitosan, agarose 
and hyaluronic acid), which generally have biocompatibility, cell-controlled degradability, and 
intrinsic cellular interaction. They may, however, exhibit batch-to-batch variations and have 
limited tunability to their structure and mechanical properties.53 
1.6.1 Proteins: collagen, gelatin and fibrin 
Collagens are the main protein of extracellular matrices (ECM) of mammalian tissues 
including skin, bone, cartilage, tendon, and ligament, and comprise 25 % of the total protein mass 
of most mammals.53-54 Collagen is basically composed of three polypeptide chains, which wrap 
around one another to form a three-stranded rope by hydrogen and covalent bonds.57 Collagen 
strands can self-assemble into entangled collagen fibers to form fibrillar gels at physiological 
temperature and pH.57-58  Collagen, composed of specific combinations of amino acid sequences, 
can be recognized by cells and degraded by metalloproteases secreted from the cells (e.g., 
collagenase, serine proteases).54 Gelatin, a derivative of collagen, is formed by the natural triple-
helix structure of collagen into single-stand molecules. Gelatin can form physical thermo-
reversible hydrogels by lowering the temperature of its aqueous solution for the chains to undergo 
coil-to-helix transition.59 The collagen- and gelatin-based hydrogels, however, are short of 
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physical strength and have potential immunogenic responses, as well as have variations between 
produced batches.53 To increase mechanical strength of the hydrogel, different chemical 
modification methods, including combining with other natural components60-61 and chemical 
crosslinking using carbodiimide62, nitrocinnamate63, or glutaraldehyde64 have been investigated. 
Collagen and gelatin hydrogels have been used for reconstruction of a variety of organs and tissues 
including liver, skin and small intestine.53 
Fibrin, a fibrous and non-globular protein, is an important component of the extracellular 
matrix involving in wound healing.55 Fibrin is biocompatible and promotes adhesion and migration 
of numerous cell types (e.g., fibroblasts). Fibrin is biodegradable through cell-associated 
enzymatic activity and the degradation rate can be controlled by apronitin, a proteinase inhibitor. 
Fibrin forms hydrogel by the enzymatic polymerization of fibrinogen in the presence of 
thrombin.53, 55 One disadvantage of the fibrin hydrogels is their weak mechanical strength.53 
1.6.2 Polysaccharides: alginate, chitosan and hyaluronic acid   
Alginate, obtained from brown algae, is a linear unbranched polysaccharide (Figure 1.9) 
which are biocompatible, non-toxic and relatively cheap.53 Alginate can simply form hydrogels 
with divalent cations such as Ca2+, Mg2+, Ba2+, and Sr2+.65 The alginate hydrogels, however, 
undergo an uncontrollable and unpredictable process involving loss of divalent ions to the 
surrounding medium and subsequent dissolution.53 Covalent cross-linking with adipic 
dihydrazide, methyl ester L-lysine, and PEG-diamines has been investigated to prevent the 
dissolution process and improve mechanical strength.66 In addition, many alginates have high 
molecular weight that are typically above the renal clearance threshold (40 KDa) of the kidney.67 
Moreover, alginate has limited cellular interaction and is unable to specifically interact with 
mammalian cells.68  
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Hyaluronic acid (HA) , consisted of alternate disaccharide units (Figure 1.9), is the only 
non-sulfated glycosaminoglycan which plays an important role in wound healing, cell motility, 
angiogenesis as well as in construction of ECM.55 Hyaluronic acid is degradable by hyaluronidase, 
which exists in cells and serum.69 High molecular hyaluronic acid at high concentrations in 
solution (e.g., 5 MDa at >0.1 mg/mL) can form viscoelastic entangled molecular networks, but the 
HA solutions do not have long-lasting mechanical integrity.70 Hyaluronic acid hydrogels can also 
be formed by covalent cross-linking with different compounds such as hydrazine derivatives71 and 
radical polymerization of glycidyl methacrylate72, or by physical cross-linking of the 
thermoresponsive moieties (e.g., PNIPAM)  attached73. The drawback of hyaluronic acid hydrogel 
is its low mechanical properties, which limited their application in tissue engineering.53  
Unlike alginate, agarose which is another type of marine algal polysaccharide, forms 
thermoreversible hydrogels containing bundles of associated double helices.53 The physical 
structure and mechanical strength can be simply tuned by changing the solution concentration of 
agarose.  
Chitosan (Figure 1.9), a copolymer of glusocamine and N-acetylglucosamine, is derived 
from natural chitin.56 Chitosan is biocompatible and biodegradable with enzymes such as 
chitosanase and lysozyme.53 Chitosan forms hydrogel through ionic or chemical cross-linking with 
glutaradehyde. Chitosan is positively charged at low pH’s, while generally insoluble in neutral 
solutions as well as in most organic solvents. Various modifications of chitosan have been reported 
to increase its water solubility and processability. 
1.7 Synthetic polymer-based hydrogels 
In contrast to hydrogels based on naturally occurring biopolymers (e.g., collagen, fibrin, 
alginate, chitosan and hyaluronic) which have potential immunologic responses, poor mechanical 
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Figure 1.9. Chemical structures of alginate, hyaluronic acid, and chitosan. 
strength and variation from batch to batch, synthetic polymer-based hydrogels offer the advantage 
of adjustable mechanical strength, chemical composition and function, and gel morphologies, as 
well as their lack of immune responses, making it possible to tune the material properties for 
specific biomedical and biotechnological applications. Most of the synthetic polymer-based 
hydrogels, nevertheless, are non-biocompatible and non-degradable in physiological environment, 
and extensive purification steps may be required to remove any toxic residue that are left from 
their synthesis or processing. In addition, in contrast to naturally occurring hydrogels, synthetic 
hydrogels often do not exhibit any substantial biological activities (e.g., cell adhesion) to induce 
differentiation and proliferation of cells and tissue regeneration. Therefore, the biodegradable and 
bioactive synthetic polymer-based hydrogels have received special attention in the recent years 
and various strategies have been applied to endow them bioactivity (e.g., cell adhesion and 
migration) for various biological applications such as tissue engineering. Importing biological cues 
such as components of specific tissues (e.g., chondroitin sulfate, hyaluronic acid), growth factors 
(e.g., TGF-β1), extracellular matrix protein-derived cell-adhesive peptide (e.g., RGD) to the 
synthetic hydrogels through covalent linkage is a common strategy to incorporate biological 
activities to synthetic hydrogels.74-77 This strategy, though effective, has the drawbacks of 
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enhanced synthetic complexity, potential emergence of cytotoxicity, and altered physicochemical 
properties of the hydrogels. By contrast, synthetic hydrogels that are inherently biologically active 
and can modulate cell function and differentiation de novo without additional biological cues or 
factors will not only facilitate the preparation of tissue engineering scaffold but also provide an 
improved platform to investigate the factors that give rise to the biological activities.74 For tissue 
engineering applications, it is desirable that the hydrogel scaffold not only have tunable 
mechanical stiffness and morphologies that can be made to match those of the native tissues but 
also exhibit biological activities that can modulate the cell migration, proliferation, and 
differentiation.52, 54  
1.7.1 Hydrogels based on amphiphilic block copolymers: AB, ABA and BAB hydrogles 
Hydrogels based on AB, ABA and BAB block copolymers, where A and B signify the 
hydrophobic/thermoresponsive and hydrophilic blocks, respectively, have been widely 
investigated in the past. The general gelation mechanisms for the amphiphilic block copolymers 
was the association of formed micelles in aqueous solution with hydrophobic A block as the core 
and hydrophilic B block as the shell. Among them, the polypeptide and polyester based 
copolymers were of significant interest due to their biocompatibility and biodegradability.  
Hydrogels based on polyesters. Aliphatic polyesters, including poly (glycolic acid) 
(PGA), poly (L-lactic acid) (PLLA), and copolymers (PLGA), have received long-standing interest 
in medical applications and are considered to be biocompatible and biodegradable by the FDA.53, 
78-80 Over the last decades, various amphiphilic copolymers of biocompatible PEG and polyesters, 
including diblock, triblock, multiblock architectures, have been developed as gelators. The block 
copolymers, PEO-PLLA (BA) and PEO-PLLA-PEO (BAB), formed micelles driven by the 
hydrophobic interactions of PLLA blocks in aqueous solutions and formed hydrogels at high 
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concentration levels (> 12wt%) caused by the association of micelles.81-82 The copolymer solutions 
exhibited sol-to-gel transition with decreasing temperature from higher temperature to the body 
temperature (37oC). The sol-gel transition temperature and the onset gelation concentration can be 
easily tuned by changing the block length of PLLA. For example, the sol state of PEO-PLLA-PEO 
(MW, 5000-2040-5000) at 45oC formed gel upon injection into a rat, making it very promising for 
drug delivery and/or tissue engineering. The aqueous solution of the ABA type copolymer (PLLA-
PEO-PLLA) bearing two hydrophobic blocks can form strong gels at body temperature with elastic 
moduli greater than 10,000 kPa, which is an order of magnitude higher than previously reported 
physically associated gels of similar chemistry.83 These ABA hydrogels showed tunable elastic 
moduli in the range 100-18,300 Pa at ambient and physiological temperatures by changing the 
solution concentration and block length of PLLA, render them potential for soft tissue engineering 
where native tissues have moduli in the kPa range. An equimolar mixture of enantiomeric 
copolymers, PLLA-PEG/PDLA-PEG or PLLA-PEG-PLLA/PDLA-PEG-PDLA, can form 
thermoresponsive hydrogels (G'~1000 Pa) with sol-gel transition occurred around 37oC by the 
stereo-complexation of the PLLA and PDLA segments.84-85 Their critical gelation concentrations 
were considerably lower compared to polymer solutions containing only the single enantiomer. 
The enantiometic PEG-(PLA)8 star block copolymers (10 wt%, 1.9 kPa) exhibited higher storage 
moduli than those based on PEG-(PLA)2 (13 wt%, 0.9 kPa).
86 One disadvantage of the 
stereocomplex hydrogels is the relatively long gelation time.87 To manipulate the degradation rate 
of copolymers of PEG and PLA, the ester bond linked the two blocks was changed to an amide 
bond. It was shown that PEG-(NHCO)-(PLA)8 displayed slow degradation in vitro compared to 
PEG-(OCO)-(PLA)8.
88 Comonomer (glycolic acid) was incorporated to PLA to manipulate the 
gelation concentration, gelation temperature and gel modulus etc.89  The sequence of lactic acid 
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and glycolic acid in the copolymer influenced the hydrophobic/hydrophilic balance and thus alters 
the macroscopic physical gelation in water.90 Mixing homopolymers or block copolymers to 
gelator solutions was another simple method to tune the gelation properties. The addition of PEG 
homopolymer to PLGA-PEG-PLGA aqueous solution lead to a gelation at a lower temperature, 
probably due to the immiscibility between the PEG and the hydrophobic PLGA block.91 The recent 
study showed the effect of molecular weight distribution (MWD) of middle block PEG on the 
phase transition of the PLGA-PEG-PLGA aqueous solutions: a wider MWD of PEG block 
enlarged the copolymer micelles and increased the solution viscosity, making it gel at low 
temperatures.92  
Poly (ε-caprolactone) (PCL) is another well-known biodegradable polyester and has been 
extensively investigated in biomedical and biotechnological fields.93-94 The triblock copolymer 
PCL-PEG-PCL (ABA) and PEG-PCL-PEG (BAB) (>15 wt%) underwent sol-gel-sol transition as 
the temperature increases from 10-60oC.95-96 The mechanism of clear sol-to-turbid gel transition 
seems to be micellar aggregation, whereas the turbid gel-to-turbid sol transition seems to be due 
to the higher extent of aggregation driven by an increase in the molecular motion of PCL 
accompanying the core-shell structure breakage. The gel modulus was increased as the pH 
increased from 2 to 8 due to the decreased water solubility of the copolymer and hence hardening 
of the gel modulus. Compared to PEG-PCL-PEG, PCL-PEG-PCL showed a lower sol-to-gel 
transition temperature and larger gel window (15-32 wt%), which seems to be related to the 
enhanced intermicellar bridges of PCL-PEG-PCL. The aqueous solutions of these triblock 
copolymers, however, were not stable at room temperature due to the crystallization of PCL.97 It 
was reported that PCTC-PEG-PCTC with incorporation of comonomer (trimethylene carbonate) 
in PCL blocks98 or multiblock PEG/PCL copolymer97 increased the sol stability while keep the 
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thermogelling property. The chondrocytes encapsulated in PCTC-PEG-PCTC hydrogel showed a 
higher expression of collagen type II and aggrecan and suppression of collagen type I (fibroblastic 
gene) compared to the control, as evidenced by RNA extraction and reverse transcription 
polymerase chain reaction (RT-PCR), suggesting the excellent differentiation of chondrocytes in 
the hydrogel.98 
Hydrogels based on polypeptide block copolymers. Polypeptides have emerged as 
attractive structural elements for hydrogel networks due to their potential biodegradability, a wide 
range of chemical functionality, and adoption of ordered conformations that can drive structure 
formation and also respond to stimuli.99-102 Various hydrogels based on amphiphilic polypeptide 
copolymers have been reported. Their self-assembled secondary structures (e.g., -helixes, -
sheets, random coil) in aqueous solutions played a critical role in the sol-to-gel transition.103-105  
The ionic hydrogels composed of poly-L-lysine-b-poly-L-leucine diblock and poly-L-
lysine-b-poly-L-leucine-b-poly-L-lysine triblock copolypeptides formed hydrogel at 
concentration as low as 0.25% induced by the rod-like helical secondary structure of 
enantiomerically pure poly-L-leucine blocks.103 These hydrogels showed high stability in high 
ionic strength media such as aqueous buffers and cell growth media,104 however, the copolymers 
containing positive charges displayed cytotoxicity to in vitro cells106 and were not 
thermoresponsive in aqueous solutions.  
The copolymers of PEG and polyalanine are one of the mostly investigated amphiphilic 
polypeptide copolymers in hydrogel formation and in both in vitro and in vivo biological studies. 
The -sheet conformation of L-polyalanine plays a critical role in developing a fibrous assemblies 
in aqueous solutions as well as the sol-to-gel transition of amphphilic PEG-polyananine.105, 107 It 
was shown that only the L-isomer showed a sol-to-gel transition in physiological important 
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temperature window (20-40 oC) at low concentration (6-12 wt%), while the DL-isomer remained 
a random coil structure and exhibited much higher gelation concentration (> 16 wt%) and gelation 
temperature (>70oC).105 The stereochemistry (L and D) also greatly affect the biological response 
of polypeptide copolymer hydrogels. The histology study showed that only the hydrogel of L-
isomer (PEG-L-PAF) was significantly degraded by cathepsin B and elastase both in vitro and in 
vivo and caused milder acute inflammation compared to the D-isomer hydrogel.108 The PEG-L-
PA thermogels were reported to be used as cell scaffolds for cell proliferation, cell differentiation 
and tissue formation. It was shown that PEG-L-PA hydrogel encapsulated with fibroblasts formed 
in situ improved the formation of collagen types I/III and accelerated the wound closure on 
incisions of rat skin compared to the controls.109 The PEG-L-PA hydrogels were also encapsulated 
with tonsil-derived mesenchymal stem cells (TMSCs) and adipose-tissue-derived stem cells 
(ADSCs), to facilitate the hepatogenic110 chondrogenic111 differentiation, respectively. Efforts 
were made to control the differentiation pathway of stem cells encapsulated in hydrogels. The 
recent study incorporated polystyrene microspheres with different functional groups in in situ 
formed PEG-L-PA hydrogels to manipulate the differentiation pathway of TMSCs. The TMSCs 
preferentially underwent adipogenesis in ammonium (-NH3
+)- or thiol (-SH)-functionalized 
polystyrene microsphere incorporated hydrogels; chondrogenesis in the thiol, phosphate (PO3
2-)-, 
or carboxylate (-COO-)-functionalized polystyrene microsphere incorporated hydrogels; and 
osteogenesis in phosphate-, carboxylate-functionalized or neat polystyrene microsphere 
incorporated hydrogels.112 The PA113-114, PAF115 or PAL116 was end-capped to commercially 
available PLX to enhance its gel duration for biomedical applications.  
-esterified Polyglutamates is another common category of hydrophobic polypeptides as 
hydrogel components. It was revealed that the subtle variation in the length of hydrophobic side 
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group of polyglutamates greatly affected the gelation behavior of the PEG-Poly (L-glutamate)s 
copolymers.117 The copolymers with polyglutamates bearing methyl and ethyl side chains 
displayed significantly lower critical gelation temperatures (CGTs) compared to those bearing n-
propyl and butyl side groups due to the increased β-sheet conformation of the formers. In addition, 
the block copolymers showed no detectable cytotoxicity against HeLa cells and accelerated 
degradation in buffer containing proteinase K compared to controls. To confer bioactivities to the 
hydrogels, poly poly (γ-propargyl-L-glutamate) (PPLG) was used to react with azide-modified 
bioactive molecules, such as biotin and galactose via click chemistry.118 The hydrogel of PEG-
PPLG functionalized with hydrophilic galactose was found to improve cell adhesion, probably due 
to its adhesion of fibronectin in cell ECM. In contrast, the biotin functionalized hydrogel lead to 
suppressed effect on cell adhesion compared to galactose functionalized hydrogels, which may 
due to the relatively hydrophobic character of biotin that tend to aggregate into the micelle core. 
The galactose and biotin changed the phase transition temperature of the block copolymer as a 
result of the variation of hydrophilic/hydrophobic balance. The sol-to-gel transitions of these PEG-
polyglutamate based copolymers, however, were relatively broad with the transition temperature 
window larger than 20oC. 
The above mentioned hydrogel formation of polypeptide copolymers is driven by 
dehydration of the PEG segments, as well as the transition of polypeptide segments to β-sheet rich 
conformation at elevated temperature. The β-sheet structures stabilized hydrogels formation via 
interchain hydrogen bonding, but also cause limited reversibility of the hydrogel transition.105, 107, 
114-117, 119 The poly(γ-[2-(2-methoxyethoxy)ethyl]-rac-glutamate)-block-poly(γ-[2-(2-
methoxyethoxy)ethyl]-L-glutamate-stat-L-leucine), (rac-EP2)-(EP2/L), was currently the only 
reported thermoreversible hydrogels based solely on synthetic polypeptide components.120 EP2 is 
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known to be -helical with a lower critical solution temperature (LCST) above 37oC in aqueous 
solutions.121 The EP2 in the EP2/L block of the copolymer was hydrophilic at low T and became 
hydrophobic with increased temperature which further associated to form 3D hydrogel networks 
with hydrophilic rac-EP2 segments exposed. The sol-gel transition was fully reversible over 
repeated heating and cooling cycles, presumably due to the stable -helix conformations of the 
thermoresponsive domains. In addition, the sol-gel transition temperature and gel stiffness can be 
well tuned by changing the solution temperature and copolymer compositions. These nonionic 
thermoreversible polypeptide hydrogels supported the viability of mesenchymal stem cells in vitro, 
in contrast to some reported polyelectrolyte hydrogels which were cytotoxic to cells.106  
Hydrogels based on PNIPAM. Poly(N-isopropylacrylamide) (PNIPAM), showing a 
LCST in water close to body temperature (∼32 °C), is the most commonly investigated 
thermoresponsive polymer in the design of thermogels.122-125 The PNIPAM-based copolymers are 
water-soluble at temperature below LCST and formed thermoreversible hydrogels in aqueous 
solutions due to hydrophobic interactions between PNIPAM blocks at elevated temperature. The 
sol-gel transition temperature and gel stiffness can be tuned by changing the solution 
concentrations and compositions of copolymers. The ABA-typed copolymer (PNIPAM-PMPC-
PNIPAM) with the bio-inspired polyphosphorylcholine as the middle block, PNIPAM-PDMA-
PNIPAM, PNIPAM-PVP-PNIPAM formed free-standing physical gels (∼ 1000 Pa) at 37oC in 
PBS at concentrations higher than 10 wt%.126-127 The hydrogels of PNIPAM-PMPC-PNIPAM 
were sufficiently biocompatible as a culture medium for V97 cells.126 
1.7.2 Hydrogels based on ABC block copolymers 
The AB-, ABA- or BAB-typed hydrogels often exhibit broad or slow sol-gel transitions or 
high critical concentration (cgc, where cgc ≥ 10 wt %). In the ABA- and BAB-type hydrogels, 
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the inefficient sol-gel transition characteristic has been attributed to the formation of loops, flower 
micells, and dangling ends in the formation of micellar network.127-129 Recently, ABC-type 
hydrogels, where A, B, and C refer to thermoresponsive block with lower critical solution 
temperature (LCST), hydrophilic and hydrophobic block, respectively, have received considerable 
interest due to their much sharper so-gel transition and lower cgc. With the formation of separate 
A and C domains, the intramolecular association of the end blocks to form loop configurations is 
significantly suppressed, thereby giving rise to a rapid and sharp thermoreversible sol-gel 
transition at low concentration  (≤ 5 wt%) upon a temperature increase.128 Although ABC triblok 
copolymer is an attractive structural motif for thermoreversible gelation, studies on the design, 
characterization, and investigation of potential biomedical uses of ABC hydrogelators have been 
limited. PNIPAM, showing a LCST in water close to body temperature (∼32 oC), is the most 
commonly investigated thermoresponsive polymer in the design of ABC hydrogelators.128, 130-131 
The earlier reported PNIPAM-PMPC-PPO triblock copolymer exhibit sol-gel transition around 37 
oC at high concentration (≥ 20 wt%) with low mechanical strength (G'∼25 Pa).130 Recently, a 5 wt 
% aqueous solution of PEP-PEO-PNIPAM (PON) triblock copolymers was shown to undergo 
thermoreversible sol−gel transition at 42 °C,128 which is higher than the physiological temperature. 
The ABC copolymer (PON) was displayed much sharper sol-gel transition at a much lower 
concentration, compared to the corresponding ABA copolymer (NON). A two-step gelation 
mechanism was proposed, involving the initial formation of micelles with PEP cores at room 
temperature and gelation due to PNIPAM block aggregation at elevated temperature. The 
separation of micellation and gelation in the PON hydrogels greatly suppressed the looping 
formation which happened in the NON hydrogels. The investigation of the aqueous solutions (1-5 
wt%) of PON at different temperatures using cryo-SEM, cryo-TEM, and SANS further confirmed 
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the two-compartment network structure consisting of distinct spherical PEP and PNIPAM cores 
upon heating above the critical gelation temperature.132 Another recently reported cell protective 
ABC copolymer (PNIPAM−PDMA−PPS) was shown to undergo rapid thermoreversible gelation 
in PBS buffer at 2.5 wt % with a gelation temperature well below 37 °C.131 The reported hydrogel 
was mechanically soft with storage modulus (G') lower than 1 kPa at 7.5 wt % polymer 
concentration. The reported ABC synthetic polymers were all based on nondegradable 
polymers.128, 130-131 
Taking advantage of the synthetic development of polypeptoids, the attractive properties 
of polypeptoids including the low cytotoxicity and potential biodegradability, and the effcient 
gelation of ABC triblock copolymers, thermoresponsive ABC triblock copolypeptoids [i.e., 
poly(N-allyl glycine)-b-poly(N-methyl glycine)-b-poly(N-decyl glycine) (AMD)] with well-
defined structure and varying composition have been synthesized by sequential primary amine-
initiated ring-opening polymerization of the corresponding N-substituted N-carboxyanhydride 
monomers (Al-NCA, Me-NCA, and De-NCA) were synthesized. The ABC block copolypeptoids 
undergo sol-to-gel transitions with increasing temperature in water and biological media at low 
concentrations (2.5−10 wt %). Detailed information was presented in Chapter 2. In Chapter 3, the 
synthesis of highly water soluble polypeptoids bearing oligomeric ethylene glycol side chains and 
their protein-resistant ability to protein lysozyme was presented. These PEGylated polypeptoids 
are potentially to be a new benchmark of antifouling material. In Chapter 4, the solution self-
assembly of coil-crystalline diblock copolypeptoids (PNMG-b-PNDG) was discussed.  
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 : THERMOREVERSIBLE AND INJECTABLE ABC 
POLYPEPTOID HYDROGELS: CONTROLLING THE HYDROGEL 
PROPERTIES THROUGH MOLECULAR DESIGN 
2.1 Abstract  
A series of ABC triblock copolypeptoids [i.e., poly (N-allylglycine)-b-poly (N-methyl 
glycine)-b-poly (N-decyl glycine) (AMD)] with well-defined structure and varying composition 
have been synthesized by sequential primary amine-initiated ring-opening polymerization of the 
corresponding N-substituted N-carboxyanhydride monomers (Al-NCA, Me-NCA, and De-NCA). 
The ABC block copolypeptoids undergo sol-to-gel transitions with increasing temperature in water 
and biological media at low concentrations (2.5−10 wt %). The sol−gel transition is rapid and fully 
reversible with a narrow transition window, evidenced by the rheological measurements. The 
gelation temperature (Tgel) and mechanical stiffness of the hydrogels are highly tunable: Tgel in the 
26.2−60.0 °C range, the storage modulus (G') and Young’s modulus (E) in the 0.2−780 Pa and 
0.5−2346 Pa range, respectively, at the physiological temperature (37 °C) can be readily accessed 
by controllingthe block copolypeptoid composition and the polymer solution concentration. The 
hydrogel is injectable through a 24 gauge syringe needle and maintains their shape upon in contact 
with surfaces or water baths that are kept above the sol−gel transition temperature. The hydrogels 
exhibit minimal cytotoxicity toward human adipose derived stem cells (hASCs), evidenced from 
both alamarBlue and PicoGreen assays. Furthermore, quantitative PCR analysis revealed 
significant up-regulation of the Col2a1 gene and down-regulation of ANGPT1 gene, suggesting 
that the hydrogel exhibited biological activity in inducing chondrogenesis of hASCs. It was also  
* Chapter 2 previously appeared as Xuan, S.; Lee, C.-U.; Chen, C.; Doyle, A. B.; Zhang, Y.; Guo, 
L.; John, V. T.; Hayes, D.; Zhang, D. Xuan, S.; Lee, C.-U.; Chen, C.; Doyle, A. B.; Zhang, Y.; 
Guo, L.; John, V. T.; Hayes, D.; Zhang, D. Thermoreversible and Injectable ABC Polypeptoid 
Hydrogels: Controlling the Hydrogel Properties through Molecular Design. Chem. Mater. 2016, 
28 (3), 727-737. It is reprinted by permission of ACS Publisher (see page 260). 
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demonstrated that the hydrogel can be used to quantitatively encapsulate water-soluble enzymes 
(e.g., horseradish peroxidase) by manipulating the sol−gel transition. The enzymatic activity of 
HRP remain unperturbed after encapsulation at 37 °C for up to 7 d, suggesting that the hydrogel 
does not adversely affect the enzyme structure and thereby the enzymatic activity. These results 
suggest that the polypeptoid hydrogel a promising synthetic platform for tissue engineering or 
protein storage applications. 
2.2 Experimental 
2.2.1 General considerations  
All chemicals used were purchased from Sigma-Aldrich and used as received unless 
otherwise noted. THF, CH2Cl2, and acetonitrile used in polymerization reaction were purified by 
passing through alumina columns under argon. 1H and 13C {1H} NMR were recorded on a Bruker 
AV-400 Nanobay spectrometer, and the chemical shifts in parts per million (ppm) were referenced 
to protio impurities of CDCl3 and CD2Cl2. SEC analyses were performed using an Agilent 1200 
system (Agilent 1200 series degasser, isocratic pump, auto sampler and column heater) equipped 
with three Phenomenex 5 μm, 300 × 7.8 mm columns, a Wyatt OptilabrEX differential refractive 
index (DRI) detector with a 690 nm light source, and a Wyatt DAWN EOS multiangle light 
scattering (MALS) detector (GaAs 30mW laser at λ = 690 nm). DMF with 0.1M LiBr was used as 
the eluent at a flow rate of 0.5 mL min-1. The column and detector temperature was room 
temperature. The standard used was twenty three pauci-disperse polystyrene standards (590 g·mol-
1-1472 kg·mol-1 MW, Polymer Laboratories, Inc.). All data analysis was performed using Wyatt 




2.2.2 Monomer synthesis 
All the monomers used were synthesized by adapting reported procedures.1 N-alkyl N-
carboxyanhydrides (R-NCAs) with allyl, butyl, octyl, decyl, and methoxyethyl, 
methoxyethoxyethyl side chains were synthesized via synthetic routes (I), whereas Me-NCA was 
synthesized via route II (Scheme 2.1). 









Figure 2.2. 13C {1H} NMR spectrum of allyl-NCA in CDCl3. 
 
 




Figure 2.4. 13C {1H} NMR spectrum of Methyl-NCA in CDCl3. 
 
 
Figure 2.5. 1H NMR spectrum of Decyl-NCA in CDCl3. 
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Figure 2.6. 13C {1H} NMR spectrum of Decyl-NCA in CDCl3. 
2.2.3 Polymer synthesis 
All the ABC triblock copolypeptoids were synthesized by primary amine-initiated ring-
opening polymerization of the corresponding N-substituted N-carboxyany-drides (R-NCAs) in a 
sequential manner. A representative procedure for the synthesis of A98M98D18 was presented. In 
the glovebox, Al-NCA (136.3 mg, 0.97 mmol, [M1]0=0.4 M) was dissolved in anhydrous 
acetonitrile. Stock solution of benzyl amine (104 µL, 92.7 mM, [M1]: [BnNH2]0=100:1) was 
added. The reaction mixture was heated at 50 oC for 24 h to reach a complete conversion of 
polymerization. Acetonitrile solution of Me-NCA (2.4 mL, 0.4 M, 0.97 mmol, [M1]0:[M2]0: 
[BnNH2]0=100:100:1) was added to the above mixture and allowed to stir at room temperature for 
another 24 h to reach a full conversion. Acetonitrile solution of De-NCA (475 µL, 0.4 M, 0.19 
mmol, [M1]0:[M2]0:[M3]0:[BnNH2]0=100:100:20:1) was added and stirred at room temperature for 
an additional 24 h. The polymer was precipitated out by the addition of excess THF. The polymer 
was collected by filtration and washed with ample THF and hexane followed by drying under 
vacuum (178 mg, 89%). The composition of the polymer was determined by 1H NMR 
spectroscopy using end-group analysis. The number average degree of polymerization (DPn) of 
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each block was calculated based on the integration ratios of characteristic proton peaks due to 
individual block. DPn (A) = (5 × integration of –CH=)/(1 × integration of C6H5); DPn (M) = (5 × 
integration of aCH3)/(3 × integration of C6H5); DPn (D) = (5 × integration of 
bCH3)/(3 × integration 
of C6H5) (a. methyl protons of M block, b. methyl protons of D block). 
 
 
Figure 2.7. 1H NMR spectrum of the A98M98D18 triblock copolypeptoid in CD2Cl2. 
 
 
Figure 2.8. 1H NMR spectrum of the A45M47O10 triblock copolypeptoid in CD2Cl2 
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Figure 2.11. 1H NMR spectrum of the A46d42D9 triblock copolypeptoid in CD2Cl2.  
2.2.4 Hydrogel preparation 
The 5 wt% aqueous solution of triblock copolypeptoids used for the rheological 
measurement was prepared by “thin-film hydration”, as reported by Zhou et al.2  Briefly, a known 
amount of dry polymer was dissolved in CH2Cl2, followed by evaporation of the solvent under a 
stream of N2 overnight to form a thin film on the wall of the vial. The thin film was further dried 
under vacuum for 1 d. Nanopure water was added, and the solution was stirred at room temperature 
for 3 d before further characterization. 1 wt% and 2.5 wt% aqueous solutions were prepared by 
direct dilution of the concentrated solution (5 wt%). 
2.2.5 Characterization of hydrogel and dilute solution of polymer 
Rheological measurements. Rheological study was conducted using a TA AR 2000ex 
rheometer. A parallel-plate geometry of 40 mm diameter was used. In each experiment, 
approximately 0.3 mL of the hydrogel sample was loaded between the plates with a gap of 200 
μm. The metallic plate covers were then put on the plates that were sealed with highly viscous oil. 
Dynamic storage modulus (G') and loss modulus (G'') were measured by oscillatory shear 
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experiments. Dynamic strain sweep experiments were conducted at a frequency of 10 rad/s at 25 
oC and 45 oC to determine the linear viscoelastic regime. Dynamic frequency sweep measurements 
were conducted within the linear viscoelastic regime with angular frequency from 0.1 to 100 rad/s. 
Temperature sweep measurements were conducted from 15 oC to 60 oC at a heating rate of 1 
oC/min. Below the critical gelation temperature, the solution was measured at a strain of 50 %, and 
above the gelation temperature at a strain of 0.75 %. The storage moduli (G') show some 
fluctuation after the sol-gel transition. This could be due to the structural reorganization within the 
gels.  
Dynamic light scattering measurement of dilute solution. An aqueous solution of 
polymers (0.5 wt% in nanopure water) that was filtered through a 0.22 µm filter. All the DLS 
measurements were conducted using Malvern Zetasizer Nano-zs (Zen3600). The He-Ne laser 
operating at 633 nm was utilized, and scattered light intensity was detected at an external angle of 
173 oC using non-invasive backscatter (NIBS) technology. Data from three measurements with 12 
scans for each measurement was recorded. At each temperature, the sample was equilibrated for 3 
min.  
Temperature dependent 1H NMR experiments of polymer solution. The temperature 
dependent 1H NMR experiments of polymer solution was conducted on a Bruker AV-400 Nanobay 
spectrometer. The A92M94D12 triblock copolypeptoid was dissolved in CD2Cl2 and D2O at 5 wt% 
respectively. In CD2Cl2, the 
1H NMR spectrum was obtained at 25 oC, whereas the spectra were 
collected at 25, 37 and 60 oC with increasing temperature in D2O. 
TEM/CryoTEM sample preparation and analysis. FEI Vitrobot was used for the sample 
preparation of cryo-TEM experiment. 5 µL aqueous solution of ABC copolymer (1 wt%) was 
applied to a 300 mesh lacey carbon coated TEM grid. Double side blotting to the grid for 2 seconds 
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leaves a thin film on the grid. The grid then was quickly plunged into liquid ethane chilled by 
liquid nitrogen. The vitrified sample grid was loaded in a single tilt liquid nitrogen cryo transfer 
holder, and was then inserted to FEI G2 F30 Tecnal TEM operated at 120keV, with a FEI digital 
camera and analyzed using FEI Digital Micrograph software. The grids for the regular TEM was 
prepared by adding 5 µL polymer aqueous solution (0.2 wt%) onto the 300 mesh carbon grid 
followed by blotting with a filter paper and drying at room temperature. The grids then were 
stained with uranyl acetate for 1 min. 
Cryo-SEM sample preparation and analysis. Aqueous Polymer solution of 5 wt% 
A92M94D12 (~40 µL) was pipetted on top of a metal rivet and was heated up by a hot plate for gel 
formation, indicated by the color change of the liquid drop from clear to white. The gel sample 
was then plunged into liquid nitrogen, followed by fracturing at -130 oC using a flat-edge cold 
knife. The solvent was sublimated at -95 oC for 5 min and the sample was sputtered with a 
platinum-palladium composite at 10 mA for 88 seconds before imaging. The vitrified sample was 
imaged on a Hitachi S-4800 field emission scanning electron microscope using cryo-mode 
operated at a voltage of 3 kV. 
Cloud point measurement of ABC triblock copolypeptoid solutions. Cloud point 
measurements of aqueous solutions of both poly(N-allyl glycine) homopolymer (A) and 
A98M98D18 triblock copolymers (1 wt%) were conducted using Varian Cary 50 Bio-UV-vis 
spectrophotometer equipped with a Thermo/Neslab RTE-7 refrigerated bath circulator for 
temperature control. The experimental temperature range is 15-60 oC and all UV-vis absorptions 
were referenced against distilled water. The temperature at 50 % UV-vis transmittance (λ = 450 
nm) is defined as the cloud point. 
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2.2.6. Protein encapsulation study of hydrogel  
10 µL of 0.14 mg/mL HRP in PBS buffer was added to 100 µL of aqueous polymer solution 
(5 wt%) and well mixed. The mixture was incubated at 37 oC in an oil bath for different time (1 h, 
4 h, 7 h, 24 h, and 7 d). After each time period, the mixture was cooled down to room temperature 
and diluted with PBS buffer using 1.0 ml volumetric flask, which was further used for the kinetic 
study. To a disposable cuvette, 3 ml of PBS buffer, 20 µL of 0.1 M Guaiacol in PBS buffer and 40 
µL of the above diluted solution was added. 20 µL of 0.1 M H2O2 in PBS buffer was quickly 
injected to the above mixture and well mixed. The cuvette was immediately monitored at room 
temperature every 40 seconds by a Varian Cary 50 Bio-UV-Vis spectrophotometer at a wavelength 
range of 200-600 nm. All UV-Vis absorptions were referenced against PBS buffer. For 
comparison, the enzymatic activity of two sets of controls was measured using the same method 
described above. One control involves incubation of HRP in PBS buffer at 37 oC for different 
duration (1, 4, 7, 24 h and 7 d). The other control is the as-received HRP whose enzymatic activity 
was directly measured in PBS at 25 oC. 
2.2.7. Biological studies of hydrogels and polymer solutions 
Adult stem cells isolation and culture. Liposuction aspirates from subcutaneous adipose 
tissue were obtained from three healthy adult subjects (male = 1 and females = 2) undergoing 
elective procedures. All tissues were obtained with informed consent under a clinical protocol 
reviewed and approved by the Institutional Review Board at the LSU Pennington Biomedical 
Research Center and used under an exempted protocol at LSU A&M College. Isolation of hASC 
was performed as published.3 Passage 2 of each individual was used for in vitro hASC evaluation 
on tissue culture treated plastic or on scaffold of hydrogel. In both cases, hASC were cultured in 
stromal (control - DMEM, 10 % FBS, and 1 % triple antibiotic solution) media with media 
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maintenance performed three times a week. For the live control, stem cells were cultured in plain 
media. For the dead control, stem cells were cultured in media and then introduced to 70 % ethanol. 
Extract cytotoxicity Assessment. The extract cytotoxicity study was modified based on 
FDA protocol.4 The hydrogel samples (0.1 g) were incubated on an orbital shaker with 5 mL 
stromal media at 37 C and 200 rpm/min for 7 days.  The extractives were filtered (0.22 μm pore 
size) and pipetted (100 μL/well) into a 96-well plate previously sub-cultured with hASC (2,500 
cells/well) and incubated in a CO2 incubator at 37 C containing 5 % CO2 for 24 hours. 10 μL 
alamarBlue® reagent to each well and re-incubated at 37 C in 5 % CO2 for 2 h. The fluorescence 
was measured at an excitation wavelength of 530 nm and an emission wavelength of 595 nm using 
a fluorescence plate reader. The tissue culture treated plastic 96-well plate served as a control 
substrate. 
hASC loading on ABC hydrogel and culture. The ABC hydrogel was filtered through a 
0.22 µm filter at 20 C and 100 µL aliquots was mixed with 1 × 104 cells/µL for total volume of 
10 µL. The cells and hydrogel mixture was transferred to a 96 well plate afterwards. 100 µL 
stromal medium was added to each well after the cells/hydrogel mixture was solidified at 37 C. 
In vitro hASCs viability on scaffolds with alamarBlue® stain. The viability of cells 
within ABC hydrogel in stromal media was determined after 3 days using an alamarBlue® 
metabolic activity assay. The cells/hydrogel mixture were removed from culture, washed three 
times in PBS, and incubated with 10 % alamarBlue® in Hank’s balanced salt solution (HBSS) 
without phenol red (pH 7) for 90 min. Aliquots (100 μL) of alamarBlue®/HBSS were placed in a 
96-well plate in triplicate, and the fluorescence was measured at an excitation wavelength of 530 
nm and an emission wavelength of 595 nm using a fluorescence plate reader. 
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In vitro quantification of DNA on scaffolds. Total DNA content was used to determine 
the number of cells on each scaffold as previously described.5 After the scaffolds were minced by 
a scalpel and the DNA was digested with 0.5 mL 0.5 mg/mL proteinase K (Sigma-Aldrich) at 56 
C overnight, aliquots (50 µL) were mixed with equal volumes of 0.1 g/mL PicoGreen dye solution 
(Invitrogen) in 96-well plates. Samples were then excited at 480 nm with a plate reader (Wallac 
1420 multilabel hts counter). Scaffolds without cells were used as negative controls. 
In vitro hASCs Viability on polymer solution with alamarBlue® Stain. The copolymer 
was dissolved in stem cell media (40 % v/v). The solution was used as a stock solution to dilute 
and receive concentration values of 20 %, 10 %, 5 %, 2 %, and 1 % copolymer in media. Stem 
cells were seeded in a 96-well plate at a density of 40,000 cells per well and incubated for 24 h at 
penicillin, streptomycin, and amphotericin) was subsequently replaced with serum-free media. 
Polypeptoids were then added at 40, 20, 10, 5, 2, and 1 % (v/v) per well. Cells were incubated for 
4 h before the medium was replaced with serum-containing media. Cell viability was assessed 
using the standard alamarBlue® cell viability assay 24 h later. Following 4 h of alamarBlue uptake, 
fluorescence data was collected at an excitation wavelength of 530 nm and an emission wavelength 
of 595 nm using fluorescence plate reader. 
Quantitative real-time polymerase chain reaction (QPCR). Quantitative real-time 
polymerase chain reaction (QPCR) was utilized to examine the effects of the hydrogel on human 
adult stem cell (hASC) differentiation. hASC were cultured in 100 µL of hydrogel (5 wt% of 
A92M94D12 in medium) and stromal media (Dulbecco's minimal essential medium (DMEM), 10 % 
fetal bovine serum (FBS), and 1 % antibiotic solution (penicillin, streptomycin, fungizone)) at 37 
C and 5 % CO2 in a humidified atmosphere. Following incubation, RNA was extracted with TRI 
57 
Reagent® (Sigma) according to the manufacturer’s instructions. The isolated RNA was then used 
to perform QPCR with iScript™ One-Step RT-PCR Kit with SYBR®Green (Bio-Rad) using a 
MiniOpticon™ Real-Time PCR Detection System (Bio-Rad). Expression of the genes Col2a1 and 
ANGPT1 was used to quantify the hydrogel’s ability to induce chondrogenic and angiogenic 
differentiation, respectively. QPCR samples were normalized against the house keeping gene 18s 
rRNA and relative to separate hASC cultures maintained in chondrogenic growth medium 
(StemPro® Chondrogenesis Differentiation Kit; Life Technologies) and endothelial growth 
medium (EGM™-2 BulletKit™; Lonza) with SingleQuots™ (Lonza) containing vascular 
endothelial growth factor (VEGF), human basic fibroblast growth factor (hFGF-b), epidermal 
growth factor, insulin-like growth factor-1, heparin, ascorbic acid, and 5 % FBS. 
Statistical analysis. The results of alamarBlue, PicoGreen and QPCR analysis were 
reported as mean ± standard deviation. Data was evaluated with one or two way analysis of 
variance (ANOVA), and analyzed by Tukey’s minimum significant difference (MSD) post hoc 
test for pairwise comparisons of main effects. A P-value < 0.05 was considered significant for all 
comparisons.6 
2.3. Results and discussion  
2.3.1. Synthesis and characterization of ABC triblock copolypeptoids 
A series of ABC triblock copolypeptoids have been synthesized by benzyl amine-initiated 
ring-opening polymerization of the corresponding N-substituted N-carboxyanhydrides (R-NCAs) 
in a sequential manner (Scheme 2.2). Representative 1H and 13C {1H} NMR spectra of the 
monomers were shown in Figure 2.1-2.6 in section 2.2. The hydrophobic C segment consists of 
poly (N-alkyl glycine) where the alkyl groups is varied from butyl (B), octyl (O) to decyl (D) with 
increasing hydrophobicity. The hydrophilic B segment consists of either poly (N-methyl glycine) 
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(M) or poly(N-methoxyethyl glycine) (m) or poly(N-methoxyethoxyethyl glycine)(d)  with 
increasing hydrophilicity. The M, m and d homopolymers are highly water soluble with solubility 
in the 20-200 mg/mL range. The thermoresponsive A segment is based on poly (N-allyl glycine) 
(A) for all samples. Poly(N-allyl glycine) has previously been demonstrated to be 
thermoresponsive with cloud point in the 27-54 C range, which is dependent on the chain length 
and concentration.7 
Scheme 2.2. Synthesis of ABC copolypeptoids. 
 
All polymerization reactions were conducted in 50 °C anhydrous acetonitrile and were 
allowed to reach complete conversion prior to the addition of another monomer. The resulting 
triblock copolymers were purified by precipitation in hexane and dried under vacuum prior to 
further analysis. The ABC triblock copolypeptoid compositions were determined by 1H NMR 
spectroscopy (Figure 2.7−2.11). For example, the number-averaged degree of polymerization 
(DPn) of the AMD polymers (Entry 1−6, Table 2.1) was determined by the integrations at 0.91, 
3.0, and 5.8 ppm due to the methyl protons in D and M blocks as well as the terminal alkenyl 
protons in the A block relative to the integration of signals at 7.3 ppm due to the benzyl end-group. 
The triblock copolypeptoids composition can be systematically adjusted by controlling the initial 
monomer to initiator feed ratio (Table 2.1). The weight fraction of individual block is varied in the 
0.31−0.50, 0.34−0.54, and 0.13−0.21 range for the A, B, and C segments, respectively (Table 2.1).  
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Table 2.1. Molecular Parameters of ABC Triblock Copolypeptoids and the Corresponding 
Hydrogel Properties. 
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a.The numbers in subscripts correspond to the DPn of individual block determined by end-group 
analysis using 1H NMR spectroscopy in CD2Cl2; 
b. initial monomer to initiator ratio; c. theoretical  
molecular weights were calculated from the initial monomer to initiator ratio; d. determined by 1H 
NMR analysis; e. determined by the SEC-DRI method using polystyrene standards (0.1 M 
LiBr/DMF, room temperature); f.f1, f2, and f3 refer to the weight fraction of the thermoresponsive 
A end block, the hydrophilic middle block and the hydrophobic end block respectively; g.Tgel is 
the crossover point of G' and G'' in the plot of G' and G'' versus temperature: average of two 
measurements; h. G' and G'' in the gel state at physiological temperature (37 oC): average of two 
measurements; i.Young’s modulus is calculated using E = 2G (1+), G = (G'2+G''2)1/2,  = 0.5,  is 
he Poisson’s ratio;8 j. The polymer solution did not form a gel at 37 oC. 
 
Size exclusion chromatographic (SEC) analysis of the polymer products obtained after the growth 
of each block revealed monomodal peaks that are consistently shifted toward lower elution time, 
in agreement with the block copolymer formation (Figure 2.12). The polymer molecular weight 
distribution remains narrow with low polydispersity indices (PDI) in the 1.03−1.15 range (Figure 
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2.13), consistent with the formation of well-defined block copolypeptoid polymers. The molecular 
parameters of the triblock copolypeptoid samples are summarized in Table 2.1. 
 
Figure 2.12. Representative SEC chromatograms showing the successful enchainment for the 
synthesis of the ABC triblock copolypeptoid (A98M98D18, Entry 1, Table 2.1).  
 
2.3.2. Preparation of the ABC hydrogels 
All aqueous solutions of ABC triblock copolymers were prepared by the “thin film 
hydration” method, as reported by Zhou et al.2 All samples underwent thermoreversible gelation 
in DI water, as evidenced by rheological measurements (vide infra). The 5 wt % solutions of 
selected polymers (Entry 1, 2, 3, 5, 7, and 9, Table 2.1) form free-standing opaque gels at close-
to-body temperature, and return to a free-flowing liquid when cooled down to room temperature  
(Figure 2.14−2.15). The ABC triblock copolymers also underwent sol-to-gel transition in 
biological media (stromal media) at the same concentrations.The sol-to-gel transition is rapid with 
the formation of free-standing gels in less than 30 s. Repeated heating and cooling experiments 
indicate that the sol-to- gel transition is fully reversible. The hydrogels appear opaque, suggesting 
the occurrence of phase separation to some extent during gelation. The hydrogels are injectable th- 
61 
 
Figure 2.13. Representative SEC chromatograms of all ABC triblock copolypeptoids (Entry 1-10, 
Table 2.1). 
rough a 24 gauge syringe needle and maintain the shape upon contact with 37 °C surfaces or DI 
water bath. 
 
Figure 2.14. Optical images showing the thermoreversible gelation of A98M98 D18 at different 
concentration in DI water. 
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Figure 2.15. Optical images showing the thermoreversible gelation of ABC triblock copolymers 
at 5 wt% in DI water. 
2.3.3. Rheological characterization of the sol−gel transition 
Rheological measurements of the ABC polypeptoid hydrogels were conducted to quantify 
the gelation temperature and assess the relative mechanical stiffness of the hydrogels. Two 
measurements were conducted for each sample (see representative data in Figures 2.16-2.18). 
Temperature-dependent dynamic shear moduli (storage moduli G' and loss moduli G'') of the 
polypeptoid aqueous solution were recorded at a frequency of 10 rad/s and heating rate of 1 °C/min 
over a  15−60 °C temperature range. A representative evolution of G' and G'' with increasing 
temperature is shown in Figure 2.18 for a 5 wt % aqueous solution of A98M98D18 (Entry 1, Table 
2.1). The storage (G′) and loss modulus (G″) are both low with G″ larger than G′ at low temperature 
range, which indicates the viscous liquid-like behavior of the solution. As the temperature 
increases to the transition point, the G′ and G″ of the sample increase sharply to reach a crossover 
point at which the G′ starts to exceed the G″, indicating an elastic solid-like behavior of the solution 
beyond the critical temperature point. Here, we define the crossover point of the G′ and G″ as the 
gelation temperature (Tgel). With further increase of the temperature, the G′ and G″ values continue 
to increase and eventually plateau, suggesting the formation of stable hydrogels with a certain 
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mechanical stiffness. To investigate the reversibility of the gelation, a second temperature sweep 
of the G′ and G″ was conducted after the sample was cooled down to the starting temperature 




Figure 2.16. Plots of storage (G', filled symbols) and loss moduli (G'', open symbols) versus 
temperature for the A92M94D12 (5 wt%): 1st trial (G', ■ ; G'', □) and 2nd trial (G', ■ ; G'', □).  
 
Figure 2.17. Plots of storage (G', filled symbols) and loss moduli (G'', open symbols) versus 




Figure 2.18. Plots of storage (G′, filled symbols) and loss moduli (G″, open symbols) versus 
temperature for the A98M98D18 (5 wt %): first heating (G′, ■ ; G″, □) and second heating (G′, ■ ; 
G″, □). 
 
Figure 2.19. Plots of storage (G′, filled symbols) and loss moduli (G″, open symbols) versus 
temperature for the A98M98D18 (Entry 1, Table 2.1) polymer solutions at 1 wt % (G′, ▲; G″ Δ), 
2.5 wt % (G′, ■; G″,□), and 5 wt % (G′, ● ; G″, ○). Inset shows the plot of Tgel versus polymer 
concentration. 
 
To further characterize the rheological properties of the sol and the gel based on the 
A98M98D18 triblock copolypeptoid (Entry 1, Table 2.1), measurement of dynamic shear moduli as 
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a function of angular shearing frequency was conducted (Figure 2.20). At 22 oC, the loss modulus 
(G″) is larger than the storage modulus (G′) and both moduli are close to zero at low frequency 
and adapt a terminal rheological behavior indicative of a viscous liquid. At 25 oC, the G′ started to 
superimpose on the G″ and approaches the critical gelation temperature when G′ and G″ follow a 
power law with an exponential of approximately 1/2 (G′ ≈ G″ ∼ ω0.5) (Figure 2.20).2 At 37 °C, G′ 
is large than G″ through the whole frequency range and is nearly frequency independent, indicating 
the formation of a stable elastic solid-like hydrogel. 
 
Figure 2.20. Plots of storage modulus (G′, filled symbols) and loss modulus (G″, open symbols) 
versus angular frequency (ω) for the 5wt % aqueous solution of A98M98D18 (Entry 1, Table 2.1) at 
different temperatures: 37 °C (G′, ■; G″, □), 25 °C (G′, ●; G″, ○), and 22 °C (G′, ▲; G″ Δ). 
 
2.3.4. Microscopic characterization of the hydrogel 
To investigate the microscopic structure of the hydrogel, cryo-SEM was conducted on the 
A92M94D12 hydrogel (5 wt %, 2.5wt% and 1 wt%) freshly formed at 37 °C. The cryo-SEM 
microgram revealed a highly porous structure with large mesh size in the micron regime (>3 μm) 
(Figure 2.21), consistent with a gel structure formed by phase separation. The pore size of the 
hydrogel can be easily tailored by controlling the concentration of the polymer solution. As 
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expected, the pore size of the hydrogel gradually increased with decreasing polymer solution 
concentration, consistent with the decreased hydrogel stiffness with increasing concentration 
measured by rheological analysis. The average pore size measured long the longest and shortest 
axis of at least 50 pores for 5wt% hydrogel (Figure 2.21 A and B) was 3.23 ± 0.68 µm and 7.26 ± 
1.46 µm, respectively. As the concentration decreased to 2.5 wt%, the pore size of the hydrogel 
(Figure 2.21 C) along the longest and shortest axis increased to 3.48 ± 0.82 µm and 10.38 ± 5.06 
µm, respectively. As the concentration further decreased to 1wt%, the hydrogel exhibited a 
lamellar morphology. The average spacing between the lamella was 4.13 ± 0.71 µm, whereas the 
lamellar morphology spans more than 50 μm continuously.  
 
Figure 2.21. Cryo-SEM images of the 5 wt % (A,B), 2.5 wt% (C) and 1wt% (D).A92M94D12 
hydrogel The scale bar in (A) and (B) is 50.0 and 10.0 μm, respectively. The scale bar in (C) and 
(D) is 20.0 μm. 
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2.3.5. Characterization of micellation of ABC triblock copolypeptoids in dilute solution 
We hypothesize that the ABC triblock copolypeptoids undergo a thermoreversible sol−gel 
transition through the formation of micellar networks (Figure 2.22) similar to early studies on other 
ABC block copolymer systems.2, 9-10As the three blocks are mutually immiscible, the C block is 
hydrophobic and the B and A blocks are water-soluble below the sol−gel transition temperature, 
the triblock copolymers are expected to form core−shell−corona micelles below Tgel. Upon 
temperature increases, the corona blocks (A) undergo cloud point transition and become 
dehydrated to form hydrophobic domains. This results in the formation of a three-dimensional 
micellar network. 
 
Figure 2.22. Schematic showing the proposed gelation mechanism of aqueous solutions of the 
ABC triblock copolypeptoids. 
The cloud point of the AMD triblock copolypeptoids, as determined from the turbidity 
measurement, was shown to be higher than of the poly (N-allyl glycine) homopolymer (A) itself 
by 8 °C (Figure 2.23). It is attributed to the attachment of hydrophilic M block at the A terminal, 
resulting in an increased cloud point of the A segment. 
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Figure 2.23. (A) Plots of transmittance at  = 450 nm versus temperature for the aqueous solutions 
of homopolymer A105 and (B) the A98M98D18 triblock copolypeptoid (both samples: 1 wt% in DI 
water).  
To verify the micelle formation, TEM analysis of the diluted triblock copolypeptoids 
solutions were conducted. Spherical micelles with a uniform diameter (13.4 ± 1.1 nm) were 
observed for the A92M94D12 sample (Entry 2, Table 2.1) (Figure 2.24A); for the A98M98D18 sample 
with slightly increased D segmental length (Entry 1, Table 2.1), rod-shape micelles with 
moderately uniform diameter (16.6 ± 1.7 nm) become notably present (Figure 2.24C). Consistent 
with the TEM analysis on the dried and uranyl acetate stained micellar samples, Cryo-TEM 
analysis of a dilute aqueous solution (1 wt %) of the same A92M94D12 and A98M98D18 sample also 
confirm the formation of spherical and rod-shape micelles, respectively (Figure 2.24B and D). In 
addition, DLS analysis of the dilute solution of A98M98D18 (0.5 wt %) at 25 °C revealed the 
presence of particles of a much larger hydrodynamic size than that of A92M94D12 (0.5 wt %, Figure 
2.25), in accordance with their different micellar morphologies observed by TEM. These results 
together with the cryo-SEM analysis of the polypeptoid hydrogel (Figure 2.21) suggest that the 
hydrogel structure is highly hierarchical with spatial features ranging from micron down to 
nanometer in dimension. 
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Figure 2.24. (A, C) TEM images of the micelles based on A92M94D12 and A98M98D18 polymers 
respectively (stained with uranyl acetate) and (B, D) cryo-TEM image of 1 wt% aqueous solution 
of the same A92M94D12 and A98M98D18 polymers respectively. 
 
Figure 2.25. (A) Hydrodynamic size distribution of the A92M94D12 and A98M98D18 micelles (0.5 
wt% in nanopure water) at room temperature (below the Tgel) and (B) the corresponding 
correlograms.  
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The micelle formation is further supported by 1H NMR spectroscopic study of a dilute 
solution of AMD. (Figure 2.26). In CD2Cl2, which is a good and nonselective solvent for all three 
blocks in the triblock copolypeptoids, proton signals from the three different blocks (A, M, D) are 
notably present. In D2O, which is a poor solvent for the D segment and a good solvent for the A 
and M segments, the proton signals due to the D segment have completely disappeared. This is 
consistent with micellation where the insoluble D block becomes buried in the core of the micelles. 
As the temperature is increased to 37 °C, which is above the cloud point of the block 
copolypeptoids, the proton signals due to the A block was significantly decreased. This indicates 
the increased dehydration of the A block above the cloud point. The broadening of the proton 
signals of the M block at elevated temperature was attributed to structural heterogeneity within the 
gel due to the phase separation during gelation. 
 
Figure 2.26. 1H NMR spectra of A92M94D12 in solvent CD2Cl2 and D2O at different temperature 
(from below to above the Tgel). 
71 
To further support the proposed mechanism, a temperature-sweep dynamic light scattering 
(DLS) measurement within 20−60 °C range was performed on the dilute aqueous solution of 
A92M94D12 (0.5 wt %) (Figure 2.27 and 2.28). At 20 °C, DLS revealed a relatively narrow 
distribution of micellar sizes with an average 40.6 ± 0.4 nm diameter. As the temperature increases, 
the average size of the particles also increases (Figure 2.27). Plot of the derived count rate of the 
micelle solution versus temperature revealed a sharp increase at 27 °C, indicating the onset of 
micellar aggregation (Figure 2.28A). The temperature- dependent DLS measurement suggests the 
association of micelles at elevated temperature, in agreement with the proposed gelation 
mechanism (Figure 2.22). 
 
Figure 2.27. Diameter distribution of the A92M94D12 micellar solution (0.5 wt%) at different 
temperature obtained by DLS measurements.  
 
2.3.6. Tuning the Hydrogel Properties 
The gelation temperature and mechanical stiffness of the ABC block copolypeptoid 
hydrogels can be adjusted by controlling the polymer solution concentration and the polymer 
composition. For example, the aqueous solutions of A98M98D18 (Entry 1, Table 2.1) in the 1−5 wt 
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% range all underwent thermoreversible sol−gel transitions (Figure 2.18). The sol−gel transition 
temperature can be systematically increased from 26.2 to 33.6 °C as the polymer concentration is 
 
Figure 2.28. (A) Plots of derived count rate and (B) Z-averaged diameter versus temperature for 
the A92M94D12 micellar solution (0.5 wt% in water) together with (C) the corresponding 
correlograms. 
 
decreased from 5 to 1 wt %. The sol−gel transition window also becomes narrower as the polymer 
concentration increases. The mechanical stiffness of the hydrogel at 37 oC, as indicated by storage 
modulus (G'), increases from approximately 2 to 251 Pa as the polypeptoid concentration increases 
from 1 to 5 wt %. It corresponds to an increase of Young’s modulus from 6 to 762 Pa. This is 
attributed to the increased cross-linking density at higher concentrations, resulting in micellar 
networks with increased stiffness.2 The concentration dependence of the sol−gel transition 
temperature is consistent with the concentration dependence of the cloud point of block 
copolymers: the higher the concentration, the lower the cloud point transition.7, 11 
To investigate the impact of polymer composition on the gelation characteristics, we 
conducted rheological measurements on the aqueous solutions of triblock copolypeptoids where 
the chain length of a selective block in the AMD triblock copolypeptoids is systematically varied 
while the chain length of the remaining two blocks are kept constant. It has been found that the 
chain length of each block impacts the gelation temperature and gel modulus to different extents. 
For example, Tgel does not change appreciably when the length of the hydrophobic D end block is 
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increased by 50% from DPn =12 to 18 (Figure 2.29C), whereas the G' at 37 
oC decreases from 780 
to 251 Pa. By comparison, when the length of the M middle block is increased by 60% from DPn 
= 98 to 158 while the chain length of the other two blocks are kept constant, Tgel is increased from 
26.2 to 30.7 oC and the G' value at 37 oC was reduced from 251 to 189 Pa (Figure 2.29B). This is 
consistent with the general observation that increasing the molar fraction of the terminal 
hydrophilic moiety in thermoresponsive block copolymers enhances the cloud point.11 By contrast, 
a dramatic increase of gelation temperature from 26.6 to 40.9 °C occurred (Figure 2.29A) when 
the length of A block is decreased by 53% from DPn = 92 to 43. The latter sample did not form a 
gel at physiological temperature (37 °C). The change in the Tgel is in agreement with the previous 
report where the cloud point of the A homopolymer exhibits chain length dependence: the shorter 
chain length of A gives rise to a higher cloud point.7 The gelation temperature (40.9 °C) is much 
higher than the reported cloud point of the A homopolymer with similar DPn (30 °C). This is 
expected as the A segment in the triblock copolypeptoids is directly attached to a long hydrophilic 
M segment, thereby resulting in an increase in cloud point.11 Compared to the ABC hydrogelators, 
the corresponding ABA triblock copolymer exhibit a very different gelation behavior: no gelation 
occurs up to 60.0 °C (Figure 2.29D). It is probably due to the long-range structural arrangement 
during the simultaneous micellation and gelation process. In addition, the same end block may 
cause loops or flower-like conformation that suppresses the formation of bridging structure.2, 12-13 
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Figure 2.29. Plots of storage (G′, filled symbol) and loss moduli (G″, open symbol) versus 
temperature for aqueous solutions (5 wt %) of triblock copolypeptoids having varying 
compositions: A98M98D18 (G′, ●; G″, ○), A92M94D12 (G′, ■; G″, □), A94M158D16 (G′, ●; G″, ○), 
A43M92D9 (G′, ●; G″, ○), A45M93A45 (G′, ●; G″, ○). 
To elucidate the influence of the total chain length on the gelation characteristics, 
rheological measurements were also conducted on aqueous solutions of AMD triblock 
copolypeptoids where the total polymer chain length is varied while the weight fraction of each 
block is kept constant (Figure 2.30 and entries 1, 5, and 6 in Table 2.1). The sol−gel transition 
temperature was shown to systematically increase from 26.2 to 31.0 to >60.0 °C as the total chain 
length (DPn) decreases from 214 to 100 to 53. In fact, the shortest chain sample remains a solution 
at the highest temperature (60.0 °C) that was tested. G' and G'' appear to crossover at this 
temperature limit (Figure 2.30). The chain length dependence of Tgel is consistent with the chain 
length dependence of the cloud point for A homopolymer: shorter chains exhibit higher cloud 
points.7 This indicates that tuning the A chain length is the most effective strategy to control the 
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sol−gel transition temperature in the triblock copolypeptoid system. In addition, the hydrogel 
stiffness at 37 oC, as indicated by the G' value, is reduced from 251 to 125 Pa with the decrease of 
total chain length (DPn) from 214 to 53 (Figure 2.30). 
 
Figure 2.30. Plots of storage (G', filled symbol) and loss moduli (G'', open symbol) versus 
temperature for aqueous solutions (5 wt %) of triblock copolypeptoids with varying block chain 
length and same block molar ratio: A98M98D18 (G', ●; G'', ○), A45M45D10 (G', ■; G'', □), A23M25D5 
(G', ▲; G'', Δ). 
To elucidate how the hydrophobicity of the core block (i.e., C segment) affect the gelation 
temperature and mechanical stiffness of the hydrogel, rheological measurements were conducted 
on the aqueous solutions of triblock copolypeptoids where the hydrophobic D end block was 
replaced with less hydrophobic O and B (Scheme 2.2), whereas the length of each block was kept 
nearly the same. As the hydrophobicity of the core block decreases (D > O > B), the Tgel was 
slightly increased from around 31.0 to 31.4 to 32.7 °C. The hydrogel at 37 °C shows decreased 
storage modulus from 125 to 0.2 Pa asthe hydrophobic core block is changed from D to B (Figure 
2.31). Thus, the hydrophobicity of the C segment plays an important role in the gelation that 
increased hydrophobicity lowers the Tgel and raises the hydrogel stiffness.  
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Figure 2.31. Plots of storage modulus (G', filled symbol) and loss modulus (G'', open symbol) 
versus temperature for aqueous solutions (5 wt %) of triblock copolypeptoids having varying 
hydrophobic end block: A45M45D10 (G', ■; G'', □), A45M47O10 (G', ●; G'', ○), A41M47B11 (G', ▲; 
G'', Δ). 
 
To further investigate how the hydrophobicity of the B middle block affects the gelation 
characteristics, rheological measurements were conducted on the aqueous solutions of triblock 
copolypeptoids where the hydrophilicity of the middle block was altered. As the hydrophilicity of 
the middle block increases in the following order: M < m < d (Scheme 2.1), the Tgel was increased 
from 31.0 to 42.6 °C. The storage modulus at 37 °C is decreased from 125 to 60 Pa with the 
increase of the middle block hydrophilicity from M to m (Figure 2.32). In contrast, as the middle 
block hydrophilicity further increased to d, the polymer solution remains in the sol state at 37 °C. 
These results strongly indicate that the gelation temperature and stiffness of the gels are highly 
dependent on the hydrophilicity and hydrophobicity of the constituent block. We are able to adjust 




Figure 2.32. Plots of storage (G', filled symbol) and loss moduli (G'', open symbol) versus 
temperature for aqueous solutions (5 wt %) of triblock copolypeptoids with varying middle block: 
A45M45D10 (G', ■; G'', □), A50m55O11 (G', ●; G'', ○), A46d42D9 (G', ▲; G'', Δ). 
 
2.3.7. Protein Encapsulation Study 
Thermoreversible hydrogels are useful for encapsulation and delivery of water-soluble 
therapeutics such as proteins/peptides or cells.14-15 For encapsulation of proteins, it is important 
that the hydrogels do not adversely affect the protein structure and function. Because the 
polypeptoids are structurally similar to polypeptides, it is of concern that the hydrogel materials 
may interact with the proteins and alter the protein functions, even though the polypeptoids only 
present in low weight fraction in the hydrogel. To assess the suitability of the polypeptoid hydrogel 
for protein encapsulation, a model water-soluble enzyme (horseradish peroxidases, HRP) was 
encapsulated in the hydrogel and examined for any functional change over an extended period of 
time. 
HRP is known to catalyze the reaction of guaiacol and H2O2, giving rise to colored product 
(Scheme 2.3).16 This allows the enzymatic activity of HRP to be readily quantified by measuring 
the initial reaction rate using an UV−vis spectrometer (Figure 2.33). HRP was encapsulated in the 
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A92M94D12 hydrogel (sample 2, Table 2.1) at 37 °C for up to 7 d, over which period the enzymatic 
activity was examined and quantified.16 The HRP encapsulated in hydrogels do not exhibit any 
appreciable changes in the specific enzymatic activity in the first 24 h of encapsulation (Table 2.2, 
Figure 2.34). The activities are comparable to thecontrol sets (no gel, Figure 2.34), where the HRP 
was kept in PBS buffer at 37 °C for the same duration. The encapsulated HRP also shows 
comparable enzymatic activity to the as-received HRP in PBS buffer at 25 °C without any 
prolonged incubation (control, Figure 2.34). Increasing the encapsulation to 7 days resulted in a 
slight decrease of the enzyme activity by 9.4%. This is ascribed to the prolonged heating as the 
control sample where the enzyme is incubated in buffer at 37 °C without hydrogel shows the 
similar percentage reduction of activity. The results indicate that the polypeptoid hydrogel does 
not adversely affect the HRP enzymatic function. 
Scheme 2.3. Catalytic Reaction of Guaiacol with HRP and H2O2. 
 
2.3.8. Cytotoxicity Assessment of the Polypeptoid Solution and Hydrogel 
AlamarBlue assay was used to assess the cytotoxicity of ABC triblock copolypeptoids 
diluted solution to human adipose-derived stem cells (hASCs). The diluted polymer solution 
(A92M94D12) was shown to be minimally cytotoxic to hASC with concentration up to 20 mg/mL 




Figure 2.33. (A) Representative UV-Vis spectra of the enzymatic reaction involving Guaiacol, 
HRP and H2O2 showing the absorbance increase over time after incubation of HRP in the 
A92M94D12 hydrogel for 24 h; (B) plot of absorbance at  = 470 nm versus time.  
 
 
Figure 2.34. Specific enzyme activity with different incubation time at 37 °C: incubation in the 
A92M94D12 hydrogel (sample 2, Table 2.1) (filled symbol: ■) and incubation without the hydrogel 
(open symbol: □). Control (circular symbol: ○): the enzymatic activity of as-received HRP was 
measured in PBS buffer at 25 °C without any treatment. 
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1 0.0054 0.187 
0.185±0.002 329.71±3.6 2 0.0053 0.183 
3 0.0053 0.183 
1h-no gelb 
1 0.0054 0.187 
0.185±0.004 329.71±7.1 2 0.0054 0.187 
3 0.0052 0.180 
4h-in gela 
1 0.0055 0.190 
0.186±0.004 331.7±7.1 2 0.0053 0.183 
3 0.0053 0.183 
4h-no gelb 
1 0.0053 0.183 
0.182±0.002 325.5±3.6 2 0.0053 0.183 
3 0.0052 0.180 
7h-in gela 
1 0.0055 0.190 
0.188±0.002 335.9±3.6 2 0.0054 0.187 
3 0.0054 0.187 
7h-no gelb 
1 0.0054 0.187 
0.183±0.003 327.6±6.2 2 0.0053 0.1837 
3 0.0052 0.180 
24h-in 
gela 
1 0.0054 0.187 
0.186±0.005 331.7±9.4 2 0.0055 0.190 
3 0.0052 0.180 
24h-no 
gelb 
1 0.0054 0.187 
0.187±0.003 333.8±6.2 2 0.0053 0.183 
3 0.0055 0.190 
7d-in gela 
1 0.0047 0.166 
0.167±0.002 298.8±3.6 2 0.0050 0.173 
3 0.0048 0.163 
7d-no gelb 
1 0.0048 0.166 
0.167±0.005 298.8±9.4 2 0.0049 0.170 
3 0.0048 0.166 
controlc 
1 0.0053 0.183 
0.185±0.002 329.7±3.6 2 0.0054 0.187 
3 0.0053 0.183 
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Figure 2.35. Relative metabolic activity of hASC cultured in dilute solutions of A92M94D12 triblock 
copolypeptoids (Entry 2, Table 2.1). The results are normalized to live control. 
AlamarBlue assay was further used to investigate the effect of ABC hydrogel on hASCs 
metabolic activity. After 24 h of culturing in the ABC hydrogel extractives or 3 d of culturing 
within the hydrogel matrix in direct contacting, hASCs showed a significant decrease (P-value 
<0.05) of relative metabolic activity compared to the live control (Figure 2.36A). The 
corresponding total DNA content was quantified using Quanti-T PicoGreen assay to analyze the 
hASC proliferation on ABC hydrogel (Figure 2.36B). No significant inhibition of hASC 
proliferation compared to the live control was observed when hASCs exposed to the ABC hydrogel 
extractives for 24 h or cultured within the hydrogel matrix in direct contact for 3 d. The results 
indicated that the slight decrease of cells proliferation rate does not correlate with a decrease in 
metabolic activity and may be indicative of stem cells leaving the proliferative cell cycle to 
differentiate. The differentiation pathway of hASCs happening within the hydrogel matrix was 
further indicated by the QPCR analysis (Figure 2.38). Moreover, hASC maintained a healthy 
spindle shape both when exposed to hydrogel extractives and cultured within hydrogel matrix 
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(Figure 2.37). Overall, the results demonstrated that ABC hydrogel is a cytocompatible material 
that can be potentially used as a tissue engineering scaffold.  
 
Figure 2.36. (A) Relative metabolic activity of hASC cultured in A92M94D12 hydrogel (Entry 2, 
Table 2.1) (5 wt % in PBS). The results are normalized to positive control. (B) Corresponding 
number of hASC obtained using Quanti-T PicoGreen assay. Star symbol (*) indicates statistical 
significant difference between two groups. 
2.3.9. QPCR Quantification of Chondrogenesis Markers 
To further investigate the effect of hydrogel on stem cell differentiation, quantitative real-
time polymerase chain reaction (QPCR) analysis were conducted to quantify the expression of two 
marker genes, Col2a1 and ANGPT1, for chondrogenesis and endotheliogenesis, respectively.17-19 
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Figure 2.37. Optical microscopic images of hASC with different treatments. 
Chondrogenesis is a multistep process characterized cell commitment, expression of 
chondrogenic markers, condensation, and cellular morphological changes.17 The product of the 
Col2a1 gene is an early and abundant marker of chondrocytes differentiation pathway.18 The 
expression of Col2a1 and ANGPT1, a marker of angiogenesis, was assessed by QPCR at the 7 and 
21 day time point. The A92M94D12 hydrogel was shown to up-regulate the Col2a1 and down-
regulated the ANGPT1 gene expression of hASCs at 7 and 21 d of the chondrogenesis study (Figure 
2.38). Others studies have also shown up-regulation of Col2a1 and down-regulation of ANGPT1 
gene expression when hASCs committed to chondrogenesis pathway.17, 19 These results indicate 
that the polypeptoid hydrogel may have potential use as scaffold or graft materials for stem cell 
based tissue repair. 
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Figure 2.38. QPCR analysis of gene expression within A92M94D12 hydrogel matrix (Entry 2, Table 
2.1).  
Several synthetic hydrogels have previously been reported to influence the differentiation 
of specific cell lines. For example, polypeptide-based hydrogels (PA-PLX-PA20and PEG-L-PA21) 
have led to chondrogenesis of chondrocytes and adipose tissue derived cells. Although many 
factors [e.g., cell morphologies, proliferation rate, cell density, size of cell aggregation, swelling 
ratio, gel modulus, gel morphology, functional group (e.g., −COO−, −SH, −NH3), and charge state 
in the hydrogel as well as degradation rate]20-29 have been suggested to contribute to this unique 
phenomenon, the exact role of each factor and their complex interplays are not well understood. 
Our future efforts will be directed toward understanding how the structural characteristics of the 
polypeptoid hydrogels affect the stem cell differentiation by systematically tuning the hydrogel 
composition and structure. 
2.4. Conclusions 
Well-defined amphiphilic ABC triblock copolypeptoids with varying composition and 
chain length can be synthesized by primary amine-initiated ring-opening polymerization. The 
polymer aqueous solutions undergo rapid thermoreversible sol−gel transitions. The gelation is 
attributed to the temperature-induced formation of micellar networks. The hydrogel exhibit shear-
thinning behavior and can be injected through 24 gauge syringe needles. The gelation temperature 
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of the hydrogel can be readily adjusted between 26.2 and 60.0 °C, and the mechanical stiffness 
(G') at physiological temperature (37 °C) can be tuned from between 0.2 and 780 Pa, corresponding 
to the Young’s modulus in the 0.5−2346 Pa range. Encapsulation of model proteins (HRP) in the 
polypeptoid hydrogel for up to 7 d does not adversely affect the enzymatic activity. Furthermore, 
the ABC hydrogel and hydrogel extractives show minimal cytotoxicity to hASCs as indicated by 
standard metabolic and proliferation assays. The study of chondrogenic marker expression 
indicated that the hydrogel may have de novo bioactivity and is capable of modulating the 
expression of chondrogenic differentiation markers in hASCs. The combination of low 
cytotoxicity and bioactivity renders the polypeptoid hydrogel a highly promising tissue 
engineering material. The ABC hydrogel motif is highly versatile and structurally tunable. We 
envision the further functionalization of the hydrogel by photoinitiated thiol-ene addition 
chemistry to incorporate various biologically active ligands (e.g., peptides) and further 
enhancement of the mechanical stiffness of the hydrogels by chemical cross-linking. These studies 
are currently in progress and will be reported in due course. 
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 : SYNTHESIS OF PEGYLATED POLYPEPTOIDS AS 
ANTIFOULING POLYMERS 
 
3.1 Introduction  
Nonspecific protein adsorption to the surface of biomaterials and medical devices 
accompanied by slow protein denaturation can induce cascades of biological responses when they 
get into contact with human blood, including thrombosis, chronic inflammation and fast 
immunological recognition.1-4 Those biological responses may hinder the function and 
effectiveness of biomedical devices and drug delivery vehicles.1-4 The resistance of nonspecific 
protein adsorption, therefore, is critical in improving the biocompatibility of biomaterials for 
various biomedical and biotechnological applications (e.g., tissue engineering, therapeutic 
delivery) 
The mechanisms responsible for non-specific protein adsorption to surfaces are not fully 
understood and more investigation is needed.3 The interaction between a protein and a surface is 
considered to be the result of a balance between van der Waals, electrostatic, hydrophobic, and 
hydration forces.3 It is believed that the water layer bound to hydrophilic polymer chains is mainly 
responsible for resisting protein adsorption.4-5 Based on the reported studies, a protein-resistant 
material usually obey four molecular-scale criteria, the so-called “Whitesides rules”: 1) 
hydrophilicity, 2) the presence of hydrogen bond acceptor groups, 3) the absence of hydrogen bond 
donor groups, and 4) the absence of net charge. 4, 6-7 The “Whitesides rules” have been widely 
applied for the rational design of protein-resistant materials. Many types of protein-resistant 
materials have been developed including poly(ethylene glycol) (PEG),3, 8 oligo/polypeptides,9-10 
polycarbonates,11 polyoxazolines,12-14 polyacrylamides15-16 and zwitterionic polymers3, 17. PEG is 
considered as the gold standard of protein-resistant stealth polymers in polymer-based therapeutic 
90 
delivery. The drug-PEG conjugates enhance the water solubility of drugs and decrease their 
interaction with blood components, leading to increased circulation half-life and decreased toxicity 
of drugs. However, PEG has obvious drawbacks including non-biodegradability, potential 
immunological recognition and hypersensitivity provocation, as well as accumulation in tissue 
when the molecular weight of PEG exceeds 40 KDa.3-4, 8 Zwitterionic polymers (e.g., zwitterionic 
polycarbonate17 and polybetanes3)  which form a very stable hydration shell through strong ion-
dipole bonding with water and absence of net charge are very promising protein-resistant 
materials.3-4 They are, nevertheless, minimally soluble in most commonly used organic solvents 
and thereby enhance their subsequent process complexity especially when conjugation to a 
hydrophobic drug is desired.11 Polyoxazolines (e.g., poly(2-methyl-2-oxazoline), with similar 
stealth behavior as PEG, is not backbone degradable and the potential formation of poly (ethylene 
imine) from enzymatic degradation of the amide bonds on the side chain may confer 
cytotoxicity.14, 18-19 Polyacrylamides are another category of protein-resistant material that is not 
backbone degradable. Moreover, the thermoresponsive behavior of, in particular, poly (N-
isopropylacrylamide) makes it absorb proteins at body temperature due to the enhanced 
hydrophobicity.15-16, 20 Some oliogomeric21-24 and polymeric peptides9, 25-26 were shown to be 
enzyme degradable, while the problem with the common water-soluble polypeptides (e.g., poly-
L-lysine and poly-L-aspartate) is their pH dependency and limited circulation lifetime caused by 
the aggregation with oppositely charged moieties.27-28 Besides, the enzymatic proteolysis of 
peptides may results in short in vivo half-lives and therefore limit their use in long-term biological 
application (e.g., long-term drug delivery). Polycarbonates have attracted considerable attention 
in the recent years due to their low toxicity, potential biocompatibility and biodegradability;29 
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however, studies showed that polycarbonates are prone to fast degradation (within several days or 
weeks) both hydrolytically30-31 and enzymatically32 and thus limit their long-term biological use.  
Poly (N-substituted glycine) (a.k.a, polypeptoids), with an N-substituted polyglycine 
backbone, are structural mimics of polypeptides. In contrast to polypeptides, which adopt 
secondary structures (e.g., helix or sheet) stabilized by hydrogen bonding, polypeptoids lack 
extensive hydrogen bonding and chirality on the backbone and render them excellent thermal 
processability, good solubility in commonly used solvents, as well as enhanced enzymatic and 
hydrolytic stability relative to polypeptides.21-23, 33-34 In addition, some studies showed that 
polypeptoids exhibit minimal cytotoxicity,35-38 and are degradable under oxidative conditions that 
mimics tissue inflammation.38 These excellent properties make polypeptoids an attractive material 
for biomedical and biotechnological applications.33, 39-43 In recent years, oligo polypeptoids (DPn 
≤ 20) (e.g., polysarcocine,44 polymethoxyethylyglycine,45-46 polyhydroxyethylglycine46) grafted 
onto TiO2 surface through a DOPA-Lys surface anchor were shown excellent antifouling 
characteristic to resist protein (e.g., human fibrinogen) adsorption and cell (e.g., mammalian cell) 
attachment. These polypeptoids prepared by solid-phase method appeared to have length limitation 
to around 50 mer.41 Surface initiated ring-opening polymerization (SI-ROP) of N-substituted 
glycine N-carboxyanhyrides (NNCA) was also reported to tether longer polypeptoid chains 
(polysarcosine) to the targeted surface for antifouling purpose.47 Studies of polypeptoids regarding 
their protein resistance, to our best knowledge, all focused on surface attached polymer chains and 
there is no study on their protein resistance in bulk solution.  
Here, for the first time, we designed and synthesized a series of polypeptoids bearing 
oligometic ethylene glycol side chains with well-defined structure by primary amine-initiated ring-
opening polymerization of the corresponding N-substituted N-carboxyanhydrides (Scheme 3.2). 
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These PEGylated polypeptoids are highly water soluble, charge neutral and have hydrogen bond 
acceptor both on the backbone and side chains, which fulfill all the criteria of the abovementioned 
“whitesides rule” for protein-resistant materials. The small angle neutron scattering (SANS) and 
dynamic light scattering (DLS) study indicated there is no obvious adsorption of lysozyme to 
PNMeOEtG. All the results suggested that the PEGylated polypeptoids are becoming a new 
benchmark of protein-resistant materials for biological applications.  
3.2 Experimental  
3.2.1 General considerations 
All chemicals were purchased from Sigma Aldrich and used as received unless otherwise 
noted. All the solvents used in monomer preparation and polymerization were purified by passing 
through alumina columns under argon. Toluene-d8 was purified by vacuum transfer after stirring 
over CaH2 overnight. 
1H and 13C {1H} NMR spectra were obtained using a Bruker AV-400 
Nanobay spectrometer (400 MHz for 1H NMR and 100 MHz for 13C {1H} NMR) and a Bruker 
AV-500 spectrometer (500 MHz for 1H NMR and 125 MHz for 13C {1H} NMR) at 298 K. 
Chemical shifts (δ) given in parts per million (ppm) were referenced to protio impurities or the 13C 
{1H} isotopes of deuterated solvents (CDCl3 and D2O).  
3.2.2 Synthesis of MeOEt-NCA and PNMeOEtG 
Synthesis of ethyl 2-((2-methoxyethyl)amino)acetate (1). 2-methoxyethylamine (10g, 
0.13mol) and triethylamine (18.6 mL, 0.13mol) was dissolved in 100 mL ethyl acetate. Ethyl 
bromoacetate (14.7 mL, 0.13 mol) dissolved in 50 mL ethyl acetate was added dropwise to the 
above mixture at room temperature and stirred at room temperature for 4h. The white precipitation 
was removed by filtration and the filtrate was condensed to obtain the crude product as pale yellow 
liquid (21.2 g, 99.1%). The crude product was purified by column chromatography performed on 
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silica gel (230-400 mesh, 60 Å, Sorbent Technologies) using ethyl acetate/methanol as the eluent 
to afford the desired product as colorless liquid (17.2 g, 82.3 % yield). 1H NMR (δ in CDCl3, 400 
MHz, ppm): 1.23-1.26 ppm (t, J = 7.16 Hz, 3H, -COOCH2CH3); 1.87 ppm (s, 1H, -NH-); 2.76-
2.79 ppm (t, J = 5.12 Hz, 2H, -CH2NHCH2CH2-); 3.33 ppm (s, 3H, -OCH3); 3.40 ppm (s, 2H, -
NHCH2COO-); 3.45-3.48 ppm (t, J = 5.08, 2H, CH3OCH2CH2-); 4.14-4.19 ppm (q, J = 7.12 Hz, 
2H, -COOCH2CH3). 
13C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 14.2 ppm (-COOCH2CH3); 
48.8 ppm (-CH2NHCH2CH2-); 51.0 ppm (-OCH3); 58.7 ppm (-NHCH2COO-); 60.7 ppm 
(CH3OCH2CH2-); 72.1 ppm (-COOCH2CH3); 172.3 ppm (-CH2COOH). 
Synthesis of ethyl 2-((2-methoxyethyl)amino)acetic acid hydrochloride (2). Compound 
1 (16.5 g, 0.10 mol) was added aqueous HCl (104 mL, 4 M) and heated at 80 oC for 24 h. The 
water was removed by rotary evaporation to obtain a colorless oil (12.8 g, 94.1 %yield). 1H NMR 
(δ in D2O, 400 MHz, ppm): 3.25-3.27 ppm (t, J = 4.00 Hz, 2H, -CH2NHCH2CH2-); 3.30 ppm (s, 
3H, -OCH3); 3.64-3.66 ppm (t, J = 4.00 Hz, 2H, CH3OCH2CH2-); 3.91 ppm (s, 2H, -NHCH2COO-
). 13C {1H} NMR (δ in D2O, 125 MHz, ppm): 46.7 ppm (-CH2NHCH2CH2-); 47.2 ppm (-OCH3); 
58.3 ppm (CH3OCH2CH2-); 66.7 ppm (-NHCH2COO-); 168.8 ppm (-CH2COOH). 
Synthesis of 2-(N, N-tert-butoxycarbonyl-2-methoxyethyl)amino)acetic acid (3). 
Compound 2 (16.0 g, 0.09 mol), triethylamine (62.7 mL, 0.45 mol) and di-tert-butyl dicarbonate 
(49 g, 0.23 mol) were mixed in distilled water (200 mL) and stirred at 25 oC for 24 h. The reaction 
mixture was extracted with hexane (2 x 200 mL) to remove extra di-tert-butyl dicarbonate. The 
aqueous phase was acidified with aqueous HCl (4 M) at 0oC and extracted with ethyl acetate (3 x 
100 mL). The organic phase was washed with brine (1 x 200 mL) followed by drying over 
anhydrous MgSO4. After filtration, the solvent was removed to obtain the desired product as white 
solid (18.5 g, 88.2 %). 1H NMR (δ in CDCl3, 400 MHz, ppm): 1.45-1.49 ppm (d, 9H, -C(CH3)3); 
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3.35-3.38 ppm (d, 3H, -OCH3); 3.47-3.53 (m, 2H, CH3OCH2CH2-); 3.59-3.61 ppm (m, 2H, 
CH3OCH2CH2-); 4.01-4.09 (d, 2H, HOOCCH2-). 
13C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 
28.2-28.3 ppm (-C(CH3)3); 48.5-48.7 ppm (CH3OCH2CH2-); 50.3-51.6 ppm (CH3OCH2CH2-); 
58.7-57.4 ppm (CH3OCH2CH2-); 71.5-71.6 ppm (HOOCCH2-); 80.9-81.0 ppm (-C(CH3)3); 155.0-
155.8 ppm (-COOC(CH3)3); 174.2-174.5 ppm (-CH2COOH).  
Synthesis of MeOEt-NCA (M1). Compound 3 (10.5 g, 0.045 mol) was dissolved in dry 
dichloromethane (150 mL) under a nitrogen atmosphere. PCl3 (3.1 mL, 0.036 mol) was added 
dropwise to the solution at 0oC and the mixture was stirred at 25oC for 2 h. The solvent was 
removed under vacuum to obtain yellowish viscous residue. In the glovebox, the residue was 
extracted with dry dichoromethane (3 x 20 mL) and filtered and the filtrate was stirred with small 
amount of sodium hydride. After filtration, the filtrate was condensed to afford a pale yellow liquid 
(5.7 g, 80.5 %). The crude monomer was washed by soxhlet extraction with hexane and further 
purified by sublimation (50oC, 20-50 militorr) to afford a colorless liquid (4.5 g, 85.1 %). 1H NMR 
(δ in CDCl3, 400 MHz, ppm): 3.38 ppm (s, 3H, CH3O-); 3.60 ppm (s, 2H,  CH3OCH2CH2-); 4.28 
ppm (s, 2H, -OOCCH2-). 13C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 43.6 ppm (CH3OCH2CH2-
); 50.8 ppm (CH3OCH2CH2-); 59.0 ppm (CH3OCH2CH2-); 70.9 ppm (-OOCCH2-); 152.2 ppm (-
CH2OCOOC-); 163.8 ppm (-CH2OCOOC-). 
Representative synthetic procedure for PNMeOEtG. In the glovebox, M1 (56.9 mg, 
0.36 mmol, [M]0 = 1 M) was dissolved in dry THF (201 µL). A volume of BnNH2/THF stock 
solution (157 µL, 91.2 mM, [M]0: [BnNH2]0 = 25 : 1) was added to the monomer solution and 
heated at 50oC for 24 h under nitrogen atmosphere to reach 100 % conversion checked by FT-IR 
or NMR spectrascopy. The polymerization was quenched by adding excess hexane. The precipitate 
was collected and washed with hexane, followed by drying under vacuum to obtain a crispy solid. 
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Freeze drying yielded a white fluffy solid (34.1 mg, 82.3 %). 1H NMR (δ in D2O, 400 MHz, ppm): 
7.25-7.33 ppm and 2.77-2.82 ppm (benzyl end group); 4.01-4.53 ppm (m, -COCH2-); 3.49-3.83 
ppm (m, -CH2CH2OCH3); 3.02-3.31(d, -CH2CH2OCH3).
  
3.2.3 Synthesis of Me(OEt)2-NCA and PNMe(OEt)2G 
Synthesis of 2-(2-methoxyethoxy)ethanamine (4). 4 was synthesized by using a reported 
procedure. overall yield: 61.3%. 1H NMR (δ in CDCl3, 400 MHz, ppm): 3.61-3.64 ppm (m, 2H, -
CH2CH2NH2); 3.51-3.58 ppm (m, 4H, CH3OCH2CH2-); 3.40 ppm (s, 3H, CH3O-); 2.87-2.90 ppm 
(t, J=5.28 Hz, 2H, -CH2NH2); 1.58 ppm (bs, 2H, -NH2).  
Synthesis of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetate (5). 5 was synthesized 
with the same protocol as 1. Yield: (70.5 %). 1H NMR (δ in CDCl3, 400 MHz, ppm): 4.18-4.24 
ppm (q, J= 7.12Hz, 2H, -COOCH2CH3); 3.56-3.65 ppm (m, 6H, CH3OCH2CH2OCH2-); 3.45 ppm 
(s, 2H, -NHCH2COO-); 3.41 ppm (s, 3H, CH3O-); 2.83-2.86 ppm (t, J=10.6 Hz, 2H, -CH2NHCH2-
); 1.83 ppm (s, -NH-); 1.28-1.31 ppm (t, J=14.3 Hz, 3H, -CH2CH3). 
13C {1H} NMR (δ in CDCl3, 
125 MHz, ppm): 172.3 ppm (-COOCH2CH3); 70.3-71.9 ppm (CH3OCH2CH2OCH2-); 59.0-60.7 
ppm (-CH2COOCH2-); 48.8-51.0 ppm (CH3OCH2CH2OCH2CH2NH-); 14.2 ppm (-COOCH2CH3). 
Synthesis of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetate hydrochloride (6). 6 
was synthesized with the same protocol as 2 in 95.1%-96.8% yield. 1H NMR (δ in CDCl3, 400 
MHz, ppm): 3.91 ppm (s, 2H, -NHCH2COOH); 3.55-3.74 ppm (m, 6H, CH3OCH2CH2OCH2-); 
3.31 ppm (s, 3H, CH3O-); 3.27-3.29 ppm (t, J=9.96 Hz, -CH2CH-). 
13C {1H} NMR (δ in CDCl3, 
125 MHz, ppm): 169.0 ppm (-COOH); 65.3-71.0 ppm (CH3OCH2CH2OCH2CH2NHCH2-); 58.0 
ppm (-CH2CH2NH-); 46.9-47.3 ppm (CH3OCH2CH2OCH2CH2-).  
Synthesis of 2-(N, N-tert-butoxycarbonyl-2-(2-methoxyethoxyethyl)amino)acetic acid 
(7). 7 was synthesized with the same protocol as 3. Yield: (82.9 %). 1H NMR (δ in CDCl3, 400 
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MHz, ppm): 4.03-4.11 ppm (d, 2H, HOOCCH2-); 3.48-3.69 ppm (m, 8H, -
CH2CH2OCH2CH2OCH3); 3.39 ppm (s, 3H, -OCH3); 1.45-1.48 ppm (d, 9H, (CH3)3-). 
13C {1H} 
NMR (δ in CDCl3, 125 MHz, ppm): 28.2-28.4 ppm (-C(CH3)3); 48.4-50.1 ppm 
(CH3OCH2CH2OCH2CH2-); 58.7-58.8 ppm (CH3OCH2CH2OCH2CH2-); 69.9-70.5 ppm 
(CH3OCH2CH2-); 71.9-72.0 ppm (HOOCCH2-); 80.5-80.6 ppm (-C(CH3)3); 155.3-155.7 ppm (-
COOC(CH3)3); 172.6-172.7 ppm (-CH2COOH). 
Synthesis of Me(OEt)2-NCA (M2). M2 was synthesized with the same protocol as M1. 
Yield: 70.8 %). 1H NMR (δ in CDCl3, 400 MHz, ppm): 4.34 ppm (s, 2H, -OOCCH2-); 3.51-3.72 
ppm (m, 8H, -CH2CH2OCH2CH2O-); 3.38 ppm (-OCH3). 
13C {1H} NMR (δ in CDCl3, 125 MHz, 
ppm): 166.1 ppm (-COOCO-); 152.3 ppm (-COOCO-); 69.4-71.7 ppm (-OOCCH2-, -
CH2CH2OCH2CH2O-); 59.1 ppm (-CH2CH2OCH2CH2O-); 50.9 ppm (-CH2CH2OCH2CH2O-); 
43.5 ppm (-OCH3). 
Representative synthetic procedure for PNMe(OEt)2G. In the glovebox, M2 (66.4 mg, 
0.33 mmol, [M]0 = 1 M) was dissolved in dry THF (184 µL). A volume of BnNH2/THF stock 
solution (143 µL, 91.2 mM, [M]0: [BnNH2]0 = 25 : 1) was added to the monomer solution and 
heated at 50oC for 24 h under nitrogen atmosphere to reach 100 % conversion checked by FT-IR 
or NMR spectrascopy. The polymerization was quenched by adding excess hexane. The precipitate 
was collected and washed with hexane, followed by drying under vacuum to obtain a crispy solid. 
Freeze drying yielded a white fluffy solid (46.1 mg, 87.8 %). 1H NMR (δ in D2O, 400 MHz, ppm): 
7.22-7.32 ppm and 2.93-2.94 ppm (benzyl end group); 4.09-4.63 ppm (m, 2H, -COCH2-); 3.51-
3.60 ppm (m, 8H, -CH2CH2OCH2CH2OCH3); 3.26-3.28(m, -OCH3).
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3.2.4 Synthesis of Me(OEt)3-NCA and PNMe(OEt)3G 
Synthesis of 2-(2-(2-Methoxyethoxy)ethoxy)ethylamine (8). 8 was synthesized by using 
a reported procedure. Yield: 67.2 %. 1H NMR (δ in CDCl3, 400 MHz, ppm): 3.40-3.55 ppm (m, 
10H, -CH2OCH2CH2OCH2CH2OCH3); 3.28 ppm (s, 3H, -OCH3); 2.77 ppm (s, 2H, -CH2NH2); 
1.77 ppm (s, 2H, NH2). 
Synthesis of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino)acetate (9). 9 was synthesized 
with the same protocol as 1 and 5. Yield: 71.6 %. 1H NMR (δ in CDCl3, 400 MHz, ppm): 4.16-
4.21 ppm (q, J=7.12 Hz, 2H, CH3CH2COO-); 3.54-3.66 ppm (m, 10H, -
CH2OCH2CH2OCH2CH2OCH3); 3.44 ppm (s, 2H, -NHCH2COO-); 3.38 ppm (s, 3H, -OCH3); 
2.80-2.83 ppm (t, 2H, -CH2NHCH2COO-); 2.09 ppm (bs, 1H, -NH-); 1.26-.1.29 ppm (t, 3H, -
COOCH2CH3). 
13C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 172.2 ppm (-COO-); 70.3-71.9 ppm 
(-CH2CH2OCH2CH2OCH2CH2NHCH2COOCH2-); 59.0-60.7 ppm (-CH2CH2NHCH2-); 48.8-50.9 
ppm (CH3OCH2CH2OCH2CH2OCH2CH2-); 14.2 ppm (-COOCH2CH3).  
Synthesis of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino)acetate hydrochloride (10). 
10 was synthesized with the same protocol as 2 and 6 in 95.8 %-97.7% yield. 1H NMR (δ in CDCl3, 
400 MHz, ppm): 3.28-3.29 ppm (m, 5H, CH3OCH2CH2OCH2CH2OCH2CH2-); 3.53-3.55 ppm (m, 
2H, CH3OCH2CH2OCH2CH2OCH2CH2-); 3.61-3.65 ppm (m, 6H, CH3OCH2CH2OCH2CH2-); 
3.74-3.75 ppm (m, 2H, CH3OCH2-); 3.92 ppm (s, 2H, HOOCCH2-). 
13C {1H} NMR (δ in CDCl3, 
125 MHz, ppm): 46.9-47.2 ppm (CH3OCH2CH2OCH2CH2OCH2CH2-); 58.0 ppm 
(CH3OCH2CH2OCH2CH2OCH2CH2-); 65.2 ppm (CH3OCH2CH2OCH2CH2-); 69.4-69.5 ppm 
(CH3OCH2CH2OCH2CH2-); 70.9 ppm (HOOCCH2-); 168.9 ppm (HOOCCH2-). 
Synthesis of 2-(N, N-tert-butoxycarbonyl-2-(2-(2-(2-ethoxyethoxy)ethyl)amino) acetic 
acid (11). 11 was synthesized with the same protocol as 3 and 7. Yield: 80.1%. 1H NMR (δ in 
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CDCl3, 400 MHz, ppm): 4.00-4.08 ppm (d, 2H, HOOCCH2-); 3.47-3.64 ppm (m, 12H, -
CH2CH2OCH2CH2OCH2CH2-); 3.39-3.41 ppm (m, 3H, -OCH3); 1.44-1.47 ppm (d, 9H, (CH3)3-). 
13C {1H} NMR (δ in CDCl3, 125 MHz, ppm): 28.2-28.3 ppm (-C(CH3)3); 48.5-51.3 ppm 
(CH3OCH2CH2OCH2CH2OCH2CH2-); 58.9-59.0 ppm (CH3OCH2CH2OCH2CH2-); 70.1-70.4 ppm 
(CH3OCH2CH2OCH2CH2-); 71.6-71.8 ppm (HOOCCH2-); 80.7-80.8 ppm (-C(CH3)3); 155.1-
155.8 ppm (-COOC(CH3)3); 173.9 ppm (-CH2COOH). 
Synthesis of Me(OEt)2-NCA (M3). M3 was synthesized with the same protocol as M1 and 
M2. Yield: 69.9 %). 1H NMR (δ in CDCl3, 400 MHz, ppm): 4.38 ppm (s, 2H, -OOCCH2-); 3.71-
3.73 ppm (m, 2H, CH3OCH2-); 3.59-3.66 ppm (m, 8H, CH3OCH2CH2OCH2CH2OCH2-); 3.53-
3.56 ppm (m, 2H, CH3OCH2CH2OCH2CH2OCH2CH2-); 3.39 ppm (CH3O-).  
13C {1H} NMR (δ in 
CDCl3, 125 MHz, ppm): 166.1 ppm (-COOCO-); 152.4 ppm (-COOCO-); 69.4-70.5 ppm 
(CH3OCH2CH2OCH2-); 71.9 ppm (-OOCCH2-); 59.0 ppm (CH3OCH2CH2OCH2CH2-); 50.9 ppm 
(CH3OCH2CH2OCH2CH2OCH2CH2-); 43.5 ppm (CH3OCH2CH2OCH2CH2OCH2CH2-). 
Representative synthetic procedure for PNMe(OEt)3G. In the glovebox, M3 (70.7 mg, 
0.29 mmol, [M]0 = 1 M) was dissolved in dry THF (160 µL). A volume of BnNH2/THF stock 
solution (126 µL, 91.2 mM, [M]0: [BnNH2]0 = 25 : 1) was added to the monomer solution and 
heated at 50oC for 24 h under nitrogen atmosphere to reach 100 % conversion checked by FT-IR 
or NMR spectrascopy. The polymerization was quenched by adding excess hexane. The precipitate 
was collected and washed with hexane, followed by drying under vacuum to obtain a crispy solid. 
Freeze drying yielded a white fluffy solid (51.2 mg, 86.9 %). 1H NMR (δ in D2O, 400 MHz, ppm): 
7.24-7.32 ppm (benzyl end group); 4.10-4.55 ppm (m, 2H, -COCH2-); 3.53-3.59 ppm (m, 12H, -
CH2CH2OCH2CH2OCH2CH2OCH3); 3.29 (m, -OCH3).
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3.2.5 Characterization of PNMe(OEt)nG (n=1-3) 
Size exclusion chromatography (SEC) analysis. SEC analysis of the polypeptoids were 
performed using an Agilent 1200 system (Agilent 1200 series degasser, isocratic pump, auto 
sampler and column heater) equipped with three Phenomenex 5 μm, 300 × 7.8 mm columns [100 
Å, 1000 Å and Linear (2)], a Wyatt OptilabrEX differential refractive index (DRI) detector with a 
690 nm light source, and a Wyatt DAWN EOS multiangle light scattering (MALS) detector (GaAs 
30mW laser at λ = 690 nm). DMF with 0.1M LiBr was used as the eluent at a flow rate of 0.5 
mL·min-1. The column and detector temperature was set at room temperature (20oC). All data 
analysis was performed using Wyatt Astra V 5.3 software. Polymer molecular weight (MW) and 
molecular weight distribution (PDI) were obtained by the Zimm model fit of the MALS-DRI data. 
The absolute polymer molecular weight (Mn) was determined using the measured refractive index 
increment dn/dc values. The refractive index increment (dn/dc) of the polymer was determined 
using Wyatt’s rEX DRI detector and Astra software dn/dc template. The polymer was dissolved 
in DMF with 0.1 M LiBr to prepare six dilute solutions with known concentrations (0.05-3.00 
mg/mL) using volumetric flasks. The solutions were injected to the DRI detector and the 
corresponding dn/dc value was determined from the linear fit to a plot of refractive index versus 
polymer concentration. The dn/dc values measured for PNMeOEtG106, PNMe(OEt)2G102 and 
PNMe(OEt)3G106 are 0.0633(4), 0.0686(8) and 0.0563(6) mL/g, respectively. 
Thermogravimetric analysis. TGA analysis of the polypeptoids was conducted on a TA 
TGA 2950 under nitrogen at the heating rate of 10 oC·min-1. The decomposition temperature (Td) 
of the polypeptoids was determined from the onsets of weight loss. 
Differential scanning calorimetry (DSC) analysis. DSC analysis of the polypeptoids 
were conducted on a TA DSC 2920 calorimeter under nitrogen. The polymer (~5 mg) was sealed 
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into the hermetic aluminum pan and an empty hermetic aluminum pan was used as the reference. 
The sample containing pans were first heated from -50 oC to 200 oC at 10 oC /min, cooled to -50 
oC at 10 oC /min and remained at -50oC for 5min, and reheated to 200 oC at 10 oC/min. The glass 
transition temperature (Tg) was determined by the inflection on the slope of heat flow shifting. 
Kinetic Studies of BnNH2-initiated ring-opening polymerization of Me (OEt)n-NCA 
(n=1-3). A predetermined amount of BnNH2 stock solutions in toluene-d8 were added to a toluene-
d8 solution of Me(OEt)n-NCA (n=1-3) ([M]0 = 0.2 M, [M]0:[BnNH2]0 = 25:1) at room temperature 
followed by transferring into a resealable J-Yong NMR tube. 1H NMR spectra were collected every 
3 min 44 s at 50oC to determine the conversion of monomers for more than four half-lives. Kinetic 
experiments were repeated twice for each monomer.  
Study of Mn vs polymerization conversion. The polymerization of Me(OEt)n-NCA (n=1-
3) was conducted in THF at 50oC ([M]0:[I]0=50:1, [M]0=1 M) and aliquots were taken at different 
time intervals and analyzed with 1H NMR spectroscopy to determine the conversion. The aliquots 
taken at different time intervals were further analyzed with MALDI-TOF spectroscopy to obtain 
the polymer molecular weight (Mn) and molecular weight distribution (PDI). The obtained Mns 
were plotted against the corresponding polymerization conversion.  
3.2.6 Study of protein-resistant behavior of polypeptoids  
Dynamic light scattering analysis. PNMeOEtG (DPn =106), PEG8000 or lysozyme was 
dissolved in PBS at 1wt% and filtered through 0.22 µm filters before measurement. All the samples 
were conducted using Malvern Zetasizer Nano-zs (Zen3600). The He-Ne laser operating at 633 
nm was utilized, and scattered light intensity was detected at an external angle of 173oC using non-
invasive backscatter (NIBS) technology. Data from three measurement with 12 scans for each 
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measurement was recorded. The hydrodynamic diameters and PDI of the samples were obtained 
from cumulant analysis.  
Small-angle neutron scattering (SANS). The small angle neutron scattering (SANS) 
studies were performed at the NIST Center for Neutron Research (NCNR) in Gaithersburg, MD, 
on the NG7 30 m SANS instrument, using neutrons with wavelength  = 6 Å and wavelength 
spread, / = 11%. The temperature was maintained to 200.1C using a circulating bath. A 
typical SANS data reduction protocol, which consisted of subtracting scattering contributions from 
the empty cell (2 mm demountable titanium cells), background scattering, and sorting data 
collected from two different detector distances was used to yield normalized scattering intensities, 
I(Q) (cm-1) a.k.a. the macroscopic scattering cross-section ( 𝑑Σ 𝑑Ω⁄ ) as a function of the 
scattering vector, Q (Å-1). Data reduction was conducted employing the NCNR Igor-pro platform. 
The SANS scattering intensity for our macromolecular solution 48 is modelled as  
𝑑Σ
𝑑Ω
= 𝜙∆𝜌2𝑉𝑃(𝑄)𝑆(𝑄) (1) 
Here, 𝜙 is the volume fraction of the molecules, ∆𝜌 and V, are their average scattering 
contrast and volume, respectively. The single molecular form factor,  𝑃(𝑄), averaged particle 
scattering over the ensemble of sizes and orientations, is related to the particle structure. The 
effective structure factor, 𝑆(𝑄), provides information about the intermolecular interaction. For 
dilute solutions of non-interacting molecules, 𝑆(𝑄) ≈ 1.   
In the current work we have modelled the form factor and the structure for lysozyme 
molecule using a hard sphere approximation49-50. The form factor for the polymer is modelled 
using the random Gaussian coil51. 
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3.2.7 Cytotoxicity study of polypeptoids 
The cytotoxicity study was conducted by adapting a reported procedure.52 The HEp2 cells 
were plated at 8600 cells per well in a Costar 96-well plate (BD biosciences) and allowed to grow 
for 48 h. The polypeptoids were dissolved in Eagle's Minimum Essential Medium (EMEM) and 
diluted to final working concentrations (0, 0.0625, 0.125, 0.25, 0.5, and 1mg/mL). The cells were 
exposed to the working solutions of polypeptoids up to 1 mg/mL and incubated for 24 h (37oC, 
95% humidity, 5% CO2). The working solution was removed, and the cells were washed with 1X 
PBS. The medium containing 20% CellTiter Blue (Promega) was added and incubated for 4 h. The 
viability of cells is measured by reading the fluorescence of the medium at 570/615 nm using a 
BMG FLUOstar Optima micro-plate reader. In this assay, the indicator dye resazurin is reduced 
to fluorescent resorufin in viable cells, while non-viable cells are not able to reduce resazurin nor 
to generate a fluorescent signal. The fluorescence signal of viable (untreated) cells was normalized 
to 100 %.   
3.3 Results and discussion 
3.3.1 Synthesis and characterization of Me(OEt)n-NCA and PNMe(OEt)nG 
It was the first time to report the synthesis of PEGylated N-carboxyanhyride monomers, 
MeOEt-NCA, Me(OEt)2-NCA and Me(OEt)3-NCA. Me(OEt)n-NCA (n=1-3) were synthesized in 
moderate overall yields (40.9 -49.7 %) by adapting a reported procedure53-54 as outlined in Scheme 
3.1. The primary amine (2-(2-methoxyethoxy)ethanamine and 2-(2-(2-
Methoxyethoxy)ethoxy)ethylamine) used were synthesized in good yields (61.3-67.2%, Scheme 
3.2, Figure 3.1 and 3.2) by adapting a reported procedue.55 The monomer precursors (3, 7 and 11) 
showed rotamers at 25oC in CDCl3 due to restricted rotating of the amide bond, which was 
supported by the broadening and merged peaks shown in 1H NMR spectra collected at elevated 
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temperature (50oC) (Figure 3.7, 3.16 and 3.25). The structures of the desired monomers were 
confirmed by 1H and 13C {1H} NMR spectroscopic analysis (Figure 3.9-3.10, 3.18-3.19 and 3.27-
3.28). The polypeptoids bearing oligomeric ethylene oxide side chains (PNMe(OEt)nG, n=1-3) 
were synthesized by ring-opening polymerizations of their corresponding monomers using benzyl 
amine as the initiator (Scheme 3.3). All polymerization reactions were conducted in anhydrous 
THF at 50oC for 24-48 h to reach 100 % conversion at different initial monomer to initiator ratios 
([M]0:[I]0). The polymers were purified by precipitation in hexane and collected by filtration 
followed by drying under vacuum to yield ether crispy white solids (PNMeOEtG) or viscous 
liquids (PNMe(OEt)nG, n=2-3) in good yields (82.3-87.8%). The number-averaged molecular 
weight (Mn) and degree of polymerization (DPn) of the polymer was determined by both the 
1H 
NMR spectroscopy using end-group analysis and by SEC analysis using dn/dc values of the 
polymers. For example, the DPn and Mn of PNMeOEtG was determined by the integrations at 
4.01-4.52 ppm due to the methylene group in the backbone relative to the integration of signals at 
7.3 ppm due to the benzyl end-group (Figure 3.11). The molecular weight of the polymers (Mn) 
increased as the initial monomer to initiator ratio ([M]0:[I]0) was systematically increased (Table 
3.1), as evidenced by 1H NMR and SEC analysis. The polymer molecular weights (Mn) agreed 
with the theoretically predicated values at low molecular weight range ([M]0:[I]0 < 200:1). 
However, at high [M]0:[I]0 ratios (200:1 and 400:1), the molecular weight of the polymers (Mn) 
determined from SEC analysis deviated from the theoretical values probably due to presence of 
impurities and the impurities were probably also behaved as initiators to react with the monomers. 
The polymer molecular weight distributions were narrow with low polydispersity indices (PDI) in 
the 1.03-1.10 range (Table 3.1, Figure 3.30, 3.32 and 3.34) as determined by SEC analysis in 0.1 
M LiBr/DMF at room temperature (oC). The structure of low molecular weight PNMe(OEt)nG 
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(n=1-3) was further confirmed by MALDI-TOF spectroscopic analysis. The spectra showed a 
symmetric monomodal set of mass ions where m/z equals to integral numbers of the desired 
repeating unit mass (115.2, 159.7 and 203.3 g/mol) for (PNMe(OEt)nG, n=1-3) plus 22 or 39 for 
sodium or potassium ion. This is consistent with the targeted polypeptoid structures bearing one 
benzyl amide and one secondary amine chain end (Scheme 2), in support of controlled 
polymerization initiated by benzyl amine initiator.  (Figure 3.31, 3.33 and 3.35). 
 
Scheme 3.1.Synthetic procedures of Me(OEt)n-NCA (n=1-3).  
 
 





Figure 3.1.1H NMR spectrum of 2-(2-methoxyethoxy)ethanamine in CDCl3. 
 




Figure 3.3. 1H NMR spectrum of ethyl 2-((2-methoxyethyl)amino)acetate in CDCl3. 
 












Figure 3.7. 1H NMR spectrum of 2-(N, N-tert-butoxycarbonyl-2-methoxyamino)acetic acid in 
CDCl3: (A) at 25 C and (B) at 50 C.  
 
Figure 3.8. 13C {H} NMR spectrum of 2-(N, N-tert-butoxycarbonyl-2-methoxyamino)acetic acid 
in CDCl3 at 25 C. 
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Figure 3.9. 1H NMR spectrum of MeOEt-NCA in CDCl3. 
 
 
Figure 3.10. 13C {1H} NMR spectrum of MeOEt-NCA in CDCl3. 
 




Figure 3.11.1H NMR spectrum of PNMeOEtG26 in D2O. 
 
Figure 3.12. 1H NMR spectrum of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetate in CDCl3. 
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Figure 3.14. 1H NMR spectrum of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetic acid 




Figure 3.15. 13C {1H} NMR spectrum of ethyl 2-((2-(2-methoxyethoxy)ethyl)amino)acetic acid 
hydrochloride in D2O. 
 
Figure 3.16. 1H NMR spectrum of 2-(N,N-tert-butoxycarbonyl-2-(2-
methoxyethoxyethyl)amino)acetic acid in CDCl3: (A) at 25 C and (B) at 50 C.  
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Figure 3.17. 13C {1H} NMR spectrum of 2-(N,N-tert-butoxycarbonyl-2-(2-








Figure 3.19. 13C {1H} NMR spectrum of Me(OEt)2-NCA. 
 
 




Figure 3.21. 1H NMR spectrum of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino)acetate in CDCl3. 
 
 





Figure 3.23. 1H NMR spectrum of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino) acetic acid 
hydrochloride in D2O. 
 
 
Figure 3.24. 13C {1H} NMR spectrum of ethyl 2-((2-(2-(2-ethoxyethoxy)ethyl)amino) acetic acid 




Figure 3.25. 1H NMR spectrum of 2-(N,N-tert-2-(2-(2-methoxyethoxy) 
ethoxyethoxycarbonylmethyl)amino) acetic acid in CDCl3: (A) at 25 C and (B) at 50 C.  
 
 
Figure 3.26. 13C {1H} NMR spectrum of 2-(N,N-tert-2-(2-(2-methoxyethoxy) 
ethoxyethoxycarbonylmethylamino) acetic acid in CDCl3 at 25
oC.   
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Figure 3.27. 1H NMR spectrum of Me(OEt)3-NCA. 
 
 




Figure 3.29. 1H NMR spectrum of PNMe(OEt)3G in D2O. 
 
Figure 3.30. SEC chromatograms of PNMeOEtGs prepared from benzyl amine initiated 
polymerization of MeOEt-NCA (M1) ([M1]0:[BnNH2]0 = 25:1 (—), 50:1 (—), 100:1 (—), 200:1 
(—), 400:1 (—)). The DPs listed in the figure were determined from the SEC-MALDI-DRI using 
the dn/dc= 0.0633(4) mL/g (0.1 LiBr/DMF, 20°C) of the polymer. 
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Figure 3.31. (A) Representative full and (B) expanded MALDI-TOF MS spectra of PNMeOEtG 
(Mn=2.7 kg/mol, PDI=1.03, matrix: CHCA).  
 
Figure 3.32. SEC chromatograms of PNMe(OEt)2Gs prepared from benzyl amine initiated 
polymerization of Me(OEt)2-NCA (M2) ([M1]0:[BnNH2]0 = 25:1 (—), 50:1 (—), 100:1 (—), 200:1 
(—), 400:1 (—), Table). The DPs listed in the figure were determined from SEC-MALDI-DRI 
using the dn/dc= 0.0686(8) mL/g (0.1 LiBr/DMF, 20°C) of the polymer. 
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Figure 3.33. (A) Representative full and (B) expanded MALDI-TOF MS spectra of PNMe(OEt)2G 
(matrix: CHCA).  
 
 
Figure 3.34. SEC chromatograms of PNMe(OEt)3Gs prepared from benzyl amine initiated 
polymerization of Me(OEt)3-NCA (M3) ([M1]0:[BnNH2]0 = 25:1 (—), 50:1 (—), 100:1 (—), 200:1 
(—), 400:1 (—), Table). The DPs listed in the figure were determined from SEC-MALDI-DRI 
using the dn/dc= 0.0563(6) mL/g (0.1 LiBr/DMF, 20°C) of the polymer. 
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Figure 3.35. (A) Representative full and (B) expanded MALDI-TOF MS spectra of PNMe(OEt)3G 
(matrix: CHCA).  
Polymerization kinetics were investigated at a constant initial monomer to initiator ratio 
([M]0:[BnNH2]0 = 25:1, [M]0 = 0.2 M) in Tolene-d
8 at 50oC in J-Yong NMR tube and the 
polymerization conversion was determined from the integration of the monomer and 
corresponding polymer peaks. The polymerizations of the three monomers all exhibited a pseudo-
first order dependence on the monomer concentration (i.e., d[M]/dt = kobs [M]), consistent with a 
living polymerization. As the number of ethylene oxide moiety on the monomer side chain 
increased from one (MeOEt-NCA) to three (Me(OEt)3-NCA), the observed rate constant (kobs) of 
the polymerization decreased from 0.01285(±6) to 0.00291(±7) min-1 (Figure 3.36C). It was 
probably due to the higher steric hindrance and more electron-withdrawing effect associated with 
the increased number of ethylene oxide moiety on the side chain that weakened the nucleophilicity 
of the secondary amino chain end and thus decreased the propagation rate. In addition, the plot of 
Mn of the corresponding polymer exhibited a linear relationship as a function of conversion (Figure 
3.36-3.37), revealing a constant concentration of propagation species, in agreement with a living 
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polymerization. The molecular weight distribution (PDI=1.01-1.18) remained relatively narrow 
during the polymerization.  
DSC and TGA analysis of (PNMe(OEt)nG, n=1-3). The PEGylated polypeptoids were 
characterized by TGA and DSC. The TGA thermograms of PNMe(OEt)nG50 (n=1-3) shown in 
Figure 3.38 and 3.39 revealed a three-stage decomposition profiles with a slow and gradual mass 
loss at low temperatures (25 oC-100 oC) which was attributed to the loss of small amount of water 
contained in the polymers due to their hydroscopic property, followed by a drastic mass loss 
occurring at 250-400 oC for all three PEGylated polypeptoids and then a gradual decrease of mass 
loss from 400-500 oC. The decomposition temperature (Td) of the three polymers was higher than 
250oC and thus temperature window (-50oC-200oC) was selected for DSC analysis. The respective 
DSC thermograms of the second heating cycle were showed in Figure 3.38 and 3.39. The absence 
of melting peak and crystallization exotherm peak revealed that all the three PEGylated 
polypeptoids (Mn = 3.26-16.9 kg/mol) are amorphous, in agreement with the previously reported 
oligomeric PEO-mimetic peptoids.55 The glass transition temperature (Tg) as determined by the 
inflection on the slope of heat flow shifting are shown in Table 3.2. The Tg values of the PEGylated 
polypeptoids decreased with increasing the length of ethylene oxide side chains (PNMeOEtG (Tg 
= 24.5 – 46.4 oC) > PNMe(OEt)2G (Tg = -6.0 – -16.9
 oC)  > PNMe(OEt)3G (Tg = -34.9 – -41.1
 oC)), 
which is consistent with the previously reported observations for oligomers.55 
The Tg values observed for all the peglated polypeptoids were significantly lower than the 
amorphous PNMG (127-143oC) and PNEG (93-114 oC) with comparable MW.56. The Tg values 
of the polymer increased with the increase of MW, in consistence with other reported 
observations,57 which is attributed to the reduction of free volume due to diminished chain end 
contents at increasing molecular weight.58 The Tg of PNMeOEtG20 (Tg = 24.5 
oC, PDI = 1.09) 
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synthesized by ROP was about 14oC lower than the corresponding 20 mer (Tg = 38.6 
oC, PDI < 
1.0003) synthesized by solid phase “submonomer” method,55 probably due to the larger PDI of the 
former polymer that increased the flexibility of the polymer chains. The discrepancy is presumably 
resulted from the difference in end-group structures and polydispersity of the samples. As the 
chains are relative short, end-group structural different will contribute significantly to a difference 
in free volume and thus Tg. The polymeric sample contains a mixture of chains that are shorter or 
longer than 20 mer in varying amounts, which will have different Tgs due to free volume 
difference.  
Table 3.1. BnNH2-initiated ROP of MeOEt-NCA (M1), Me(OEt)2-NCA(M2) and Me(OEt)2-
NCA(M3).a 
PNMeOEtG 






SECb NMRc 24 100 
1 25:1 2.98 3.26 3.09 1.10 24 100 
2 50:1 5.86 6.26 6.32 1.08 24 100 
3 100:1 11.6 11.1 12.4 1.05 48 100 
4 200:1 23.1 17.0 24.6 1.04 48 100 
5 400:1 46.1 24.8 - 1.04 24 100 
PNMe(OEt)2G 
1 25:1 4.08 4.03 4.24 1.06 24 100 
2 50:1 8.06 8.57 8.69 1.09 24 100 
3 100:1 16.0 13.5 16.3 1.03 48 100 
4 200:1 31.9 18.9 33.9 1.04 48 100 
5 400:1 63.7 26.8 - 1.05 24 100 
PNMe(OEt)3G 
1 25:1 5.18 5.29 5.18 1.07 24 100 
2 50:1 10.3 9.34 11.7 1.05 24 100 
3 100:1 20.4 16.9 21.6 1.07 48 100 
4 200:1 40.7 28.2 41.3 1.06 48 100 
5 400:1 81.3 28.6 - 1.08 24 100 
 
aAll the polymerizations were conducted in THF at 50oC with [M]0=1M. SEC analysis were 
conducted by directly injecting the polymerization solutions into SEC column after reaching 100% 
conversion. bDetermined from a tandem SEC-MALS-DRI system using dn/dc 0.0633(4) mL/g for 
PNMeOEtG, 0.0686(8) mL/g for PNMe(OEt)2G and 0.0563(6) mL/g for PNMe(OEt)3G in 0.1 M 
LiBr/DMF at room temperature. cDetermined by 1H NMR end-group analysis. Entry 4: the BnNH2 
content is too low to be accurately integrated and therefore the Mn cannot be reliably determined 




Figure 3.36. (A) MALDI-TOF MS of PNMeOEtG (PDI = 1.07-1.11) at different polymerization 
conversion. (B) Plots of Mn and PDI verses conversion for BnNH2 initiated polymerization of 
MeOEt-NCA in THF ([M]0:[I]0=50:1, [M]0 =1 M). (C) Plots of ln ([M]/[M]0) versus the reaction 
time for BnNH2 initiated polymerization of Me(OEt)n-NCA (n=1-3) ([M]0:[BnNH2]=25:1, 




Figure 3.37. (A,B) MALDI-TOF MS of PNMe(OEt)nG (n=2-3) at different polymerization 
conversion in THF ([M]0:[I]0=50:1, [M]0 =1 M).: (A) PNMe(OEt)2G and (B) PNMe(OEt)3G .  
(C,D) Plots of Mn and PDI verses conversion for BnNH2 initiated polymerization of Me(OEt)n-
NCA (n=2-3): (C) Me(OEt)2-NCA and (D) Me(OEt)3-NCA. 
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Figure 3.38. (A) Thermogravimetric analysis of PNMeOEtG58. (B) DSC thermograms of 
PNMe(OEt)nG (n=1-3). (C) DSC thermograms of PNMeOEtG at different MW during the second 
heating cycle. (D) Plot of Tg verses Mn of PNMe(OEt)nG (n=1-3). The DPns listed in the figures 









Figure 3.39. Thermogravimetric analysis of PNMe(OEt)2G (A) and PNMe(OEt)3G (B); DSC 
thermograms of PNMe(OEt)2G (C) and PNMe(OEt)3G (D) at different MW during the second 
heating cycle. 
 
Table 3.2. Tg of PNMe(OEt)nG (n=1-3) at different MW.  
 















3.3.2 Protein adsorption investigation on PNMeOEtG by DLS analysis 
As the PEGylated polypeptoids are highly water soluble, charge neutral and have hydrogen 
bond acceptor both on the backbone and side chains, which fulfill all the criteria of the abovementi- 
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Figure 3.40. DLS analysis of 1wt% PNMeOEtG106 in PBS (A, C) Hydrodynamic size 
distribution, (B) correlograms and (D) derived count rates up to 24 h. 
oned “whitesides rule” for protein-resistant materials, we hypothesized that the PEGylated 
polypeptoids may display antifouling property. PNMeOEtG was selected as the model polymer to 
study the protein resistant characteristics of the PEGylated polypeptoids. DLS was used to monitor 
the size change of PNMeOEtG, protein (lysozyme) and their mixture in PBS. Lysozyme was 
selected here as the protein due to their comparable size with PNMeOEtG. Increased 
hydrodynamic size would be expected for the mixture of lysozyme and PNMeOEtG in PBS if 
appreciable amount of lysozyme was absorbed to the polymer chains. Both the PNMeOEtG and 
lysozyme at 1wt% in PBS showed no apparent aggregation up to 24 h investigated based on their 
hydrodynamic size distribution, correlograms and derived count rates (Figure 3.40-3.41). The 
mixture of 1wt% lysozyme and 1wt% PNMeOEtG in PBS revealed no obvious hydrodynamic size  
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Figure 3.41. DLS analysis of 1wt% lysozyme in PBS (A, C) Hydrodynamic size distribution, (B) 
correlograms and (D) derived count rates up to 24 h. 
increase up to 24 h investigated (Figure 3.42). Furthermore, the hydrodynamic size (dh =5.56 ± 
0.16 nm), derived count rates and correlograms of the mixture lies in between that of 1wt% 
PNMeOEtG (6.39 ± 0.09 nm) and 1wt% lysozyme (4.69 ± 0.25 nm) in PBS, indicating there is no 
apparent adsorption of lysozyme onto polymer chains (Figure 3.43). For comparison purposes, 
PEG, a well-known antifouling material, was selected as a positive control to be investigated by 
DLS analysis. Similarly, the hydrodynamic size (dh = 5.48 ± 0.10 nm), derived count rates and 
correlograms of the mixture also lies in between that of 1wt% PEG8000 (5.84 ± 0.40 nm) and 
1wt% lysozyme (4.69 ± 0.25 nm) in PBS (Figure 3.44), which further supported our hypothesis 
that no appreciable adsorption of lysozyme was absorbed onto polymer chains.  
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Figure 3.42. DLS analysis of mixture of 1wt% lysozyme and PNMeOEtG106 in PBS: 
hydrodynamic size distribution (A, C), correlograms (B) and derived count rates (D) up to 24 h.  
 
Figure 3.43. DLS analysis of mixture of 1wt% PNMeOEtG106, 1wt% lysozyme, 1wt% lysozyme 
and 1wt% PNMeOEtG106 in PBS: hydrodynamic size distribution (A) and derived count rates (B) 




Figure 3.44. DLS analysis of mixture of 1wt% PEG8000, 1wt% lysozyme, 1wt% lysozyme and 
1wt% PEG8000 in PBS: hydrodynamic size distribution (A) and derived count rates (B) up to 24 
h; hydrodynamic size distribution (C) and correlograms (D) at 5h. 
 
3.3.3 Protein adsorption investigation on PNMeOEtG by SANS analysis 
To further support our hypothesis, the interaction between PNMeOEtG and lysozyme was 
investigated by small angle neutron scattering (SANS) studies in D2O. The data presented in Figure 
3.45 is after background subtraction of the buffer solvent in D2O. 
Figure 3.45(a) represents the SANS diffraction data for the Lysozyme at pH 7.0 and 7.4. 
The structure factor at low Q, 𝑆(𝑄 = 0), is proportional to the osmotic compressibility and it 
decreases with increase in concentration (𝜙). In addition, 𝑆(𝑄) shows a peak at small angles that 
is related to the average distance between the neighbouring molecules.  
Interestingly we saw the evolution of the structure factor with lowering of the pH value. 
Following equation (1) at pH 7.4 the data was modelled using a hard sphere form factor (𝑆(𝑄) =
1)59, whereas the data at pH 7.0 was modelled using a hard sphere (HS) form factor and a structure 
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Figure 3.45. SANS diffraction pattern: (a) lysozyme in buffer for different pH values (b) 
comparison of the scattering pattern among lysozyme, polymer (PNMeOEtG) and 1:1 lysozyme – 
polymer mixture. The solid lines are the fits using equation (1) as explained in the text. 
 
factor (Percuss Yevick approximation)49-50. The solid blue line is the calculated form factor from 
the atomic coordinates of the lysozyme60-61. It should be noted that the modelled form factor is in 
good agreement with that calculated from the atomic coordinates of the lysozyme. The small 
discrepancy is attributed to the concentration effect. The HS form factor for the lysozyme yields a 
radius of, RL = 1.750.01 nm which is in agreement with that obtained from the literature 
62. 
However we do not find difference in size while modelling with an ellipsoidal form factor 60. The 
contrast in water is calculated, ∆𝜌 ~ 2.6 1010 cm-2, for the density of 1.32 g/cm3 63. In Figure 3.45 
(a) the highlighted box shows an increase in scattering, that illustrates the formation of clusters or 
aggregates. It results from the attractive interaction between the lysozyme molecules. However, 
the HS S(Q) interaction radius yields, RC = 4.850.02 nm, which is ~ 2.8 times larger than RL. 
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This point towards the fact that the formation of equilibrium clusters as a result of lowering of the 
pH value (from 7.4 to 7.0) is responsible for the structure factor peak in Figure 3.45 (a). Formation 
of dynamic clusters was also reported by Shukla et al. 60 where the S(Q) peak position was found 
to be independent of concentration for lysozyme molecules. The strong repulsive interaction 
between the clusters causes a sharp decrease in the overall forward scattering, 
𝑑Σ
𝑑Ω
(𝑄 → 0), that is 
manifested as a structure factor (interaction) peak. The interaction peak reveals the distance 
between the clusters (~ 2RC) but not the individual lysozyme molecules. Our studies also point to 
the fact that formation of such clusters might be related to the change in the pH or the surface 
charge density of the lysozyme molecules.  
In Figure 3.45 (b) a comparison of the SANS diffraction pattern for a mixture of lysozyme 
and PNMeOEtG polymer is presented. For the pure polymer the form factor was modelled using 
a Debye function that resembles a random Gaussian coil 51 in equation (1) for, 𝑆(𝑄) = 1. It yields 
a radius of gyration, Rg = 2.620.02 nm. The corresponding open square data, represents 1:1 
mixture of the polymer and the lysozyme in a pH 7.4 buffer solution. We can model the data simply 
by calculating 1:1 ratio of the scattering pattern obtained from the Debye function for the polymer 
and the HS form factor for the lysozyme. This univocally point out the fact that there is no 
interaction between the polymer and the lysozyme. The resulting scattering curve is a mere sum 
of the individual scattering pattern. The small discrepancy of the modelled line for the mixture at 
high Q (> 0.26 Å-1) is due to the absence of correct resolution data for the lysozyme solution. It 
should be noted that these are in contrast to the previous study on hemoglobin protein interaction 
with polyethylene oxide (PEO), where a marked increase in interaction was observed64. 
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3.3.4 Cytotoxicity 
The cytotoxicity study was investigated in HEp2 cells, and the result was shown in Figure 
3.46. PEG (8000 Da), a gold standard for antifouling material, is used as a positive control. The 
PNMeOEtG of different molecular weight (3.26-11.1 kg/mol) showed minimal toxicity (cell 
viability > 90 %)  towards HEp2 cells up to concentration of 1mg/mL investigated, which is critical 
for them to be used as biomaterials in biomedical and biotechnological fields.  
 
Figure 3.46. Cell viability study of PNMeOEtG polypeptoids compared to PEG (8000 Da). 
3.4 Conclusions 
N substituted N-carboxyanhydride monomers bearing oligomeric ethylene glycol side 
chains (Me(OEt)n-NCA, for the first time, were successfully synthesized with moderate yields. 
PEGylated polypeptoids (PNMe(OEt)3G, n=1-3) were successfully synthesized by BnNH2-
initiated ring-opening polymerization of the corresponding monomers with controlled molecular 
weight ([M]0:[I]0 < 200:1) and narrow molecular distribution (PDI=1.03-1.10). Kinetic studies 
revealed a pseudo-first order dependence on the monomer concentration (i.e., d[M]/dt = kobs [M]), 
consistent with a living polymerization. The resulting PEGylated polypeptoids are hydrophilic 
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both on the polymer backbone and side chain with good water solubility (>200 mg/ml). Similarly 
to the previously reported PEO-mimetic oligomers (20 mer), the PEGylated polypeptoids are 
amorphous and the glass transition temperature (Tg) is increased with decreasing side chain length: 
PNMe(OEt)3G (Tg = -34.9 – -41.1
 oC) < PNMe(OEt)2G (Tg = -6.0 – -16.9
 oC) <PNMeOEtG (Tg = 
24.5 – 46.4oC). The glass transition temperature (Tg) of the PEGylated polypeptoids is also 
increased with increasing of molecular weight investigated. The preliminary DLS results showed 
that the PNMeOEtG remained fully hydrated without apparent aggregation in PBS buffer for more 
than one month and no obvious hydrodynamic size increase was observed for the mixture of 
lysozyme and PNMeOEtG up to 24 h based on dynamic light scattering (DLS) analysis. The 
preliminary small angle neutron scattering (SANS) analysis of lysozyme, PNMeOEtG, and 
mixture of lysozyme and PNMeOEtG in D2O revealed no appreciable interaction between 
lysozyme and PNMeOEtG, indicating minimum adsorption of lysozyme to PNMeOEtG. The 
SANS structure factor analysis has pointed out a sharp increase in repulsive interaction with the 
change in pH content of the buffer that results in equilibrium cluster formation. In addition, the 
polypeptoids at different MW showed minimum cytotoxicity towards HEp2 cells. All of these 
results suggest the PEGylated polypeptoids a potential antifouling material for the biomedical and 
biotechnological application. 
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 : SOLUTION SELF-ASSEMBLY OF COIL-CRYSTALLINE 
DIBLOCK COPOLYPEPTOIDS (PNMG-b-PNDG) 
 
4.1 Introduction 
The solution self-assembly of amphiphilic coil-crystalline AB diblock copolymers has 
attracted growing interest recently; however, the theoretical and experimental studies on their 
solution equilibrium morphologies are limited so far. Studies have shown that a variety of 
unconventional micellar morphologies (e.g., cylindrical1-2, discal3, tape-like4, platelet micelles5-6) 
can be obtained by the solution self-assembly of amphiphilic coil-crystalline AB diblock 
copolymers. Recently, we have shown that both linear and cyclic diblock copolypeptoids (c/l-
PNMG-b-PNDG) self-assembled into spherical micelles that reorganized into long cylindrical 
micelles with uniform diameter in methanol, which was driven by the crystallization of the 
crystalline PNDG domain (section 1.3.3).7 At higher concentrations in methanol (5-10 wt%), both 
cyclic and linear diblock copolyeptoids (c/l-PNMG-b-PNDG) were shown to form free-standing gels 
consisting of entangled fibrils at room temperature.8 
Following our previous studies, we have synthesized a series of linear amphiphilic 
crystalline-coil diblock copolypeptoids (i.e., l-PNMG-b-PNDG and l-PNMG-b-PNBG) having 
well-controlled degree of polymerization but different compositions by sequential benzyl amine-
initiated ROPs of the corresponding N-substituted N-carboxyanhydrides (Me-NCA, De-NCA and 
Bu-NCA).The preliminary study of the copolypeptoid composition effect on their solution 
morphologies was conducted.  
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4.2 Experimental  
4.2.1 Synthesis and characterization of diblock copolymers  
All the crystalline-coil AB diblock copolypeptoids were synthesized by primary amine-
initiated ring-opening polymerization of the corresponding N-substituted N-carboxyanhydrides 
(R-NCAs) in a sequential manner. A representative procedure for the synthesis of l-PNMG-b-
PNDG was presented. In the glovebox, Me-NCA ([M1]) (87.2 mg, 0.76 mmol, [M1]0=0.4 M) was 
dissolved in anhydrous acetonitrile. Stock solution of benzyl amine in acetonitle (82 µL, 92.7 mM, 
[M1]: [BnNH2]0=100:1) was added. The reaction mixture was stirred at room temperature for 16 h 
to reach a complete conversion of polymerization. Acetonitrile solution of De-NCA ([M2]) (189 
µL, 0.4 M, 0.076 mmol, [M1]0:[M2]0: [BnNH2]0=100:10:1) was added to the above mixture and 
allowed to stir at 50oC for another 24 h to reach a full conversion. The polymer solution was dried 
under vaccume and re-dissolved in DCM followed by addition of excess hexane to precipitate out 
the polymer. The polymer was collected by filtration and washed with ample hexane followed by 
drying under vacuum to afford white solid (55.8 mg) in 81.2% yield. The molecular weights (Mns) 
were determined by end-group analysis using 1H NMR spectroscopy.  
4.2.2 Self-assembly of diblock copolypeptoids 
The diluted solutions of diblock copolypeptoids (l-PNMG130-b-PNDG70, l-PNMG114-b-
PNDG89, l-PNMG125-b-PNDG117, PNMG105-b-PNBG115) were prepared by dialysis method due to 
their limited solubility in MeOH: the diblock polymers were dissolved in DCM at 1.0 mg/mL 
concentration followed by dialysis against MeOH for 7days. The resulting solutions were heated 
at 70-80oC, above the side chain melting point of PNDG, for 1h and slowly cooled down to room 
temperature. All the dilute solutions of other diblock copoypeptoids were prepared by directly 
dissolving in MeOH at 1.0 mg/ml and heated at 70oC for 1h followed by slowly cooling down to 
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room temperature. The prepared dilute solutions of diblock copolypeptoids were characterized by 
DLS and TEM analysis at different time intervals.  
4.2.3 DLS measurement of dilute polymer solutions  
Polymer solution in MeOH (1.0 mg/mL) was filtered through a 0.22 µm filter and heated 
at 70-80 oC for 1 h followed by slowly cooling down to room temperature. The polymer solution 
was characterized by DLS at different time intervals. All the DLS measurements were conducted 
using Malvern Zetasizer Nano-zs (Zen3600). The He-Ne laser operating at 633 nm was utilized, 
and scattered light intensity was detected at an external angle of 173 oC using non-invasive 
backscatter (NIBS) technology. Data from three measurements with 12 scans for each 
measurement was recorded. At each temperature, the sample was equilibrated for 3 min.  
4.2.4 TEM/cryo-TEM analysis of dilute polymer solutions 
Polymer solution in MeOH (1.0 mg/mL) was filtered through a 0.22 µm filter and heated 
at 70-80 oC for 1 h followed by slowly cooling down to room temperature. The polymer solution 
was stored at room temperature for 3 d. FEI Vitrobot was used for the sample preparation of cryo-
TEM experiment. 5 µL of the above polymer solution in MeOH (1 mg/mL) was applied to a 300 
mesh lacey carbon coated TEM grid. Double side blotting to the grid for 2 seconds leaves a thin 
film on the grid. The grid then was quickly plunged into liquid ethane chilled by liquid nitrogen. 
The vitrified sample grid was loaded in a single tilt liquid nitrogen cryo transfer holder, and was 
then inserted to FEI G2 F30 Tecnal TEM operated at 120keV, with a FEI digital camera and 
analyzed using FEI Digital Micrograph software. The grids for the regular TEM was prepared by 
adding 5 µL of the above polymer solution in MeOH (1mg/mL) onto the 300 mesh carbon grid 
followed by blotting with a filter paper and drying at room temperature. The grids then were 
stained with uranyl acetate for 1 min. 
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4.3 Results and discussion 
4.3.1 Synthesis and characterization of AB diblock copolypeptoids 
A series of linear AB diblock copolypeptoids (l-PNMG-b-PNDG and l-PNMG-b-PNBG) 
have been synthesized by benzyl amine-initiated ROP of the corresponding R-NCAs in a 
sequential manner (Scheme 4.1). The compositions of the AB diblock copolypeptoids were 
determined by 1H NMR spectroscopy (Table 4.1, Figure 4.1 and 4.2). For example, the number-
averaged degree of polymerization (DPn) of l-PNMG-b-PNDG (l-AB) was determined by the 
integrations at 2.89-3.04 ppm and 0.91 ppm due to the methyl protons in the PNMG block and the 
methyl protons in the PNDG block relative to the integration of the benzyl end-group signals at 
7.31 ppm. The compositions of the AB diblock copolypeptoids can be well tuned by controlling 
the initial monomer to initiator ratio ([M]0:[BnNH2]0). The volume fraction of the PNDG block 
was systematically varied in the 0.27-0.79 range. The l-PNMG-b-PNDG diblock copolymers were 
not suitable for size exclusion chromatographic (SEC) analysis using LiBr/DMF and THF due to 
their limited solubility in these solvents. The molecular weights (Mns) determined by 
1H NMR 
spectroscopy were comparable to the theoretically predicted values, as shown in table 4.1. 





Figure 4.1.1H NMR spectrum of l-PNMG99-b-PNDG9 in CD2Cl2. 
 
 






Table 4.1. Molecular parameters of AB diblock copolytoids. 
Entry aSample b[M]1:[M]2:[I]0 
Φ PNDG eMicelle 
Sturcture 
fDiameter 






















































































aThe actual DPn was determined by 
1H NMR. bTheoretical monomer to initiator ratio cTheoretical 
volume fraction of PNDG using the known density of PNMG (1.405 g/cm3) and PNDG (0.95 
g/cm3). dActual volume fraction of PNDG determined by 1H NMR. eEntry 6,7,8 and 15 were 
prepared by dialysis method and other entries were prepared by direct dissolving method at 
1mg/ml in MeOH. fAverage diameter of more than 30 individual micelles from TEM. The error 
bar is the standard deviation of the measured diameters. gThere is no large aggregation formed 
from DLS results.  
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4.3.2 Solution self-assembly of AB diblock copolypeptoids  
Self-assembly of l-PNMG-b-PNDG in MeOH. To investigate the effect of polymer 
compositions on the self-assembled morphology of l-PNMG-b-PNDG in MeOH, the self-
assembly of l-PNMG-b-PNDG bearing constant chain length of PNMG block (targeted DPn = 100) 
while different chain length of PNDG block (Φ PNDG = 0.27-0.62) were investigated by 
transmission electron microscopy (TEM) using uranyl acetate as the staining reagent, as shown in 
Figure 4.3 (A-F). At 3 d, cylindrical micelles were observed for all the three samples, l-PNMG99-
b-PNDG9, l-PNMG90-b-PNDG17 and l-PNMG92-b-PNDG37. The cylinder like structures of sample 
l-PNMG92-b-PNDG37 were also confirmed by cryo-TEM, as shown in Figure 4.3 (G,H). For 
sample PNMG90-b-PNDG17 with longer PNDG block length, cylindrical micelles with larger 
diameters were observed, probably due to the aggregation of individual cylindrical micelles during 
the TEM preparation process, as evidenced by the cryo-TEM images of the micelles showing no 
aggregation of individual micelles (Figure 4.4). The diameters of the individual micelles in Figure 
4.3 (A-F) (average of at least 50 micelles) were measured for these three samples: d (PNMG99-b-
PNDG9) = 12.6 ± 0.8 nm, d (PNMG90-b-PNDG17) = 13.0 ± 0.9 nm and d (PNMG92-b-PNDG37) = 
13.4 ± 1.8 nm. It is interesting that the diameter of the cylindrical micelles formed by PNMG99-b-
PNDG9 well matched the diameter of a zig-zag conformation of a fully stretched PNDG segment, 
whereas the diameters of the cylindrical micelles formed by PNMG90-b-PNDG17 and PNMG92-b-
PNDG37 were much smaller than the theoretically predicated diameter assuming the PNDG was 
fully stretched, indicating that the PNDG micellar core adopted a chain folded structure.  
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Figure 4.3. TEM images of dilute solutions of l-PNMG99-b-PNDG9 (A, B), l-PNMG90-b-PNDG17 
(C, D), and l-PNMG92-b-PNDG37 (E, F) in MeOH after 3 d. The samples were prepared by direct 
dissolution method and stained with uranyl acetate. Cryo-TEM images of dilute solutions of l-
PNMG92-b-PNDG37 (1mg/mL) in MeOH after 3 d (G,H). 
 
 
Figure 4.4. Cryo-TEM images of dilute l-PNMG90-b-PNDG17 solution in MeOH at 3 d.  
To investigate the effect of different sample preparation method on micelle morphology, 
solution of l-PNMG92-b-PNDG37 in MeOH (1mg/mL) prepared by dialysis method was also 
analyzed by TEM. As shown in Figure 4.5, longer cylindrical micelles (d = 12.6 ± 1.0 nm) were 
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formed by dialysis method compared to that formed by direct dissolution method (Figure 4.3 G,H), 
probably due to the slow diffusion of MeOH in the dialysis method that allow the micelles to 
crystallize slowly.  
 
Figure 4.5. TEM images of dilute solutions of l-PNMG92-b-PNDG37 in MeOH prepared by dialysis 
method. The sample was stained with uranyl acetate prior to TEM imaging.  
The self-assembly of the diblock copolypeptoids (l-PNMG-b-PNDG) with constant total 
chain length (targeted DPn = 220) while different volume fraction ratio of PNMG and PNDG (Φ 
PNDG = 0.46-0.79), were also investigated in MeOH. Miceller solutions of l-PNMG168-b-PNDG35 
and l-PNMG145-b-PNDG52 were prepared by direct dissolution in MeOH, whereas miceller 
solutions of l-PNMG130-b-PNDG70, l-PNMG114-b-PNDG89 and l-PNMG125-b-PNDG117 were 
prepared by dialysis method due to their higher hydrophobicity and limited solubility in methanol. 
All the samples formed cylinder-like structures in MeOH at 3 d (Figure 4.5). The core of the 
cylindrical micelles were more likely to adopt a chain folded structure, as evidenced by the average 
diameters of the individual cylindrical micelles (d = 12.9 ± 1.0 – 29.0 ± 4.5 nm) which were much 
smaller than the theoretically predicated value assuming the PNDG core adopted a fully stretched 
conformation. Sample l-PNMG125-b-PNDG117 was too hydrophobic that precipitation occured 
151 
after dialysis against MeOH and sheet-like structure was observed of the suspension under TEM 
(Figure 4.6). 
 
Figure 4.6. TEM images of dilute solutions of l-PNMG168-b-PNDG35 (A), PNMG145-b-PNDG52 
(B), PNMG130-b-PNDG70 (C) and PNMG114-b-PNDG89 (D). (A) and (B) were stained with uranyl 
acetate, whereas (C) and (D) were not.  
 
Figure 4.7. TEM images of l-PNMG125-b-PNDG117 in MeOH stained with uranyl acetate.  
The self-assembly of the polymers was also monitored by DLS for l-PNMG168-b-PNDG35 
and l-PNMG145-b-PNDG52.in dilute methanol solution (1.0 mg/mL) at room temperature. For 
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sample l-PNMG168-b-PNDG35 (Figure 4.7 A), two size distribution peaks were observed after 
immediately dissolution in MeOH, which was tentatively attributed to the spherical micelles and 
short cylinders formed at the beginning. The peaks shifted to larger size with increasing time, 
indicating the formation of longer cylinders, consistent with the TEM results (Figure 4.5). For 
sample l-PNMG145-b-PNDG52 of higher PNDG volume fraction (Φ PNDG = 0.60), monomodel 
size distribution was observed at all time investigated (from t=0 to t=10d) (Figure 4.7B), probably 
due to the “freezed morphology” of short cylinders as shown in TEM (Figure 4.5).   
 
Figure 4.8. DLS-determined hydrodynamic size distribution of 1.0 mg/mL PNMG168-b-PNDG35 
and 1.0 mg/mL PNMG145-b-PNDG52 in methanol at room temperature.  
Self-assembly of l-PNMG-b-PNBG in MeOH. Cylindrical micelles were observed in 
MeOH under TEM in a wide composition window (Table 4.1 and Figure 4.8). The crystallization 
of the solvophobic PNDG block including both main chain and side chain crystallization, was 
expected to drive the formation of cylindrical micelles. To support our hypothesis, l-PNMG-b-
PNBG polymers where the PNBG blocks only undergo main chain crystallization were 
synthesized and their solution self-assembly in MeOH was compared with that of l-PNMG-b-
PNDG. As expected, no evidence of cylindrical micelle formation for l-PNMG-b-PNBG polymers 
at the entire compositions range, as indicated by the lack of large particle formation over time from 
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DLS analysis. Representative DLS measurement (Figure 4.9A and B) indicated that diameters of 
micelles formed by PNMG205-b-PNBG60 and PNMG163-b-PNBG65 remained almost constant (< 10 
nm) over time, indicating no large aggregates formed. No cylindrical micelles were observed under 
TEM for sample PNMG105-b-PNBG115 with the highest volume fraction of PNBG block in room 
temperature MeOH at 1.0 mg/mL (Figure 4.9C). The results were consistent with the observation 
that no gel was formed for PNMG105-b-PNBG45 at 20 wt% in MeOH at room temperature over a 
period of two months.  
 
Figure 4.9. Composition-solution morphology diagrams for (A) l-PNDG-b-PNMG and (B) l-
PNBG-b-PNMG in 1.0 mg/mL MeOH solution at room temperature. NA: DPn of PNMG; NB: DPn 
of PNDG or PNBG. The non-cylindrical region in (B) is determined by DLS analysis.  
 
 
Figure 4.10. DLS-determined hydrodynamic size distribution of (A) PNMG205-b-PNBG60 and (B) 
PNMG163-b-PNBG65 in MeOH at room temperature. (C) TEM images of dilute solution of 
PNMG105-b-PNBG115 in MeOH stained with uranyl acetate.  
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4.4 Conclusion and future work 
A series of amiphiphilic coil-crystalline l-PNMG-b-PNDG and l-PNMG-b-PNBG diblock 
copolypeptoids were synthesized by ROP of the corresponding monomers. l-PNMG-b-PNDG 
formed cylindrical micelles in MeOH in a wide composition window (Φ PNDG = 0.27-0.79). By 
contrast, l-PNMG-b-PNBG bearing shorter alkyl side chains in the solvophobic segment than that 
in l-PNMG-b-PNDG showed no evidence of cylindrical micelle formation based on DLS and TEM 
analysis. TEM analysis revealed that the cylindrical micelles formed by l-PNMG99-b-PNDG9 with 
short PNDG block (Φ PNDG = 0.27) appears to adopt a core of fully stretched PNDG chains, 
while the micellar core of all other l-PNMG-b-PNDG polymers were likely to adopt a chain folded 
conformation. To further investigate the driving force of the cylindrical micelle formation of the 
coil-crystalline diblock copolypeptoids (l-PNMG-b-PNDG) in methanol, l-PNMG-b-PNEHG 
with the hydrophobic block PNEHG having no side chain crystallization will be synthesized and 
its solution self-assembly in methanol will be investigated. A systematic study on how the polymer 
composition, architecture and crystalline packing affect the morphology of crystalline-coil block 
copolymers in dilute solution is currently in progress. The solution morphologies will be fully 
characterized by, TEM/crto-TEM, S/WAXS, and SANS methods to determine the micellar 
structure and the crystalline packing in the micellar core.  
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 : INTRODUCTION TO DIPYRROMETHENES (BODIPYS) 
AND BORON NEUTRON CAPTURE THERAPHY (BNCT)  
5.1 Introduction to BODIPYs 
5.1.1 Synthetic methodologies of BODIPYS 
Boron dipyrromethene (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene), abbreviated as BODIPY 
(Figure 5.1), has been considered as a versatile fluorophore dye in the last three decades.1 BODIPY is 
formed by boron complexation of a dipyrromethene with boron trifluoride diethyl etherate (BF3O 
(CH2CH3)2), leading to a rigid tricyclic system usually associated with narrow absorption and emission 
spectra and high fluorescence quantum yields.2 
 
Figure 5.1. Structure of BODIPY fluorophore and its IUPAC numbering system.  
Since the first BODIPY reported by Treibs and Kreuzer in 19683, numerous BODIPYs have 
been synthesized using several following strategies. The first synthetic approach (Scheme 5.1), which 
usually is used to build symmetrical BODIPYs, involves the acid-catalyzed condensation between α-
free pyrroles (1) and various aldehydes (2)4. The resulting dipyrromethanes (5) were further oxidized 
to corresponding dipyrromethenes (6) using dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) followed 
by complexation with boron trifluoride diethyl etherate (BF3·OEt2) under basic conditions to afford 
the desired BODIPYs (7). Additionally, the condensation can also be achieved between α-free 
pyrroles (1) and acyl chloride (3)5, or anhydride (4)6 to directly yield the dipyrromethene (6) followed 
by deprotonation with base (e.g., triethylamine) and boron complexation to afford the symmetrical 
BODIPYs (7). As shown in Scheme 5.2, the second method7, which generally is used to approach both 
157 
symmetrical and unsymmetrical BODIPYs, involves the acid catalyzed condensation of 2-acetyl 
pyrroles (8) and an α-free pyrroles (9) followed by oxidation with DDQ to provide the corresponding 
dipyrromethenes (11). Subsequent complexation of 11 with BF3·OEt2 provides symmetrical or 
unsymmetrical BODIPYs (12). The third method (Scheme 5.3)8 is usually used to synthesize meso-
unsubstituted symmetrical BODIPYs. It involves the condensation between two identical α-
formylpyrroles (13) catalyzed by POCl3 to produce the corresponding dipyrromethenes (14), 
followed by boron complexation to afford desired BODIPYs (15). One advantage of this method is 
that it can afford higher yields in comparison with the first method.  
A new synthetic method (Method 4, Scheme 5.4), using dipyrro (thio) ketone, to synthesize 
symmetrical or unsymmetrical BODIPYs, has been developed and investigated in recent years.9-15 The 
dipyrrothioketone precursors can be obtained from the condensation between α-free pyrroles (16) and 
thiophosgene (CSCl2), further treated with CH3I, organic base, and BF3·OEt2 to obtain meso-thioester 
BODIPYs (18), or treated with KOH/H2O2 to yield dipyrroketones (19).
9 Alternatively, dipyrroketones 
(19) can also be synthesized using Pb(OAc)4/PbO2 oxidation of dipyrromethanes, which can be 
prepared by condensation of readily available 2-methyl pyrroles (21) in the presence of bromine, 
followed by DDQ oxidation.11 Another alternative way to synthesize both symmetrical (19) or 
unsymmetrical dipyrroketones (25) is via a reaction between α-(N,N-dimethyl-amido) pyrroles (24) 
in the presence of POCl3, followed by hydrolysis with aqueous sodium acetate.
13-15 Oxidative 
halogenation using POX3 (X = Cl or Br) or phosgene (COCl2) of the dipyrroketones (19 and 25), 
followed by deprotonation with base and complexation with BF3·OEt2 yields the corresponding 





Scheme 5.1. The first synthetic method of symmetric BODIPYs.  
 
 
Scheme 5.2. The second synthetic method of symmetrical or unsymmetrical BODIPYs.  
 
 
Scheme 5.3. The third synthetic method of symmetrical BODIPYs with meso position unsubstituted.  
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Scheme 5.4. The fourth synthetic method of symmetrical and unsymmetrical BODIPYs.  
 
5.1.2 Functionalization of BODIPYs 
To synthesize versatile BODIPYs for different applications, different methodologies have 
been developed to introduce various functional substituents to the BODIPY skeleton. The 
convention method, the so-called pre-functionalization, is to develop various pyrrole precursors 
for the synthesis of BODIPYs as shown in Scheme 5.1-5.4. For example, five- or six-member ring 
cyclic anhydride can be used as the carbonyl source in Method 1 to introduce carboxylic acids at 
the meso position of BODIPYs.6 The carboxylic acid group can be activated with N-
hydroxysuccinimide (NHS) and N,N'-dicyclohexylcarbodiimide (DCC) for further conjugation 
with peptides or proteins.  
Scheme 5.5. Resonance structures of BODIPY. 
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As outlined in Scheme 5.5, the BODIPY skeleton have different resonance structures with 
carbons 1, 3, 5, 7 and 8 bearing more positive charge character, therefore is more electrophilic than 
carbons 2 and 6. Post-functionalization of BODIPYs can be realized by taking advantage of the 
different electrophilicity at different carbon positions to introduce different functional groups to 
BODIPYs.14  
Halogenated BODIPYs have emerged as a versatile platform for the post-functionalization 
of BODIPYs to introduce a variety of functionalities to the BODIPY core by both metal-catalyzed 
cross-coupling (e.g., Suzuki, Stille, Heck, and Sonogashira)16-17 and nucleophilic substitution 
reactions18-20.  
Halogenated BODIPYs can be prepared from halogenated precursor including halogenated 
pyrroles, dipyrromethanes and dipyrroketones, as shown in Scheme 5.4. Another alternative 
strategy to synthesize halogenated BODIPYs is to employ direct electrophilic substitution 
reactions at different positions of BODIPYs. As shown in Scheme 5.6. mono-, di-, tetra, 
hexabromo-BODIPYs were synthesized via regioselective electrophilic bromination of pyrrolic-
unsubstituted BODIPYs using bromine.21 The step-wise bromination first took place at 2,6-, then 
at 3,5-, and eventually at 1,7-positions, as confirmed by NMR and X-ray analysis. These 
polybrominated BODIPYs showed regioselectivity towards the nucleophilic aromatic substitution 
(SNAr) reaction and exhibited a decreasing reactivity order as followed: 3,5-bromo > 1,7-bromo > 
2,6-bromo. On the other hand, tetrabromo BODIPY exhibited a high reactivity towards Suzuki 





Scheme 5.6. Bromination of BODIPY.  
 
To increase the regioselectivity of the post-functionalization of halogenated BODIPYs, a 
pentachloro-BODIPY synthesized from meso-chloro-BODIPY (32) using TCCA/AcOH was 
reported recently (Scheme 5.7A).14 The regioselective chlorination reaction produced di-, tri-, 
tetra-, and pentachloro-BODIPYs in moderate to good yields. In this work, the pentachloro-
BODIPY 36 was shown to undergo regioselective Pd (0)-catalyzed Suzuki and Stille cross-
coupling reactions, first at the 8-position, followed by the 3,5- and then the 2,6-positions. The 
similar reactivity trend was also observed for the nuceophilic substitution reactions. To illustrate 
the versatility of BODIPY 36, multifunctionalization was performed on this BODIPY. 4-
Methoxylphenyl group was selectively introduced at the 8-position via a Suzuki coupling reaction, 
followed by a Stille coupling reaction to introduce the phenylethynyl groups at the 3,5-positions. 
The second Stille coupling reaction catalyzed by Pd(PCy3)G2 introduced the thienyl group at the 
2,6-positions to provide penta-coupled BODIPY 37 that absorbs and emits in the NIR region, as 




Scheme 5.7. Chlorination of meso-Cl-BODIPY (A) and multifunctionalization of penta-Cl-
BODIPY (B) 
 
Extending the above work, three-perhalogenated BODIPYs (40-1, 40-2, 40-3), bearing 
chloro and bromo groups at all carbon positions of the BODIPYs were synthesized recently from 
the corresponding chloro-BODIPYs (39-1, 39-2, 39-3) using bromine (Scheme 5.8). The 
regioselectivity of the BODIPY 40-3 was investigated at all carbon positions by using Stille cross-
coupling reactions and boron substitution reactions.15 The reactivity order of the halogens under 
these conditions is: 8-Cl ≈ 1,7-Br > 3,5-Cl > 2,6-Cl > 4,4’-F. It was also the first time to report the 
nona-functionalized BODIPYs.  
Scheme 5.8. Synthesis of perhalogenated BODIPYs.  
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5.1.3 Application of BODIPYs 
BODIPYs, featuring strong UV-vis absorbance and sharp fluorescence with high quantum 
yields, are relatively stable in the physiological environment, and also have high photostability. 
Moreover, the functionalizability of the halogen-BODIPYs in section 5.1.2 render them high 
tunability to approach various BODIPYs for different applications. Therefore, BODIPYs have 
shown growing interest in various applications such as biological imaging, biological labeling, 
drug delivery, and sensing.1, 22-24 For example, the 2,6-diiodo BODIPYs, were shown to be 
efficient photodynamic (PDT) sensitizers due to the enhanced quantum yield of singlet oxygen 
induced by the heavy atom effect.25  Also, a variety of fluorescent probes for Pd2+,26 and 
Cu2+,27could be prepared by substitution reactions between dihalo-BODIPYs and nuleophiles (e.g., 
azacrown) in high yields. 
5.2 Introduction to BNCT 
5.2.1 Mechanisms of BNCT 
BNCT is a promising binary anticancer therapy that selectively targets and destroys 
malignant tumor cells, while spare the damage to healthy normal cells.28-32 BNCT involves the 
irradiation of non-radioactive 10B-containing tumors with low-energy thermal or epithermal 
neutrons, produces excited 11B nuclei which spontaneously fission to give cytotoxic high linear 
energy transfer (high-LET) α and recoiling 7Li particles, along with γ radiation, and approximately 
2.4 MeV of kinetic energy (Figure 5.2). Low-energy epithermal neutrons are able to penetrate 8 
cm into tissues to reach deep-located tumors. The generated high-LET particles have short path 
lengths of 5-9 µM in tissue (about the diameter of a single cell), restricting the damage to 10B-
containing tumor cells. The biologically abundant nuclei 12C (0.0034 barn), 1H (0.33 barn), and 
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14N (1.8 barn) show negligible interference with the 10B (n,)7Li neutron capture reaction due to 
their much smaller nuclear cross sections in comparison with 10B. 
 
Figure 5.2. The 10B(n, α)7Li neutron capture and fission reactions 
BNCT has been used clinically for several decades in the treatment of various types of 
tumors including head and neck cancers, primary and metastatic melanomas, and high-grade brain 
tumors (e.g., glioblastoma multiforme, GBM).31, 33-34  
5.2.2 General criteria for BNCT agents 
Generally, an effective boron delivery drug for BNCT should display the following 
characteristics:28-32 1) deliver therapeutic amounts of 10B to tumor, estimated to be at least 20 μg/g 
tumor or approximately 109 atoms/cell), 2) high tumor-to-normal tissue and tumor-to-blood 
concentration ratios (> 5), 3) low systemic toxicity, 4) rapid clearance from blood and normal 
tissues while persisting in tumor during the irradiation treatment, and 5) easy quantification of 
tissue-localized boron. In addition, for brain tumor treatment, the BNCT drugs should be able to 
permeate across the blood-brain barrier (BBB), either by passive transmembrane diffusion or 
through targeting of transporters and receptors that are expressed at the BBB.35 The passive 
diffusion of compounds across cellular membranes and the BBB depends on various factors, 
including the compound’s lipophilicity, molecular weight, electrical charge, degree of ionization, 
hydrogen bonding ability, and intermolecular interactions.35-37 In general, low molecular weight 
(< 500 Da) boron delivery agents with favorable lipophilicity (octanol−water partition coefficient, 
log P <5) show enhanced passive diffusion across cellular membranes and the BBB.36-39 However, 
a major challenge in drug development for BNCT has been the selective delivery of therapeutic 
amounts of boron to tumor cells, with minimal toxicity to normal tissues. Another challenge in the 
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treatment of brain tumors is the often inefficient BBB permeability of the BNCT drugs. Over the 
last few decades, thousands of boron carriers for BNCT have been designed and synthesized, but 
only a few have been tested in pre-clinical trials. Among these, many are able to deliver higher 
amount of boron to tumors relative to the surrounding normal tissue, due to the so-called “enhanced 
permeability and retention (EPR) effect”. However, the selectivity of boron accumulation is often 
low, which can cause undesired toxic effects to healthy tissues. In order to improve the tumor 
selectivity of BNCT agents, their encapsulation into delivery agents, such as liposomes, and/or 
association with tumor-targeting moieties (e.g. peptides, folic acid, antibodies) has been explored. 
In addition, several administration methodologies and combination therapies have also been 
investigated. One very promising methodology that bypasses the BBB and enhances boron tumor 
uptake is convection-enhanced delivery (CED), a method for local drug infusion directly into 
brain. CED bypasses the BBB and is able to delivery high amounts of boron (>100 µg/g tumor) to 
intracerebral tumors, with very high tumor-to-blood and tumor-to-normal brain ratios.32, 40 More 
recently, another tumor treatment strategy designated magnetic drug targeting (MDT) has also 
been introduced.41 MDT uses an external magnetic field to direct boron-containing magnetic 
nanoparticles, administrated intraarterially, to tumor tissues. The MTD strategy is independent 
from molecular and biological recognition or passive accumulation, and allows selective 
accumulation of the drug. 
5.2.3 Main categories of BNCT agents 
The two clinically used boron-containing drugs are the sodium salt of sulfhydryl boron 
hydride Na2B12H11SH (BSH) and the amino acid (L)-4-dihydroxyborylphenylalanine (BPA) 
(Figure 5.3, 41-42).31, 33-34, 42-45 Although BSH and BPA show low toxicity and have recorded 
efficacy in clinical BNCT trials, they have only low selectivity for tumors, and low retention 
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times.32, 45-46 Other promising classes of boronated compounds, including boronated amino acids, 
peptides, monoclonal antibodies (MAb), nucleosides, lipids, carbohydrates, liposomes, porphyrin 
derivatives, BODIPYs, and nanoparticles, have been synthesized and investigated as potential 
BNCT agents.30, 32, 40, 47 The preferred boron sources in these compounds are the neutral isomeric 
carboranes ortho-, meta-, and para-C2B10H12, negatively charged closo-B12H12
2-, closo-CB11H12
-, 
the open cage nido-C2B9H12
-, and metallo-bis(dicarbollides) such as [3,3’-Co(1,2- C2B9H11)2]
- 
(Figure 5.3, 43-49) as a result of their remarkable properties that include: 1) high boron content, 
2) amphiphilicity, 3) high photochemical, kinetic, and hydrolytic stabilities, and 4) ease of 
functionalization and attachment to targeting molecules.40, 48 Several reviews have been published 
on compound development for BNCT.29-30, 32, 40, 47-57 Among the different classes of boron delivery 
agents, nucleosides, amino acids, porphyrin derivatives and tumor-targeted compounds that 
recognize a tumor-associated epitope, are amongst the most promising BNCT agents due to their 
generally lower toxicity and increased tumor specificity and uptake. Porphyrin derivatives and 
boron dipyrromethenes (BODIPYs) have attracted considerable interest as potential BNCT drugs 
due to their fluorescent characteristic which facilitate the quantification of tissue-localized boron.  
 
Figure 5.3. Structures of BSH, BPA and common boron clusters currently used in BNCT drug 
development.  
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Taking advantage of the synthetic development of BODIPYs and the attractive properties 
of BODIPYs including strong absorbance and fluorescence with high quantum yields, high 
stability in physiological environment, and high photostability, as mentioned in section 5.1, a series 
of carborane-containing BODIPYs were synthesized and their in vitro biological studies were 
investigated. Detailed information was included in Chapter 6. In Chapter 7, a series of push-pull 
BODIPYs were synthesized and their photophysical and electrochemical properties were 
compared.  
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CHAPTER 6 : SYNTHESIS AND IN VITRO STUDIES OF A SERIES OF 
CARBORANE-CONTAINING BORON DIPYRROMETHENES (BODIPY) 
 
6.1 Introduction 
Boron neutron capture therapy (BNCT), which can selectively target and destroy malignant 
cells in the presence of healthy normal cells, is a very promising binary anticancer methodology 
especially for the treatment of brain tumors1-3 BNCT involves the irradiation of nonradioactive 
10B-containing tumors with low-energy thermal neutrons, causing the excitation of 10B to 11B, 
which rapidly produces cytotoxic high linear energy transfer (high-LET) α and 7Li particles, γ 
radiation, and about 2.4 MeV of kinetic energy through a nuclear fission reaction. The generated 
high-LET particles have short path lengths about the diameter of a single cell (< 10 μm), therefore 
restricting the damage to 10B-containing tumor cells. In addition, there is little interference with 
the 10B (n,α)7Li capture reaction due to the very small nuclear cross sections of biologically 
abundant nuclei including 12C, 1H, and 14N. Another advantage of BNCT is that thermal and 
epithermal neutrons are able to penetrate deep into tissues to reach deep-seated tumors. However, 
a relatively high boron tumor concentration of at least 20 μg 10B/g tumor or approximately 109 
atoms/cell is required for effective BNCT treatment, and this has driven recent research in the 
areas of boron drug development and delivery methodologies for BNCT. 
BNCT has been used clinically for several decades in the treatment of high-grade brain 
tumors, such as glioblastoma multiforme (GBM), and other difficult-to-treat malignancies, 
including primary and metastatic melanomas and recurrent head and neck cancers.3-5 One major 
challenge in the BNCT modality for brain tumors is the existence of the blood−brain barrier (BBB)  
* Chapter 6 previously appeared as Xuan, S.; Zhao, N.; Zhou, Z.; Fronczek, F. R.; Vicente, M. G. 
H. Synthesis and in Vitro Studies of a Series of Carborane-Containing Boron Dipyrromethenes 
(BODIPYs). J. Med. Chem. 2016, 59, 2109-2117. It is reprinted by permission of ACS Publisher 
(see page 261). 
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that prevents most drugs from penetrating into the brain and from reaching the targeted tumor 
cells.6-11 In the brain tumor treatment, the prerequisite is that the boron drug should permeate across 
the BBB, ether by passive transmembrane diffusion or through active transportation of targeting 
transporters and receptors that are expressed at the BBB.12 The passive diffusion of boron drugs 
across the BBB are strongly dependent on the physicochemical properties of the drugs, including 
their lipophilic character, molecular weight (MW), size, polar surface area, charge, and extent of 
ionization.13-15 Among these, the two main characteristics in a small molecule that favor its 
crossing of cellular membrane and BBB by passive diffusion are (1) molecular weight under 500 
Da and (2) high lipophilic character, usually measured by the octanol−water partition coefficient, 
log P <5.6, 13-15 Although significant hydrophobicity is important for enhanced permeability across 
the BBB, BNCT drugs also need to be soluble in aqueous media to enable their systemic 
administration.2 Therefore, there is continued need to develop amphiphilic boron drugs with 
appropriate hydrophilic and lipophilic balance (HLB) and low molecular weight of <500 Da for 
efficient BBB permeability and tumor cell uptake. 
The two boron drugs that have been extensively used in BNCT clinical trials are the sodium 
salt of the sulfhydryl boron hydride Na2B12H11SH (BSH) and L-4- dihydroxyborylphenylalanine 
(BPA).3-5 Although BSH and BPA have demonstrated efficacy in BNCT clinical trials, they have 
low selectivity, low tumor retention time and limited BBB permeability,10, 16 which limit their use 
in brain tumor treatment. Other boronated compounds have been investigated as potential BNCT 
drugs, including amino acids, peptides, carbohydrates, nucleosides, liposomes, porphyrins, 
monoclonal antibodies (mAbs), and nanoparticles.2-3, 7 the Among these, particularly promising 
are mAbs due to their very high specificity for a tumor-associated epitope, and porphyrin 
derivatives due to their ability to transport large amounts of boron within cells. However, these 
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BNCT agents have limited BBB crossing ability, mainly due to their large size, high molecular 
weight, and hydrophobicity.2, 16 
Recently, we have reported the investigation on the BBB crossing ability of a series of 
carboranylporphyrins conjugated to polyamines, glucose, arginine, and an opioid peptide,17 but 
they all exhibited low permeabilities (Pe < 3.3 × 10−6 cm/s) across hCMEC/D3 cell monolayers as 
the BBB model. In contrast, amphiphilic boron dipyrromethene (BODIPY), referred to as “semi-
porphyrins”, of low molecular weight displayed enhanced BBB permeability and promise as boron 
delivery drugs for BNCT.18 BODIPY dyes have attracted special interest in recent years due to 
their various applications in biological labeling, drug delivery, imaging, sensing, and 
theranostics.19-22  As mentioned in Chapter 5, BODIPYs are strongly UV−vis absorbing and 
generally emit sharp fluorescence with high quantum yields, which can facilitate detection and 
quantification of tissue-localized boron in BNCT. BODIPYs have also shown negligible 
sensitivity toward solvent polarity and solution pH, high permeability across cellular membranes, 
and relatively high stability under physiological conditions. 
BODIPYs functionalized with carborane clusters have been prepared using Suzuki18 and 
Sonogashira23 cross-coupling reactions of the corresponding 2,6-diiodo-substituted BODIPYs. 
Alternatively, carboranes can be introduced onto the BODIPY at the 3(5)- and/or 8-positions 
through substitution reactions of the corresponding chlorinated derivatives.18, 24-25 Herein we report 
the synthesis of a series of seven carboranyl-BODIPYs from the corresponding chloro-BODIPY 
derivatives, with molecular weights in the range 366−527 Da and log P in the range 1.5−2.7. The 
cytotoxicity and uptake of the BODIPYs in human glioma T98G cells, as well as their permeability 




6.2.1 General considerations 
All the chemicals and reagents were purchased from Sigma-Aldrich and Fisher Scientific 
and used as received. 1-Mercapto-1,2-carborane was purchased from Katchem. Reactions were 
monitored by analytical thin-layer chromatography (TLC) performed on precoated plates 
(polyester-back, 60 Å, 0.2 mm, Sorbent Technologies). Purifications were conducted by column 
chromatography on silica gel (230−400 mesh, 60 Å, Sorbent Technologies) or preparative TLC 
plates (f254, VWR). 1H and 13C {1H} NMR spectra were obtained using a Bruker AV-400 
NanoBay (400 MHz for 1H NMR and 100 MHz for 13C NMR) and a Bruker AV-500 spectrometer 
(125 MHz for 13C NMR) at room temperature. 11B NMR was obtained on a Bruker AV-400 III 
(128 MHz), using BF3·OEt2 as reference. Chemical shifts (δ) are given in parts per million (ppm) 
in CDCl3 (7.27 ppm for 1H NMR, 77.0 ppm for 
13C NMR); coupling constants (J) are given in Hz. 
High resolution mass spectrometry (HRMS) spectra were obtained using a 6210 ESI-TOF mass 
spectrometer (Agilent Technologies). 4-(1-Methyl-1,2-carborane)-methylphenylboronic acid26 
and BODIPYs 1a,27 3a,24 3b,18 6a,25and 725 were synthesized as previously reported. 
6.2.2 General procedure for synthesis of BODIPYs via nucleophilic substitution reaction 
The starting chloro-BODIPY (0.05 mmol) was dissolved in 2 mL of THF. 1-Mercapto-1,2-
carborane (0.055 mmol) and K2CO3 (0.5 mmol) were added, and the final mixture was stirred at 
room temperature. TLC was used to monitor the reaction until completion (2−5 h). The crude solid 
product was filtered and purified by column chromatography or preparative TLC using 
CH2Cl2/hexanes or ethyl acetate/hexanes for elution. 
8-(1,2-Carboranyl-1-thio)-BODIPY 1b. 16.1 mg (88%), mp 213-215 °C. 1H NMR 
(CDCl3, 400 MHz): δ 8.01 (2H, s), 7.36 (2H, s), 6.64 (2H, s), 3.77 (1H, s), 1.8−3.5 (10H, br). 
13C 
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NMR (CDCl3, 100 Hz): δ 148.6, 139.4, 133.3, 132.2, 120.4, 72.2, 65.0. 
11B NMR (CDCl3, 128 
MHz): δ −0.08 (1B, t, 1J(B,F) = 27.8 Hz), −12.97 to - −1.57 (10B, m). HRMS (ESI-TOF) m/z 
calcd for C11H17B11F1N2S [M − F]
+ 347.2199; found 347.2200. 
8-(1,2-Carboranyl-1-thio)-1,3-dimethyl-BODIPY 2b. 18.7 mg (95%). 1H NMR (CDCl3, 
400 MHz): δ 7.71 (1H, s), 7.10 (1H, s), 6.49 (1H, s), 6.29 (1H, s) 3.79 (1H, s), 2.65 (1H, s), 2.55 
(1H, s), 1.8-3.5 (10h, br); 13C NMR (CDCl3, 100 Hz): δ 166.9, 148.6, 141.4, 138.3, 137.2, 130.0, 
127.0, 126.0, 117.4, 73.3, 65.1, 16.7, 15.7; 11B NMR (CDCl3, 128 MHz): δ 0.14 (1B, t, 1J(B,F)= 
29.8 Hz), -12.97-(-1.60) (10B, m); HRMS (ESI-TOF) m/z calcd for C13H22B11F2N2S [M+H]
+ 
395.2576; found 395.2566. 
BODIPY 5b. 20.9 mg (93%). 1H NMR (CDCl3, 400 MHz): δ 7.44 (1H, s), 3.70 (2H, s), 
2.58 (3H, s), 2.44-2.45 (8H, overlap, m), 2.02 (3H, s), 1.8-3.5 (10h, br), 1.05-1.09 (3H, t, 3J(H,H)= 
7.4 Hz); 13C NMR (CDCl3, 100 Hz): δ 162.7, 141.5, 141.1, 137.8, 137.2, 134.1, 130.1, 128.4, 74.9, 
64.1, 17.3, 14.5, 14.2, 14.0, 13.4, 10.2; 11B NMR (CDCl3, 128 MHz): δ -0.06 (1B, t, 1J(B,F)= 30.0 
Hz), -11.89-(-1.64) (10B, m); HRMS (ESI-TOF) m/z calcd for C17H30B11F2N2S [M+H]
+ 451.3204; 
found 451.3195. 
BODIPY 6b. 17.9 mg (74%). 1H NMR (CDCl3, 400 MHz): δ 3.69 (1H, s), 2.60 (3H, s), 
2.44 (8H, overlap, m), 2.00 (3H, s), 1.8-3.5 (10h, br), 1.06-1.10 (3H, t, 3J(H,H)= 7.6 Hz); 
13C NMR 
(CDCl3, 125 Hz): δ 163.1, 141.3, 141.2, 137.8, 137.7, 137.6, 132.7, 128.5, 126.4, 74.9, 64.1, 17.3, 
14.8, 14.6, 14.1, 13.5, 9.1;  11B NMR (CDCl3, 128 MHz): δ 0.08 (1B, t, 
1J(B,F) = 30.0 Hz), -12.94-
(-1.45) (10B, m);  HRMS (ESI-TOF) m/z calcd for C17H29B11ClF2N2S [M+H]
+ 485.2818; found 
485.2824. 
BODIPY 4. BODIPY 1a (11.3 mg, o.o5 mmol) was dissolved in toluene (4 ml). 1M 
Na2CO3 (aq) (1 ml), Pd(PPh3)4 (5% mol), and 4-(1-methyl-ortho-carborane)methylphenyl boronic 
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acid (29.2 mg, 0.1 mmol) were added and the final mixture was refluxed overnight. The mixture 
was poured into water (10 ml) and extracted with dichloromethane (10 ml  3). The organic layers 
were collected, washed with H2O and brine, and dried over anhydrous Na2SO4. The solvents were 
removed by rotary evaporation to give the crude products. The further purification was performed 
by column chromatography (ethyl acetate/hexanes as the eluent) to provide the titled product (10.6 
mg), in 45% yield. 1H NMR (CDCl3, 400 MHz): δ 8.0 (2H, s), 7.56-7.58 (2H, m), 7.37-7.39 (2H, 
m), 6.92 (2H, s), 6.58 (2H, s), 3.57 (2H, s), 2.22 (3H, s), 1.8-3.5 (10h, br); 13C NMR (CDCl3, 100 
Hz): δ 146.4, 144.5, 137.7, 134.9, 133.6, 131.5, 130.7, 130.4, 118.7, 75.0, 40.9, 23.8; 11B NMR 
(CDCl3, 128 MHz): δ 0.18 (1B, t, 
1J(B,F)= 28.6 Hz), −10.74- −3.16) (10B, m); HRMS (ESI-TOF) 
m/z calcd for C19H25B11FN2 [M-F]
+ 419.3108; found 419.3111. 
6.2.3 HPLC analysis of BODIPYs 
Normal-phase HPLC was performed on a Dionex system including a P680 pump and UVD 
340 detector connected to a Dynamax axial compression column packed with Rainin 60 Å irregular 
silica gel. The flow rate of 1 mL/min was used. For compound 1b, a stepwise gradient of 50% B 
(ethyl acetate) and 50% A (hexane) in the first 3 min to 80% B and 20% A during the next 18 min 
to 50% B and 50% A for the next 6 min was used. For all other compounds, a stepwise gradient 
of 10% B and 90% A in the first 5 min to 70% B and 30% A during the next 10 min to 10% B and 
90% A for the next 10 min was used.  
6.2.4 Spectroscopic studies 
UV−visible and fluorescence spectra were collected on a PerkinElmer Lambda 35 UV/vis 
spectrometer and PerkinElmer LS 55 luminescence spectrometer at room temperature. Quartz 
cuvettes (10 mm path length) and spectroscopic grade solvents were used for both measurements. 
Optical density (ε) was determined by using the solutions with absorbance at λmax (0.5−1). 
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Quantum yields were determined by using the dilute solutions with absorbance (0.04−0.06) at the 
particular excitation wavelength. Cresyl violet perchlorate (0.54 in methanol) and rhodamine 6G 
in ethanol (0.95) were used as external standards for the carboranyl BODIPYs 5b, 6b, and 1b−3b, 
4, 7, respectively. The relative fluorescence quantum yields (Φf) were determined by calculations 
using the following equation,28 
ΦX = ΦR × (FX/FR)×(AR/AX)×(nX/nR)
2 
 
where Φ stands for fluorescence quantum yields; n stands for refractive indexes; F stands 
for the areas under the emission peaks; A stands for absorbance at the particular excitation 
wavelength, subscripts X and R refer to the tested samples and standard sample, respectively.  
6.2.5 Crystallography 
X-ray data for 2b and 5b were collected at 90 K with Mo Kα radiation (λ = 0.71073 Å) on 
a Bruker Kappa Apex-II DUO diffractometer. For BODIPY 2b, C13H21B11F2N2S, monoclinic 
space group P21/c, a = 10.7729(5), b = 15.7487(7), c = 12.5738(6) Å, β = 104.222(2)°, V = 
2067.88(17) Å3, Z = 4,22,855 measured data. Final R = 0.040, Rw = 0.106 for 264 refined 
parameters and 7883 independent reflections having θmax = 33.2°. For BODIPY 5b, 
C17H29B11F2N2S, monoclinic space group P21/c, a = 13.688(2), b = 12.1938(17), c = 15.488(2) Å, 
β=113.231(6)0, V = 2375.3(6) Å3, Z = 4,47,866 measured data. Final R = 0.040, Rw = 0.110 for 
303 refined parameters and 8658 independent reflections having θmax = 32.6°. The CIFs have been 
deposited at the Cambridge Crystallographic Data Centre (CCDC 1426277-1426278). 
6.2.6 Octanol-water partition coefficients 
The partition coefficients (Log P) were measured by adapting a reported procedure.29 1-
Octanol and Milli-Q water were mutually saturated and the two phases were separated. A 64 µM 
stock solution was prepared by dissolving the BODIPY into water-saturated 1-octanol. 2 mL of 
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the stock solution was added to 6 mL Milli-Q water in a 15 mL volumetric tube and the mixture 
was intensively vortexed for 10 min. After complete separation of the two phases, an aliquot from 
the 1-octanol layer was diluted with water-saturated 1-octanol and its absorbance was recorded 
with a Varian Cary 50 Bio UV-Vis spectrophotometer with a 10 mm path length quartz cuvette. 













where A0 and Aoct are the absorbance of the compound in the water-saturated octanol before 
and after partitioning; Vw and Vo are the water and 1-octanol volumes, respectively.  
6.2.7 Cell studies of BODIPYs 
The T98G cell line used in this study was purchased from ATCC and cultured in ATCC-
formulated Eagle's Minimum Essential Medium containing 10% FBS and 1% antibiotic 
(Penicillin-streptomycin). The hCMEC/D3 cells were obtained from Dr. Pierre-Olivier Couraud 
from Institut COCHIN in Paris (France). All other reagents were purchased from Life 
Technologies. 
Dark Cytotoxicity. A 32 mM compound stock solution wasprepared by dissolving the 
BODIPY in 100% DMSO. The stock solution was diluted into final working concentrations (0, 
6.25, 12.5, 25, 50, and 100 μM). Human glioma T98G cells were plated at 15 000 cells per well in 
a Costar 96-well plate (BD biosciences) and allowed to grow for 24 h. The cells were exposed to 
the working solutions of compounds up to 100 μM and incubated overnight (37 °C, 95% humidity, 
5% CO2). The working solution was removed, and the cells were washed with 1× PBS. The 
medium containing 20% CellTiter Blue (Promega) was added and incubated for 4 h. The viability 
of cells is measured by reading the fluorescence of the medium at 570/615 nm using a BMG 
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FLUOstar Optima microplate reader. This fast, sensitive, and popular assay uses the indicator dye 
resazurin which is reduced to fluorescent resorufin in viable cells, while nonviable cells are not 
able to reduce resazuin or to generate a fluorescent signal. The fluorescence signal of the untreated 
cells was normalized to 100%.  
Phototoxicity. Human glioma T98G cells were prepared as described above. The cells 
were incubated with compound concentrations of 100, 50, 25, 12.5, 6.25, 3.125, and 0 μM for 24 
h. The loading medium was removed, and the cells were washed with 1×PBS buffer and then 
refilled with fresh media. The cells were exposed to a 600 W halogen lamp light source filtered 
with a water filter (transmits radiation 250−950 nm) and a beam turning mirror with 200 nm to 30 
μm spectral range (Newport), for 20 min. The total light dose was approximately 1.5 J/cm2. After 
light exposure, the cells were returned to the incubator for 24 h and assayed for cell viability as 
described above.  
Time-dependent cellular uptake. Human T98G cells were prepared as described above. 
The cells were exposed to 10 μM of each compound solution for 0, 1, 2, 4, 8, and 24 h. The loading 
medium was removed at the end of each incubation period, and the cells were washed with 1× 
PBS and solubilized by adding 0.25% Triton X-100 in 1× PBS. Standard curves using 10, 5, 2.5, 
1.25, 0.625, and 0.3125 μM concentrations were obtained by diluting 400 μM of each BODIPY 
solution with 0.25% Triton X-100 (Sigma-Aldrich) in 1× PBS. A cell standard curve was prepared 
using 104, 2 × 104, 4 × 104, 6 × 104, 8 ×104, and 105 cells per well. The cell number was quantified 
using a CyQuant cell proliferation assay (Life Technologies). The compound concentration in cells 
at each time period was determined using a BMG FLUOstar Optima microplate reader at 485/590 
nm. Cellular uptake is expressed in terms of compound concentration (nM) per cell. 
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Microscopy. Human HEp2 cells were incubated in a six-well plate (MatTek) and allowed 
to grow overnight. The cells were exposed to 10 μMof each BODIPY and incubated for 6 h (37 °C, 
95% humidity, 5% CO2), followed by the addition of organelle tracers obtained from Invitrogen. 
The organelle tracers were used at the following concentrations: LysoSensor Green, 50 nM; 
MitoTracker Green, 250 nM; ER Tracker Blue/White, 100 nM; and BODIPY FL C5 Ceramide, 
50 nM. The cells were incubated with the BODIPY and tracers for 30 min and washed with PBS 
three times before imaging. The images were acquired using a Leica DMRXA2 upright 
microscope with a water immersion objective and DAPI, GFP, and Texas Red filter cubes (Chroma 
Technologies). 
hCMEC/D3 cell line (BBB model) (Figure 6.1).  
 
Figure 6.1. The blood-brain mimic for experimental in vitro BBB study. The upper chamber 
mimics the blood compartment, the lower chamber mimics the cerebral compartment, and the 
hCMEC/D3 cell monolayer represents the BBB. 
The BBB permeabilities were determined following a pulished procedure.30-31 Specifically, 
the hCMEC/D3 cells were incubated in a six-well, 0.4 μm porosity PET Transwell plate (Corning) 
for 48 h, allowing the formation of a model brain capillary endothelial monolayer (checked by 
microscopy). EBM-2 medium containing 5% FBS, 1% penicillin/streptomycin, hydrocortisone, 
ascorbic acid, chemically defined lipid concentrate (1/100), HEPES, and bFGF was used as the 
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growth medium. The coated PET Transwell plates with and without endothelial cells were 
transferred into six-well plates. The measurements were performed in triplicate for each compound, 
using three PET Transwell plates with cells and three without cells. The time points of the 
treatment were 0, 10, 25, and 45 min. At time 0, a 0.5 mL sample of each BODIPY or standard 
Lucifer yellow (LY) at 50 μM concentration in transport buffer was added to the upper chamber 
(mimicking the blood), and 1.5 mL of transport buffer was added to the lower chamber (mimicking 
the BBB); see Figure S24 in the Supporting Information. The transport buffer was prepared by 
adding 5 mL of HEPES (1 M) and 5 mL of sodium pyruvate (100 μM) to 400 mL of HBSS. The 
plates were incubated at 37 °C, 95% humidity, and 5% CO2. At time 10 and 25 min, each upper 
PET Transwell was transferred to the corresponding prepared six-well plate containing 1.5 mL of 
transport buffer: the so-called “25 min” first and then the “45 min”. At each time point, solution 
in the lower chamber was added into a 96-well plate with 100 μL for each well (five wells). The 
fluorescence intensity of the solution was measured by using a BMG FLUOstar plate reader at 
485/590 nm and 425/538 nm (excitation/emission) for BODIPYs and LY, respectively, and the 
concentrations were determined from the corresponding standard curves. The calculations of 
permeability coefficients (Pe, in cm/s) were performed following the clearance principle as 
described in the equations below (eqs 1 and 2), where X is the amount of sample in the lower 
chamber and Cd is the concentration of sample in the upper chamber at each time point. The total 
cleared volume at each time point is calculated by summing the incremental cleared volumes up 
to the given time point.  
clearance (mL) = X/Cd   (1) 
The cleared volume is plotted vs time, and a linear fit is applied. 




   (2) 
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where PSt is the slope of the clearance curve for the culture, PSf is the slope of the clearance 
curve with the control Transwell plate without cells, and A is the surface area of the PET Transwell 
plate. 
6.3 Results and discussion 
6.3.1 Synthesis and characterization 
Synthesis of carboranyl BODIPYs. A series of seven carboranyl-BODIPYs 1b, 2b, 
3b,184, 5b, 6b, and 7,25 were synthesized as shown in Scheme 6.1. The ortho-carborane cluster was 
chosen as the boron source because of its high boron content, high hydrophobicity, high stability 
under physiologic conditions, and low toxicity.7, 11 The key chloro-BODIPY starting materials 
were synthesized from the corresponding dipyrroketones, as previously reported.24-25, 27 8-Chloro-
BODIPYs 1a−3a and 5a were converted into their corresponding 8-carboranylthio-BODIPYs by 
reaction with 1.1 equiv of 1-mercapto-o-carborane in THF at room temperature, in yields ranging 
from 88% to 95%. We have previously reported that 3,8-dichloro-BODIPY 6a undergoes highly 
regioselective substitutions at the 8-position in the presence of N- and O-centered nucleophiles.25 
Using more reactive S-nucleophiles, the 8- vs 3-substitution regioselectivity tends to decrease. 
However, due to the electron-withdrawing nature of the carborane cluster, BODIPY 6a reacted 
smoothly with 1.1 equiv of 1-mercapto-o-carborane, affording 6b with high regioselectvity in 74% 
yield. On the other hand, BODIPY 7 was prepared from 6a via two successive regioselective 
reactions, a Stille cross-coupling at the 8-position using 1 equiv of tributylphenylstannane and 
Pd(PPh3)4, followed by substitution using an excess of 1-mercapto-o-carborane, as we have 
previously reported.25 The Suzuki cross-coupling reaction of BODIPY 1a with 1.5 equiv of 4-(1-
methyl-o-carborane)-methylphenylboronic acid in toluene and in the presence of Pd(PPh3)4 and 1 
M Na2CO3(aq) produced BODIPY 4 in 45% isolated yield. 
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Scheme 6.1. Synthesis of carborane-containing BODIPYs. 
 
HPLC, NMR and X-ray analysis. All compounds were of ≥95% purity, as determined by 
HPLC (Figures 6.2-6.8). The commercially available LY standard is of 97% purity, as provided 
by Life Technologies. The structures of the new BODIPYs 1b, 2b, 5b, 6b and 4 were confirmed 
by 1H-, 13C- (Figures 6.9-6.18) and 11B-NMR (Figures 6.19-6.24), HRMS, and in the case of 2b 
and 5b by X-ray crystallography (Figure 6.25). The X-ray structures of 3b20 and 7.27 have been 
previously reported. Crystals of BODIPYs 2b and 5b suitable for X-ray analysis were obtained by 
slow diffusion of hexanes into chloroform. In 2b, the B atom of the central C3N2B ring lies slightly 
(0.214 Å) out of the plane of the other five atoms, which are fairly coplanar, having a mean 
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deviation of 0.013 Å. The carborane lies on the bisector of this plane, with C-C-S-C torsion angle 
93.9°. In 5b, the central ring is slightly more planar, with the meso C atom lying 0.098 Å out of 
the C2N2B plane. The S atom lies 0.319 Å out of this plane, and as in 2b, the carborane lies on the 
bisector, with C-S-C-C torsion angle 94.1°. The ethyl group is also approximately perpendicular 
to the ring system, with C-C-CH2-CH3 torsion angle 83.7°. 
 
Figure 6.2. HPLC trace for BODIPY 1b.  
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Figure 6.3. HPLC trace for BODIPY 2b. 
 
Figure 6.4. HPLC trace for BODIPY 3b. 
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Figure 6.5. HPLC trace for BODIPY 4. 
 
Figure 6.6. HPLC trace for BODIPY 5b. 
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Figure 6.7. HPLC trace for BODIPY 6b. 
 
Figure 6.8. HPLC trace for BODIPY 7. 
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Figure 6.9. 1H NMR spectrum of BODIPY1b. 
 
 




Figure 6.11. 1H NMR spectrum of BODIPY2b. 
 
 




Figure 6.13.1H NMR spectrum of BODIPY 5b. 
 
 




Figure 6.15. 1H NMR spectrum of BODIPY6b. 
 
 
Figure 6.16. 13C {1H} NMR spectrum of BODIPY6b. 
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Figure 6.17. 1H NMR spectrum of BODIPY4. 
 
 





Figure 6.19. 11B NMR spectrum of BODIPY 1b. 
 
 




Figure 6.21. 11B NMR spectrum of BODIPY3b. 
 
 




Figure 6.23. 11B NMR spectrum of BODIPY 5b. 
 
   
Figure 6.24. 11B NMR spectrum of BODIPY 6b. 
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Figure 6.25. X-ray crystal structure of 2b (left) and 5b (right). 
Spectroscopic analysis. The spectroscopic properties of all BODIPYs in dichloromethane 
solution were investigated and the results are summarized in Table 1 (see also Figures 6.26-6.27). 
The absorption spectra of all BODIPYs followed the Lambert-Beer law, indicating there is no 
appreciable aggregation in this solvent at the concentrations investigated. The introduction of an 
ortho-carboranylthio group at the 8-position in BODIPYs 1b-3b, 5b and 6b, caused large red-
shifts on the maximum absorption (up to 57 nm) and emission (up to 73 nm) bands (Figure 6.26). 
This is probably due to the stabilization of the LUMO by this group, which decreases the HOMO-
LUMO gap.34 On the other hand, introduction of the same group at the 3-position, as in BODIPY 
7, induced a slight blue-shift (ca. 5 nm) relative to the starting BODIPY 6a.27 Arylation at the 8-
position, as in BODIPY 4, also produced a slight blue-shift compared with the starting 8-chloro-
BODIPY 1a probably due to a large dihedral angle between the aryl group and the BODIPY core. 
The fluorescence quantum yields were higher for BODIPY 1b, suggesting low rotational freedom 
for the 8-carboranylthio group, and it decreased with increasing alkyl substitution for 2b, 3b and 
5b. This is attributed to increased energy lost to non-radiative deactivation processes.27,34 On the 
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other hand, BODIPY 4 shows much lower quantum yield than 7, probably due to the higher 
rotation of the 8-aryl group in the absence of 1,7-methyl groups. 








a Stokes shift 
(nm) 
1b 544 4.42 556 0.52 12 
2b 537 4.54 553 0.29 16 
3b 554 4.45 576 0.065 22 
4 502 4.50 517 0.034 15 
5b 577 4.29 608 0.060 31 
6b 582 4.16 609 0.090 27 
7 521 4.18 540 0.58 19 
 
aRhodamine 6G in ethanol (0.95) was used as standard for all compounds except for 5b and 6b, 
which used crystal violet perchlorate in methanol (0.54) as the standard. 
 
Figure 6.26. (A, B) Normalized UV/Vis spectra of BODIPYs 1b, 2b, 4, 3b, 5b and 6b; (C, D) 
Normalized fluorescence spectra of BODIPYs 1b, 2b, 4, 3b, 5b and 6b in dichloromethane at 
room temperature.  
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Figure 6.27. (A-C) Absorption spectra of BODIPY 1b, 2b and 3b at different concentrations in 
dichloromethane; (E-F) Plot of absorbance intensity of BODIPY 1b, 2b and 3b vs. concentration 
in dichloromethane. 
6.2.2 Cytotoxicity and uptake in T98G Cells 
This is the first report on the cytotoxicity and cellular uptake of carborane-containing 
BODIPYs. The cytotoxicity (dark and light, using 1.5 J/cm2 light dose) and time-dependent uptake 
of all carboranyl-BODIPYs were investigated in human glioma T98G cells and the results are 
summarized in Table 6.2 and Figures 6.28-6.29. The IC50 values were calculated from 
dose−response curves.  
None of the BODIPYs, with the exception of 5b, showed any toxicity in the dark at 
concentrations up to 100 μM investigated, as shown in Figure 6.28A. Upon irradiation with light, 
all the BODIPYs, with exception of 3b (IC50 = 80 μM) and 5b (IC50 = 40 μM), exhibited minimal 
photocytotoxicity (IC50 > 98 μM) (Figure 6.28B). The higher phototoxicity observed for 5b (IC50 
= 40 μM ) might be a result of its higher uptake by T98G cells, which was evidenced by the cellular 
201 
uptake study showing 5b accumulated the most within cells at all the time points investigated. 
BODIPY 7 accumulated the least, among this series of BODIPYs, which was probably due to its 
poor aqueous solubility. The lipophilic character of this series of BODIPYs was evaluated by 
determining their distribution between 1-octanol and water, and the values obtained for the 
partition coefficients (log P) are given in Table 6.2. The extent of cellular uptake did not correlate 
with the hydrophobic character of the BODIPYs, which increased in the order 1b < 2b < 3b < 5b 
∼ 6b < 4 ≪ 7. 
Table 6.2. Dark, photocytotoxicity (1.5 J/cm2) and uptake plateau concentration of BODIPYs in 
human glioma T98G cells. Permeabilty coefficients (Pe) of BODIPYs and lucifer yellow (LY) in 


















LY 457.24 - - - - - 2.2±0.8 
1b 366.25 1.50 >100 >100 0.23±0.05 Lyso, Mito, 
Golgi, ER 
16.4±3.3 
2b 394.31 1.69 >100 >98 0.36±0.03 Lyso, Mito, 
Golgi, ER 
6.0±1.0 
3b 422.36 1.73 >100 >80 0.11±0.02 Lyso, Mito, 
Golgi, ER 
4.4±0.5 
4a 438.33 2.11 >100 >100 0.41±0.03 Lyso, Mito, 
Golgi, ER 
- 
5b 450.41 1.95 >100 >40 1.5±0.05 Lyso, Mito, 
Golgi, ER 
2.6±0.9 
6b 484.85 1.93 >100 >100 0.46±0.06 Lyso, Mito, 
Golgi, ER 
5.4±0.6 









Figure 6.28. Dark cytotoxicity (A) and Phototoxicity (B) of 1b-7 using human glioma T98G 
cells. 
 
Figure 6.29. Time-dependent uptake of BODIPYs 1b (green), 2b (black), 3b (red), 4 (blue), 5b 
(purple), 6b (dark red) and 7 (orange) at 10 µM in human glioma T98G cells. 
203 
All compounds, with the exception of 7, were taken up rapidly in the first 2 h after which 
slower uptake was observed for all compounds except for 1b where a plateau was reached. After 
24h, the amount of compound accumulated within cells varied considerably (Table 6.2); 
compound 5b showed the highest uptake, about 436-fold higher than 7, followed by 6b (135-fold 
higher than 7), 4 (118-fold higher than 7), 2b (106-fold higher than 7), 1b (67-fold higher than 7), 
and 3b (33-fold higher than 7). These results indicate that among this series of compounds, 
BODIPY 5b could deliver the largest and therapeutic amount of boron within glioma cells, with 
very low dark toxicity. 
To investigate the sites of subcellular localization of the carboranyl-BODIPYs, HEp2 
rather than T98G cells were used for fluorescence microscopy, as the HEp2 cells facilitate imaging 
by nicely spreading on the surface of the six-well plate. This work was done in collaboration with 
Ms. Zehua Zhou. The organelle-specific probes BODIPYCeramide (Golgi), LysoSensor Green 
(lysosomes), MitoTracker Green (mitochondria), and ER Tracker Blue/White (endoplasmic 
reticulum) were used in the overlay experiments. The results are shown in Figures 6.30-6.33 for 
BODIPYs 1b-7. All carboranyl-BODIPYs localized preferentially in the cell ER, as shown in 
Figures 6.30-6.33. In addition, the BODIPYs were also observed, but to a smaller extent, in the 
lysosomes, mitochondria, and Golgi apparatus. These results are in agreement with previous 
studies showing preferential ER-localization for BODIPY molecules. 
6.2.3 BBB permeability 
The in vitro BBB model, as shown in Figure1, was used for the evaluation of BBB 
permeability of the carboranyl BODIPYs. The hCMEC/D3 cell line is a useful model for studies 




Figure 6.30.Subcellular localization of 1b (left) and 5b (right) in HEp2 cells at 10 μM for 6 h: (a) 
phase contrast, (b) overlay of BODIPY and phase contrast, (c) ERTracker Blue/White, (d) overlay 
of BODIPY and ER Tracker, (e) BODIPY ceramide, (f) overlay of BODIPY and BODIPY 
ceramide, (g) MitoTracker Green, (h) overlay of BODIPY and MitoTracker, (i) LysoSensor Green, 
(j) overlay of BODIPY and LysoSensor. Scale bar: 10 μm. 
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Figure 6.31. Subcellular localization of 2b (left) and 3b (right) in HEp2 cells at 10 μM for 6 h: (a) 
phase contrast, (b) overlay of BODIPY and phase contrast, (c) ERTracker Blue/White, (d) overlay 
of BODIPY and ER Tracker, (e) BODIPY ceramide, (f) overlay of BODIPY and BODIPY 
ceramide, (g) MitoTracker Green, (h) overlay of BODIPY and MitoTracker, (i) LysoSensor Green, 




Figure 6.32. Subcellular localization of 4 (left) and 6b (right) in HEp2 cells at 10 μM for 6 h: (a) 
phase contrast, (b) overlay of BODIPY and phase contrast, (c) ERTracker Blue/White, (d) overlay 
of BODIPY and ER Tracker, (e) BODIPY ceramide, (f) overlay of BODIPY and BODIPY 
ceramide, (g) MitoTracker Green, (h) overlay of BODIPY and MitoTracker, (i) LysoSensor Green, 





Figure 6.33. Subcellular localization of 7 in HEp2 cells at 10 μM for 6 h: (a) phase contrast, (b) 
overlay of BODIPY and phase contrast, (c) ERTracker Blue/White, (d) overlay of BODIPY and 
ER Tracker, (e) BODIPY ceramide, (f) overlay of BODIPY and BODIPY ceramide, (g) 
MitoTracker Green, (h) overlay of BODIPY and MitoTracker, (i) LysoSensor Green, (j) overlay 
of BODIPY and LysoSensor. Scale bar: 10 μm. 
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of human brain endothelial cells.31-33 Recently, the BBB permeability of a series of carboranyl 
porphyrins17 and BODIPYs18 have been investigated using this model. All the carboranyl 
porphyrins and BODIPYs tested showed low permeability values (Pe < 3 × 10
−6 cm/s) with the 
exception of BODIPY 3b which showed higher permeability (Pe = 4 × 10
−5 cm/s) than LY. This 
was attributed to its smaller MW and lower hydrophobic character among the compounds tested. 
To investigate the effect of MW and lipophilicity of compounds on their ability to cross the BBB, 
a new series of derivatives of 3b (MW = 422, log P = 1.7), with MW and hydrophobic character 
(log P) in the ranges 366−527 Da and 1.5−2.7, respectively, were evaluated. For comparison 
purposes and for evaluation of the cell monolayer integrity, the BBB permeability of LY, a polar 
fluorescent molecule with MW in the same range (457.24 Da) as the BODIPYs, was also 
determined. The results obtained are shown in Table 6.2. The Pe values could not be determined 
for 4 and 7, due to the precipitation of these compounds in buffer associated with their high 
lipophilicity and poor water solubility. All carboranyl-BODIPYs tested showed higher BBB 
permeability compared with LY, a marker for low BBB permeability. Among this series of 
compounds, 1b showed the highest Pe value (7-fold higher than LY), probably due to its lower 
MW (366 Da) and favorable hydrophobic character (log P = 1.50), conferring it the highest 
solubility in buffer as well as lipophilicity. Compound 2b, of similar MW (394 Da) and 
hydrophobicity (log P = 1.69) to 1b, showed the second highest Pe value. The other BODIPYs, 
including 3b, with increased alkyl and/or aryl substitution, MW > 400 Da, and log P > 1.7, showed 
lower Pe values although still higher than that determined for LY. Compound 5b showed the lowest 
Pe value among this series of BODIPYs, slightly higher than LY, and therefore is considered to 
have low BBB permeability, although it was the most efficiently taken up by the T98 glioma cells 
(Figure 6.29). All other BODIPYs displayed BBB permeabilities higher than that reported for 
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phenytoin, which has been used as a marker for medium BBB permeability.31, 34 Among the new 
BODIPYs, 1b, 2b, and 6b showed higher permeability than 3b, which displays a slightly higher 
Pe value than phenytoin. These results show that both the MW and amphiphilicity of the BODIPYs 
influence their permeability across the BBB and that small amphiphilic carboranyl-BODIPYs of 
MW < 400 Da and log P < 1.7, such as 1b and 2b, are the most efficient at diffusing across the 
BBB by passive diffusion. 
6.4 Conclusions 
A series of seven amphiphilic carboranyl-BODIPYs with MW within the range 366−527 
Da, including a previously reported BODIPY known to permeate across a BBB model, were 
synthesized in good yields from the corresponding chloro-BODIPYs by nucleophilic substitution. 
The structures of the BODIPYs were confirmed by NMR, HRMS and, in the cases of 2b and 5b, 
by X-ray crystallography. The carboranyl-BODIPYs display strong absorption and emission bands 
in the visible region of the spectrum and quantum yields in dichloromethane in the range 0.6−0.03. 
All BODIPYs showed low dark toxicity (IC50 > 100 μM) in human glioma T98G cells, an 
important property of potential boron delivery agents because of the high boron concentration 
requirement in BNCT (>20 μg/g tumor). The BODIPYs also showed low phototoxicity (IC50 >80 
μM) with the exception of 5b (IC50 =40 μM), probably as a result of its remarkably high uptake 
into T98G glioma cells. On the other hand, BODIPY 1b showed the largest permeability across 
the BBB model consisting of hCMEC/D3 cells. Our results showed that the BODIPYs with MW 
< 400 Da and log P < 1.7 are the most efficient at crossing the BBB model. The most hydrophobic 
compound 7 (log P = 2.7) was poorly soluble in aqueous solutions, showed very low uptake into 
T98G cells, and its precipitation in buffer precluded determination of its BBB permeability. All 
BODIPYs tested showed higher BBB permeability compared with LY, as well as low dark 
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cytotoxicity and therefore could potentially be efficient boron delivery agents for BNCT of brain 
tumors. Among this series, 1b and 2b showed the highest BBB permeability while 5b and 6b 
accumulated the most within tumor cells; therefore, these are the most promising BNCT agents. 
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CHAPTER 7 : SYNTHESIS AND OPTOPPHYSICAL INVESTIGATION OF 
A SERIES OF PUSH-PULL BORON DIPYRROMETHENES (BODIPYS) 
 
7.1 Introduction 
Push-pull chromophores with electron donors (D) and electron acceptors (A) attached to a 
π spacer (D- π -A) have been a subject of interest due to their wide applications in organic light-
emitting devices,1 two photon dyes,2-3 and dye-sensitized solar cells4-6. Porphyrins and 
phthalocyanines, bearing both electron donors and electron acceptors (D- π -A), have attracted 
considerable interest in the recent decades to be potentially used as dye-sensitized solar cells.5, 7-13 
Recently, boron dipyrromethanes (BODIPYs), an analogue of porphyrins, featuring excellent 
optical and electrochemical properties, have emerged as the π spacer of growing interest owing to 
their potential applications in biological imaging, biological labeling, drug delivery, sensing and 
in theranostics as well as in photovoltaic field.14-19 BODIPYs are usually strongly UV-vis 
absorbing and emit sharp fluorescence peaks with high quantum yields. BODIPYs are also 
relatively stable in physiological environment and have high photostability. Besides, BODIPYs 
have high structural tunability which render them easy access to manipulate their properties (e.g., 
photophysical properties, water solubility, redox potential).  
The BODIPY core itself is electron deficient and the installation of electron donating group 
to the BODIPY endow them the push and pull effect within the molecule.20-22 In the recent years, 
to increase the push-pull effect of the BODIPY, electron withdrawing group is also introduced to 
the BODIPY core to further enhance the pull effect; however, the study of design, characterization 
and investigation of BODIPYs with both push and pull substituents is limited so far. Currently, 
the push-pull effect has been studied mainly on three BODIPY platforms with both electron 
donating (push) and withdrawing (pull) substituents23-31 (Figure 7.1: I, II and III). The push-pull 
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investigation on extended dimeric aza-BODIPY dyes was also reported.32  The attachment of push 
and pull moieties to the BODIPY skeleton can cause dramatic change in their spectroscopic and 
electrochemical properties.24-26, 33 For example, the strong electron donating group (e.g., 
diphenylaminophenyl) and electron withdrawing group (e.g., 4-carboxylic phenyl) on the 
BODIPY could lead to enhancement of charge transfer within the molecule for them to be 
potentially used as dye-sensitized solar cells27-30 or two photon excitation dyes2, 31. The push-pull 
effects can also red-shift the BODIPYs to the near-infrared (NIR) absorbing region and render 
them potential use in biological sciences (e.g., biological imaging and sensing).34 For example, a 
66 nm bathochromic shift was caused by introducing electron withdrawing cyano group (-CN) and 
electron donating methoxy group (-OMe) to the para positions of 1,7-phenyl and 3,5-phenyl 
substituents of the tetra-phenyl aza BODIPY, respectively.34  
 
Figure 7.1. Platforms of push-pull BODIPYs.  
The reported DFT calculated electronic structure of an unsubstituted model BODIPY 
showed large electron density of HOMO at 3,5-positions and large electron density of LUMO at 
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8-position.16 Therefore, introducing the electron donating group to the 3,5-positions and electron 
withdrawing group to the 8-positon of the BODIPYs should have effect on their spectroscopic and 
electrochemical properties by changing the characteristics of  HOMO and LUMO (e.g., lower the 
energy gap between HOMO and LUMO).  
Herein, we design and synthesize three new push-pull BODIPY platforms (Figure 7.1: IV, 
V, VI) with multiple sets of push-pull moieties from the penta-Cl BODIPY using Pd (0)-catalyzed 
Stille and Suzuki cross-coupling reactions with easily obtained boronic acids and stannane 
reagents. For all the platforms, electron donating group (-OMe) and electron withdrawing group 
(-COOBn, -CN) were introduced to para positions of 3,5- and 8- phenyl substituents on the 
BODIPYs, respectively. As the electron-rich thiophene, especially at the 2 and 6 positions, was 
shown to cause large bathochromic shift and Stokes shift of BODIPYs,35-37 two thiophene groups 
(donor) were additionally installed at 2 and 6 positions to have platform V (Figure 7.1). To 
investigate how push-pull effect on 2,6 positions affect the spectroscopic and electrochemical 
properties of BODIPYs, an additional set of push-pull moiety was introduced to 2,6 position to 
have platform VI (Figure 7.1). Cyclic voltammetry and DFT calculations were conducted on all 
the BODIPYs and a systematic comparison of these BODIPYs was made to investigate the 
influence of push-pull effect on their spectroscopic and electrochemical properties. The systematic 
structure-property investigation exhibit tunability of BODIPY’s spectroscopic and electrochemical 






7.2.1 Synthesis of BODIPYs 
All reagents and solvents were purchased from Sigma-Aldrich and Fisher Scientific and 
used as received. Reactions were monitored by analytical TLC (precoated, polyester backed, 60 
Å, 0.2 mm, Sorbent Technologies). Purifications were completed by column chromatography that 
was performed on silica gel (230-400 mesh, 60 Å, Sorbent Technologies) or preparative TLC 
plates (f 254 VWR). 1H and 13C {1H} NMR spectra were obtained using a Bruker AV-400 
Nanobay spectrometer (400 MHz for 1H NMR and 100 MHz for 13C {1H} NMR) and a Bruker 
AV-500 spectrometer (500 MHz for 1H NMR and 125 MHz for 13C {1H} NMR) at 298 K. 11B 
NMR spectra were obtained on a Bruker AV-400 III (128 MHz), using BF3•OEt2 as reference. 
Chemical shifts (δ) are given in parts per million (ppm) in CDCl3 (7.27 ppm for 
1H NMR, 77.0 
ppm for 13C {1H} NMR) and coupling constants (J) are given in Hz. All High resolution mass 
spectra (HRMS) were obtained using a 6210 ESI-TOF mass spectrometer (Agilent Technologies). 
Melting points were measured using a MEL-TEMP® capillary melting point apparatus equipped 
with a FLUKE 51 II thermometer. Crystal structures were determined using data collected at low 
temperature (90K) on a Bruker Kappa Apex-II DUO diffractometer equipped with a Triumph 
focusing monochromator for the Mo X-ray beam, a Cu microfocus X-ray source, and an Oxford 
Cryosystems Cryostream chiller. 
General Procedure for Suzuki Cross-Couplings of BODIPYs. The starting BODIPY 
was added to a 15 mL round-bottomed flask followed by the addition of either 3 mol % of 
Pd(PPh3)4 (for 5a, 5b) or Pd(PCy3)G2 (for 6a, 6b and 8). The flask was evacuated and refilled 
with nitrogen three times and toluene (4 mL) and 1M Na2CO3 (aq) (1 mL) were added under 
nitrogen. Boronic acid was added portionwise, and the reaction mixture was stirred and heated 
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under nitrogen at 90-100oC. The reaction was monitored by analytical TLC every 30-60 min. After 
completion, the reaction mixture was added water (20 mL) and extracted with dichloromethane 
(10 mL × 3). The organic layers were combined, washed with aqueous saturated brine and water, 
and dried over anhydrous Na2SO4. The solvent was removed by rotary evaporator and the obtained 
reaction residue was purified by column chromatography with dichloromethane/hexanes or ethyl 
acetate /hexanes as the elution solvents. 
8-(4-benzyloxycarbonylphenyl)-2,3,5,6-tetrachloro-BODIPY 5a. The BODIPY 5a was 
prepared from BODIPY 1 (20.00 mg, 0.0549mmol) synthesized as previously reported35 and 2.5 
eq of 4-benzyloxycarbonylphenyl boronic acid (70.3 mg, 0.275 mmol), yielding 20.8 mg, 70.0 % 
of BODIPY 5a as red solid: mp (185.9-187.5 oC); 1H NMR (CDCl3, 400 MHz) δ (ppm) = 8.26-
8.28 (m, 2H), 7,57-7.59 (m, 2H), 7.42-7.51 (m, 5H), 6.79 (s, 2H), 5.45 (s, 2H); 13C NMR (CDCl3, 
125 MHz) δ (ppm) = 166.2, 143.9, 142.2, 135.8, 235.5, 132.9, 131.2, 130.3, 130.1, 128.7, 128.6, 
128.3, 127.9, 122.3, 67.4; 11B NMR (CDCl3, 128 MHz ) δ (ppm) = -0.24-0.18 (1B, t, 
1J(B,F) = 26.4 
Hz); HRMS (ESI-TOF): m/z calculated for C23H13BCl4F2N2O2: 536.9834; found: 536.9809 [M
-]. 
8-(4-cyanophenyl)-2,3,5,6-tetrachloro-BODIPY 5b. The BODIPY 5b was prepared 
from BODIPY 1 (11.4 mg, 0.0310mmol) and10 eq of 4-cyanophenyl boronic acid (46.0 mg, 0.320 
mmol), yielding 6.68 mg, 50.2 % of BODIPY 5b as red solid: mp (280.1-282.2 oC); 1H NMR 
(CDCl3, 400 MHz) δ (ppm) = 7.89-7.90 (m, 2H), 7.62-7.64 (m, 2H), 6.76 (s, 2H); 
13C {1H} NMR 
(CDCl3, 125 MHz) δ (ppm) = 144.6, 140.6, 135.9, 132.6, 131.0, 130.8, 127.6, 122.7, 117.4, 115.3; 
11B NMR (CDCl3, 128 MHz ) δ (ppm) = -0.26-0.15 (1B, t, 
1J(B,F) = 26.7 Hz); HRMS (ESI-TOF):  
m/z calcd for C16H6BCl4F2N3: 427.9419; found: 427.9412 [M
-]. 
8-(4-benzyloxycarbonylphenyl)-3,5-di (4-methoxyphenyl)-2,6-dichloro-BODIPY 6a. 
The BODIPY 6a was prepared from BODIPY 5a (12.9 mg, 0.0239 mmol) and 3 eq of 4-
218 
methoxyphenyl boronic acid (36.3 mg, 0.238 mmol), yielding 9.83 mg, 60.2 % of BODIPY 6a as 
dark blue solid: mp (233-235 oC); 1H NMR (CDCl3, 500 MHz) δ (ppm) = 8.28-8.29 (m, 2H), 7.66-
7.69 (m, 6H), 7.51-7.53 (m, 2H), 7.41-7.47 (m, 3H), 6.98-6.99 (m, 4H), 6.82 (s, 2H), 3.87 (s, 6H); 
13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 165.5, 161.0, 155.2, 137.9, 135.7, 132.6, 132.1, 
132.0, 130.4, 129.9, 128.7, 128.5, 128.3, 127.8, 123.2, 121.4, 113.6, 67.2, 55.3; 11B NMR (CDCl3, 
128 MHz ) δ (ppm) = 0.35-0.82 (1B, t, 1J(B,F) =30.7 Hz); HRMS (ESI-TOF): m/z calcd for 
C37H27BCl2F2N2O4: 681.1451; found: 681.1450 [M
-]. 
8-(4-cyanophenyl)-3,5-di(4-methoxyphenyl)-2,6-dichloro-BODIPY 6b. The BODIPY 
6b was prepared from BODIPY 5b (8.50 mg, 0.0197 mmol) and 3 eq of 4-methoxyphenyl boronic 
acid (30.0 mg, 0.197 mmol), yielding 7.47 mg, 66.0 % of BODIPY 6b as dark blue solid: mp (288-
290 oC); 1H NMR (CDCl3, 500 MHz) δ (ppm) = 7.87-7.89 (d, J = 7.7 Hz, 2H), 7.66-7.71 (m, 6H), 
6.97-6.98 (d, J = 8.2 Hz, 4H), 6.76 (s, 2H), 3.86 (s, 6H); 13C {1H} NMR (CDCl3, 125 MHz) δ 
(ppm) = 161.1, 155.7, 139.6, 138.0, 132.3, 132.0, 131.0, 128.0, 127.5, 123.6, 121.2, 117.8, 114.5, 
113.6, 55.3; 11B NMR (CDCl3, 128 MHz ) δ (ppm) = 0.35-0.82 (1B, t, 
1J(B,F) =30.6 Hz); HRMS 
(ESI-TOF): m/z calcd for C30H20BCl2F2N3O2: 572.1035; found: 572.1026 [M
-]. 
8-(4-cyanophenyl)-3,5-di(4-methoxyphenyl)-2-(4-methoxyphenyl)-6-(4-
cyanophenyl)-BODIPY 8. The BODIPY 8 was prepared from BODIPY 6b (8.12 mg, 0.0141), 5 
eq of 4-methoxyphenyl boronic acid (10.7 mg, 0.0707 mmol), and 5 eq of 4-cyanophenyl boronic 
acid (10.4 mg, 0.0707 mmol), yielding 5.43 mg, 54.0 % of BODIPY 8 as dark blue solid: mp (273-
275 oC); 1H NMR (CDCl3, 500 MHz) δ (ppm) = 7.90-7.88 (m, 2H), 7.78-7.80 (m, 2H), 7.44-7.47 
(m, 4H), 7.38-7.40 (m, 2H), 7.12-7.10 (M, 2H), 6.93-6.95 (M, 2H), 6.83-6.89 (m, 6H), 6.73-6.75 
(m, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 3.77 (s, 3H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 
160.8, 160.5, 160.0, 159.1, 155.2, 139.4, 138.9, 138.8, 136.5, 134.9, 133.7, 132.3, 132.1, 132.0, 
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131.9, 131.1, 129.6, 128.7, 128.1, 126.6, 125.7, 123.4, 123.3, 118.9, 118.0, 114.2, 113.8, 113.8, 
113.6, 110.2, 55.3, 55.2; 11B NMR (CDCl3, 128 MHz ) δ (ppm) = 0.68-1.15 (1B, t, 
1J(B,F) =30.5 
Hz); HRMS (ESI-TOF): m/z calcd for C44H31BF2N4O3: 711.2499; found: 711.2482 [M
-]. 
General Procedure for Stille Cross-Couplings of BODIPYs. The starting BODIPY 1 
was added to a 15 mL round-bottomed flask followed by the addition of organotin reagent, 3% 
mol of Pd(PPh3)4 (for 2) or Pd(PCy3)G2 (for 3, 4, 7). The flask was evacuated and refilled with 
nitrogen three times. Toluene (5 mL) was added, and the reaction mixture was stirred and heated 
at 90-100oC under nitrogen. Analytical TLC was used to monitor the reaction every 30-60 min. 
After completion, toluene was removed by rotary evaporator, and the resulting residue was purified 
by column chromatography with dichloromethane/or ethyl acetate /hexanes as the elution solvents. 
The BODIPY 2 was prepared from BODIPY 1 (10.5 mg, 0.0288 mmol) and 10 eq of 
tributylphenylstannane (106 mg, 0.288 mmol), yielding 8.55 mg, 60.7 % of BODIPY 2 as purple 
solid: mp (215-217 oC); 1H NMR (CDCl3, 400 MHz) δ (ppm) = 7.58 – 7.68 (m, 9H), 7.44-7.45 
(m, 6H), 6.91 (s, 2H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 155.0, 144.6, 133.4, 133.0, 
130.9, 130.4, 130.2,130.2, 130.0, 129.2, 128.7, 128.4, 127.9, 123.0, 122.9; 11B NMR (CDCl3, 128 
MHz ) δ (ppm) = 0.27-0.74 (1B, t, 1J(B,F) = 29.9 Hz); HRMS (ESI-TOF): m/z calcd for 
C27H17BCl2F2N2: 487.0872; found: 487.0868 [M
-]. 
3,5,8-triphenyl-2,6-dithiophen-BODIPY 3. The BODIPY 3 was prepared from BODIPY 
2 (6.21 mg, 0.0127 mmol) and 10 eq of 2-(tributylstannyl) thiophene (47.4 mg, 0.127 mmol), 
yielding 4.60 mg, 62.0 % of BODIPY 3 as dark blue solid: mp (178-180 oC); 1H NMR (CDCl3, 
500 MHz) δ (ppm) = 7.72 – 7.70 (m, 2H), 7.68 – 7.62 (m, 3H), 7.54-7.53 (m, 4H), 7.46-7.39 (m, 
6H), 7.10-7.09 (dd, J = 5.1, 1.1 Hz, 2H), 7.01 (s, 2H), 6.84-6.82 (dd, J = 5.1, 3.6 Hz, 2H), 6.56-
6.55 (dd, J = 3.7, 1.1 Hz, 2H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 156.2, 144.27, 135.8, 
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134.5, 134.1, 131.4, 130.6, 130.5, 130.2, 129.5, 128.6, 128.1, 128.0, 127.2, 126.8, 125.1, 124.7; 
11B NMR (CDCl3, 128 MHz ) δ (ppm) = 0.44-0.90 (1B, t, 
1J(B,F) = 29.7 Hz); HRMS (ESI-TOF) 
m/z calcd for C35H23BFN2S2: 564.1411; found: 564.142 [M-F]
+. 
2,3,5,6,8-pentaphenyl-BODIPY 4. The BODIPY 4 was prepared from BODIPY 2 (6.51 
mg, 0.0133 mmol) and 10 eq of tributylphenylstannane (48.8 mg, 0.133 mmol) with , yielding 3.12 
mg, 41.0 % of BODIPY 4 as dark blue solid: mp (273-275 oC). 1H NMR (CDCl3, 400 MHz) δ 
(ppm) = 7.71-7.73 (m, 2H), 7.58-7.66 (m, 3H), 7.50-7.52 (m, 4H), 7.32-7.39 (m, 6H), 7.17-7.19 
(m, 6H), 7.03 (s, 6H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 156.5, 143.9, 134.7, 134.4, 
133.9, 131.8, 130.7, 130.4, 130.3, 129.1, 128.6, 128.4, 128.3, 128.2, 127.9, 126.9; 11B NMR 
(CDCl3, 128 MHz ) δ (ppm) = 0.69-1.16 (1B, t, 
1J(B,F) = 30.4 Hz); HRMS (ESI-TOF): m/z calcd 
for C39H27BF2N2Na: 594.2164; found: 594.2147 [M+Na]
+. 
8-(4-cyanophenyl)-3,5-di(4-methoxyphenyl)-2,6-dithiophen-BODIPY 7. The BODIPY 
7 was prepared from BODIPY 6b (4.81 mg, 0.00838 mmol) and 10 eq of 2-(tributylstannyl) 
thiophene (31.3 mg, 0.0838 mmol), yielding 3.11 mg, 55.4 % of BODIPY 7 as dark blue solid: mp 
(268-270 oC); 1H NMR (CDCl3, 500 MHz) δ (ppm) =7.93 (m, 2H), 7.81 (m, 2H), 7.49 – 7.48 (m, 
4H), 7.14 (dd, J = 5.1, 1.1 Hz, 2H), 6.94 (m, 4H), 6.87 (dd, J = 5.1, 3.6 Hz, 2H), 6.84 (s, 2H), 6.62 
(dd, J = 3.7, 1.2 Hz, 2H), 3.86 (s, 6H); 13C {1H} NMR (CDCl3, 125 MHz) δ (ppm) = 160.7, 157.2, 
139.8, 138.7, 135.5, 134.0, 132.3, 131.8, 131.1, 128.7, 127.3, 125.9, 125.4, 125.0, 123.2, 118.1, 
114.2, 113.6, 55.2; 11B NMR (CDCl3, 128 MHz ) δ (ppm) = 0.47-0.94 (1B, t, 
1J(B,F) = 29.8 Hz); 
HRMS (ESI-TOF): m/z calcd for C38H26BFN3O2S2: 649.1574; found: 649.1546 [M-F]
+. 
7.2.2 Crystallography 
Crystal structures were determined using data collected at T=90K on a Bruker Kappa 
Apex-II DUO diffractometer. MoKα radiation was used for 2, 4, 5a, 6a, and 6b, while CuKα was 
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used for 7 and 8. Compound 5a exhibited a small amount (ca. 10%) of rotational disorder which 
was evident from partially-populated secondary sites for all the Cl atoms. Compound 6a was a 
twin and has two molecules in the asymmetric unit.  Compound 7 had both thiophenes disordered 
into two orientations, with relative occupations 70:30 and 80:20. It also had disordered solvent, 
which was removed using the SQUEEZE procedure. Compound 8 had one methoxy group 
disordered into 54:46 orientations and also had disordered solvent removed by SQUEEZE. Crystal 
Data: 2, C27H17BCl2F2N2, monoclinic, a = 15.5375(10), b = 6.0426(4), c = 23.7983(16) Å,  = 
93.080(3)°, space group P21/c, Z = 4, 48,015 reflections measured, max = 36.5°, 10,891 unique 
(Rint = 0.052), final R = 0.041 (8237 I>2(I) data), wR(F
2) = 0.109 (all data), CCDC 1509815; 4, 
C39H27BF2N2, monoclinic, a = 27.801(3), b = 8.5828(11), c = 25.471(4) Å,  = 105.021(10)°, space 
group C2/c, Z = 8, 16,414 reflections measured, max = 23.3°, 4177 unique (Rint = 0.115), final R 
= 0.077 (2159 I>2(I) data), wR(F2) = 0.218 (all data) , CCDC 1509816; 5a, C23H13BCl4F2N2O2, 
monoclinic, a = 13.7912(4), b = 10.6546(4), c = 15.2354(6) Å,  = 99.863(2)°, space group P21/n, 
Z = 4, 24,073 reflections measured, max = 31.0°, 7034 unique (Rint = 0.035), final R = 0.045 (5519 
I>2(I) data), wR(F2) = 0.130 (all data) , CCDC 1509817; 6a, C37H27BCl2F2N2O4, triclinic, a = 
13.0943(15), b = 13.8006(16), c = 17.659(2) Å, α = 83.546(7),  = 83.396(7), γ = 80.198(7)°, 
space group P-1, Z = 4, 27,197 reflections measured, max = 24.0°, 16,564 unique (Rint = 0.119), 
final R = 0.093 (8684 I>2(I) data), wR(F2) = 0.264 (all data), CCDC 1509818; 6b, 
C30H20BCl2F2N3O2, triclinic, a = 6.4378(3), b = 13.1056(7), c = 15.3828(8) Å, α = 84.902(2),  = 
79.560(2), γ = 84.620(2)°, space group P-1, Z = 2, 14,444 reflections measured, max = 28.3°, 5922 
unique (Rint = 0.030), final R = 0.038 (4794 I>2(I) data), wR(F
2) = 0.092 (all data), CCDC 
1509819; 7, C38H26BF2N3O2S2, triclinic, a = 9.8322(8), b = 13.3203(11), c = 15.0587(12) Å, α = 
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72.208(6),  = 74.473(6), γ = 81.456(6)°, space group P-1, Z = 2, 19,146 reflections measured, 
max = 62.8°, 5632 unique (Rint = 0.074), final R = 0.062 (3310 I>2(I) data), wR(F
2) = 0.170 (all 
data), CCDC 1509820; 8, C44H31BF2N4O3 . CHCl3, triclinic, a = 10.3829(9), b = 14.3659(14), c = 
15.0975(14) Å, α = 75.674(7),  = 89.346(7), γ = 78.359(7)°, space group P-1, Z = 2, 19,963 
reflections measured, max = 68.4°, 7279 unique (Rint = 0.061), final R = 0.105 (5062 I>2(I) data), 
wR(F2) = 0.341 (all data), CCDC 1509821. 
7.2.3 Spectroscopic Studies 
All UV-Visible and fluorescence spectra were collected on a Varian Cary 50 spectrometer 
and Perkin Elmer LS 55 luminescence spectrometer at 298 K, respectively. A 10 mm path length 
quartz cuvette and spectroscopic solvents were used for all the measurements. Molar absorption 
coefficient (ε) was determined from the slope of absorbance vs concentration of five dilute 
solutions with absorbance in the range of 0.2-1.0. Quantum yields (Φf) were determined by using 
a series of dilute solutions with absorbance in the range of 0.02-0.06 at particular excitation 
wavelength. Cresyl violet perchlorate (0.55 in methanol) and methylene blue (0.03 in methanol) 
were used as external standards for BODIPYs 2, 6a, 6b, 4 and 3, 7, 8, respectively. The relative 





























where Φ stands for fluorescence quantum yields; ƞ stands for refractive indexes of solvents; 
Grad stands for the gradient from the plot of integrated fluorescence intensity vs absorbance at λex; 
subscripts X and R stands for the tested sample and standard sample, respectively.  
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7.2.4 DFT calculations  
The DFT calculations were carried out using the Gaussian 09 software package.39 The 
ground state geometries of the BODIPYs were optimized by the DFT method with the B3LYP 
functional and 6-31G (d) basis sets. 
7.2.6 Cell studies 
The cell studies were conducted by adapting reported procedures.40 All cell culture media 
and reagents used in this study were purchased from Invitrogen. The Human HEp2 cells were 
purchased from ATCC and maintained in a 50 : 50 mixture of DMEM : AMEM supplemented 
with 5% FBS and 1% penicillin/streptomycin antibiotic. The cells were sub-cultured twice weekly 
to maintain sub-confluent stocks.  
Dark Cytotoxicity: The HEp2 cells were plated at 7500 cells per well in a Costar 96-well 
plate (BD biosciences) and allowed to grow for 48 h. The stock solution of BODIPY compound 
(32 mM) was prepared in 100% DMSO and diluted into final working concentrations (0, 6.25, 
12.5, 25, 50, and 100 μM). The cells were exposed to the working solutions of compounds up to 
200 μM and incubated overnight (37oC, 95% humidity, 5% CO2). The working solution was 
removed, and the cells were washed with 1X PBS. The medium containing 20% CellTiter Blue 
(Promega) was added and incubated for 4 h. The viability of cells is measured by reading the 
fluorescence of the medium at 570/615 nm using a BMG FLUOstar Optima micro-plate reader. In 
this assay, the indicator dye resazurin is reduced to fluorescent resorufin in viable cells, while non-
viable cells are not able to reduce resazurin nor to generate a fluorescent signal. The fluorescence 
signal of viable (untreated) cells was normalized to 100% and non-viable (treated with 0.2% 
saponin from sigma) cells was normalized to 0%.   
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Phototoxicity: The human HEp2 cells were prepared as described above and incubated 
with compound concentrations of 100, 50, 25, 12.5, 6.25, 3.125, and 0 μM for 24 h. The loading 
solution was removed and the cells were washed with 1 X PBS, and then refilled with fresh 
medium.  The cells were exposed to a 600 W halogen lamp light source filtered with a water filter 
(transmits radiation 250 - 950 nm) and a beam turning mirror with 200 nm to 30 μm spectral range 
(Newport), for 20 min. The total light dose provided was approximately 1.5 J/cm2. After light 
exposure, the cells were stored in the incubator for 24 h and assayed for cell viability as described 
above. 
Time-Dependent Cellular Uptake: Human HEp2 cells were prepared as described above. 
The cells were exposed to 10 μM of each compound solution for 0, 1, 2, 4, 8, and 24 h. The loading 
medium was removed at the end of each incubation period and the cells were washed with 1X 
PBS, and solubilized by adding 0.25% Triton X-100 in 1X PBS. Each compound solution was 
diluted to 10, 5, 2.5, 1.25, 0.625 and 0.3125 μM concentrations using 0.25% Triton X-100 (Sigma-
Aldrich) in 1X PBS for standard curve. A cell standard curve was prepared using 104, 2  104, 4 
104, 6  104, 8  104, and 105 cells per well. The cell number was quantified using a CyQuant Cell 
Proliferation Assay (Life Technologies). The compound concentration in cells at each time period 
was determined using a BNM FLUOstar Optima micro-plate reader at 485/590 nm. Cellular uptake 
is expressed in terms of compound concentration (nM) per cell. 
7.3 Results and discussion 
7.3.1 Synthesis and structural characterization 
A series of BODIPYs 2, 3, 4, 6a, 6b, 7, and 8 were synthesized as shown in Schemes 7.1 
and 7.2. The starting penta-chloro-BODIPY (1) was synthesized from 8-chloro-BODIPY, as 
previously reported.35 Based on the regioselectivity of the penta-chloro-BODIPY (reactivity 8-Cl 
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> 3,5-Cl > 2,6-Cl) as previously reported,35 different functional groups can be introduced for the 
design of versatile push-pull BODIPYs through facile Pd (0) catalyzed cross-coupling reactions. 
In this initial study, 4-methoxyphenyl boronic acid was chosen as the electron-donating source and 
4-Benzyloxycarbonylphenyl and 4-Cyanophenyl boronic acid were chosen as the electron-
withdrawing source to endow the BODIPYs push-pull characteristics. 4-
Benzyloxycarbonylphenyl boronic acid was synthesized by adapting a reported procedure.41 The 
4-Benzyloxycarbonyl group can be further de-benzylated to carboxylic acid and used for 
conjugation with peptides. All the compounds were synthesized by ether Suzuki or Stille cross-
coupling reactions in fair to good yields. Penta-chloro-BODIPY was treated with 2.5 eq of 4-
Benzyloxycarbonylphenyl or 10 eq of 4-Cyanophenyl boronic acid with 3 mol % of Pd(PPh3)4 and 
1M Na2CO3 (aq) in refluxing toluene to regioselectively produce BODIPY 5a and 5b in 70.0 % 
and 50.2 % yield, respectively. Subsequently, BODIPY 5a and 5b were treated with 3 eq 4-
methoxyphenyl boronic acid with 3 mol% of Pd(PCy3)G2 and 1M Na2CO3 (aq) in refluxing 
toluene to regioselectively produce 6a and 6b in 60.2 % and 66.0 % yield, respectively. 
BODIPY 8 was synthesized by two-step Suzuki-cross coupling reactions using 5 eq of 4-
methoxyphenyl boronic acid and 4-cyanophenyl boronic acid, respectively, in overall 54.0 % 
yield.  Compared to catalyst Pd(PPh3)4, Pd(PCy3)G2 greatly increase the yield of 6a, 6b and 8 
from around 10 % to nearly 70 %. The increased yields are due to the more reactive complex 
formed by the more bulky ligands of Pd(PCy3)G2 catalyst.
35, 42 For comparison purpose, BODIPY2 
and 4 with no electron donor and acceptor on the phenyl substituents were synthesized with 
tributylphenylstannane and 3 mol % of Pd(PPh3)4 in refluxing toluene, yielding 60.7 % and 41.0 
%, respectively. BODIPY 7 was prepared by treating BODIPY 6b with 2-(tributylstannyl) 
thiophene and Pd(PCy3)G2 in refluxing toluene in 55.4 % yield.  
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Scheme 7.1. Synthetic routes of BODIPY 2-4, 5a, 5b, 6a and 6b.  
 
Scheme 7.2. Synthetic routes of BODIPY 7-8. 
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For comparison purpose, BODIPY 3 with no substituents on the phenyl ring were also 
prepared using the 2-(tributylstannyl) thiophene and Pd(PCy3)G2, yielding 62.0 %. All the 
compounds were characterized by 1H NMR, 13C NMR, and 11B NMR spectroscopy (Figures 7.2-
7.28) as well as HRMS. The structures of BODIPYs 2, 4, 5b, 6b, 7 and 8 were further confirmed 
by X-ray crystallography (Figure 7.29).  
 
Figure 7.2. 1H NMR spectrum of BODIPY 5a. 
 
 
Figure 7.3.13C {1H} NMR spectrum of BODIPY 5a.  
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Figure 7.4. 1H NMR spectrum of BODIPY 5b.  
 
 




Figure 7.6. 1H NMR spectrum of BODIPY 2.  
 
 




Figure 7.8. 1H NMR spectrum of BODIPY 6a.  
 
 




Figure 7.10. 1H NMR spectrum of BODIPY 6b.  
 
 




Figure 7.12. 1H NMR spectrum of BODIPY 3.  
 
 




Figure 7.14. 1H NMR spectrum of BODIPY 7.  
 
 




Figure 7.16. 1H NMR spectrum of BODIPY 4.  
 
 




Figure 7.18. 1H NMR spectrum of BODIPY 8.  
 
 






Figure 7.20. 11B NMR spectrum of BODIPY 5a.  
 
 




Figure 7.22. 11B NMR spectrum of BODIPY 2.  
 
 




Figure 7.24. 11B NMR spectrum of BODIPY 6b.  
 
 




Figure 7.26. 11B NMR spectrum of BODIPY 4.  
 
 




Figure 7.28. 11B NMR spectrum of BODIPY 8.  
 
 
Figure 7.29. Crystal structures of BODIPY 2, 6a, 6b, 4, 7 and 8.  
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7.3.2 X-ray crystallography 
According to the crystal structures, the dihedral angles of meso substituents with the 12-
atom BODIPY core for 2, 4, 6a, 6b, 7 and 8 were 62.0, 59.4, 56.6, 63.7, 54.1, and 60.7o, 
respectively. With substituents (e.g., phenyl, thiophene) on 1,7 positions, the meso plane is almost 
perpendicular (~90o) with the BODIPY core.37, 43 The dihedral angle of these BODIPYs without 
1,7 substituents was much smaller (about 30o decrease) due to less steric interaction around the 
meso positions. The decrease of the dihedral angle could lead to better conjugation of meso 
substituents to the BODIPY core, and therefore enhance the transfer of pull effect. The dihedral 
angle of the 3,5 substituents with the 12-atom BODIPY core is in the range of 45-65o for all the 
compounds, except for BODIPY 7 which has a dihedral angle of 70.3 and 86.1, respectively. The 
dihedral angle of 2,6 substituents, especially for BODIPY 7 with thiophene on 2,6 positions, is 
smaller than the dihedral angle of 8, 3, and 5 substituents with the 12-atom BODIPY core. This 
suggests that the push-pull moieties on the 2,6 positions have better electronic coupling with the 
BODIPY core.  
7.3.3 Spectroscopic properties 
The spectroscopic properties of the push-pull BODIPYs were evaluated in solvents with 
different polarities and the results are summarized in Table 7.1 and Figure 7.30-7.39. All the 
compounds show a strong S0-S1 transition with an absorption coefficients in 25000-72000 M
-1 cm-
1 range. A weak broad absorption band centered at around 400 nm was observed at higher energy, 
which can be attributed to the S0-Sn (n ≥ 2) transition of the BODIPY moiety.
16, 22, 24 The π-π* 
transitions at 230-320 nm were also observed for all the compounds.24 In comparison with 
BODIPY 2, BODIPY 6a and 6b with electron donor (MeO) on para positions of 3,5 phenyls and 
electron acceptor (-CN, -BOOCN) on para position of 8 phenyl exhibit 25-37 nm and 40-48 nm 
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bathochromic shifts for absorption and emission in different solvents, respectively. BODIPY 6b 
displayed a larger red-shift for both absorbance and emission compared to 6a as the -CN group 
(Hammett parameter σp = 0.66)
44 is more electron withdrawing than -COOBn group (Hammett 
parameter σp = 0.56)
44 and results in enhanced pull effect associated with smaller HOMO-LUMO 
gap, as evidenced by DFT calculation and cyclic voltammetry analysis (Table 7.2, Figure 7.40 and 
7.42). Similarly, compared with BODIPY 3, BODIPY 4 showed a bathochromic shift of 22-25 nm 
for absorption and 23-27 nm for emission in different solvents investigated. With three sets of 
push-pull moieties installed on BODIPY 5, BODIPY 6 exhibited a bathochromic shift of 30-34 
nm and 55-60 nm for absorption and emission in different solvents investigated, respectively. 
These results indicated that the substituents of different push and pull ability on BODIPYs can 
cause bathochromic shift to different extent. In solvents with different polarities, BODIPY 4 
having two thiophene groups at 2 and 6 positions showed the longest λmax for absorption (635-653 
nm) and emission (706-707 nm) and the largest Stokes shift (54-71 nm), which is consistent with 
the reported studies showing that thiophene group, especially at 2,6 positions, can cause large 
bathochromic shift and Stokes shift on BODIPYs.35, 37, 43 The larger Stokes shift was presumably 
due to the geometry difference between S0 and S1 states upon excitation, resulting in increased 
geometry relaxation.43, 45-46 As the polarity of solvents increased from toluene (solvent polarity 
ET
N=0.099) to acetonitrile (solvent polarity ET
N=0.460)47, hypsochromic shift was observed to 
different extent for both absorption (6-22 nm) and emission (0-15 nm) associated with a gradual 
decrease of quantum yield. The slight hyperchromic shift of both emission and absorbance is 
probably due to the decrease of dipole moment (µ) of BODIPY upon excitation associated with 
the intromolecular charge transfer (ICT) between donor and acceptor (µg > µe, where µg and µe are 
the ground- and excited-state dipole moments) and thus the ground state is better stabilized in polar  
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Table 7.1. Spectroscopic properties of BODIPYs in toluene, tetrahydrofuran and acetonitrile at 
298 K. 





Tol 572 603 31 71258 0.30 
THF 566 597 31 67346 0.13 
CH3CN 558 588 30 51609 0.12 
6a 
Tol 604 643 39 54004 0.13 
THF 594 637 43 31809 0.077 
CH3CN 583 632 49 40192 0.061 
6b 
Tol 609 650 41 50350 0.085 
THF 597 643 46 39753 0.048 
CH3CN 587 636 49 44983 0.038 
3 
Toluene 628 680 52 32361 0.079 
THF 620 680 60 26262 0.042 
CH3CN 613 683 70 25952 0.013 
7 
Toluene 653 707 54 38630 0.027 
THF 645 706 61 32363 0.015 
CH3CN 635 706 71 33438 0.0055 
4 
Toluene 592 622 30 67517 0.64 
THF 586 620 34 54568 0.33 
CH3CN 576 616 40 57143 0.34 
8 
Toluene 626 677 51 29550 0.055 
THF 618 676 58 25219 0.025 
CH3CN 606 676 70 23216 0.0072 
 
aSolvent polarity (ET
N): toluene=0.099; THF=0.207; CH3CN=0.460.
47 bCresyl violet perchlorate 
(0.55 in methanol) and methylene blue (0.03 in methanol) were used as external standards for 
BODIPY 2, 6a, 6b, 4 and 3, 7, 8, respectively.  
solvent.47-48 The decreased quantum yield with the increase of solvent polarity was consistent with 
many reported results and was attributed to the increase of nonradiative decay in more polar 
solvents.24, 26, 33-34, 49 A 2-4 fold decrease of quantum yield was observed from BODIPY 2 to 6a 
and 6b, 3 to 7, and 4 to 8, which could be attributed to the ICT between donor and acceptor25, 29 
and the internal conversion between narrower band gaps50-51. ICT is known to affect the rate of 
nonradiative relaxation of fluorophores and results in decreased quantum yields.52 Another reason 
associated with the low quantum yield of BODIPYs 3 and 7 is the greater freedom of rotation of 
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the smaller thiophene groups in comparison with phenyl, increasing the energy lost to nonradiative 
decay.43 Interestingly, the quantum yield of BODIPY 8 was decreased 11-48 fold in different 
solvents compared to BODIPY 4, which could be due to the enhanced ICT resulting from the 
multiple sets of push-pull moieties in the compound. The Stokes shift was increased as the polarity 
of solvent increased for all the compounds. Among them, the Stokes shift of BODIPY 8 increased 
the most (19 nm) from toluene to acetonitrile and indicated a large difference in dipole moment 
between ground and excited state.24, 49 
 
Figure 7.30. Absorbance (A) and fluorescence (B) of BODIPY 2, 6a and 6b in toluene. 
 
 
Figure 7.31 Absorbance (A) and fluorescence (B) of BODIPY 3 and 7 in toluene. 
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Figure 7.32. Absorbance (A) and fluorescence (B) of BODIPY 4 and 8 in toluene. 
 
 
Figure 7.33. Absorbance (A) and fluorescence (B) spectra of BODIPY 2 in toluene, 





Figure 7.34. Absorbance (A) and fluorescence (B) spectra of BODIPY 6a in toluene, 
tetrahydrofuran and acetonitrile. 
 
 
Figure 7.35. Absorbance (A) and fluorescence (B) spectra of BODIPY 6b in toluene, 





Figure 7.36. Absorbance (A) and fluorescence (B) spectra of BODIPY 3 in toluene, 
tetrahydrofuran and acetonitrile. 
 
 
Figure 7.37. Absorbance (A) and fluorescence (B) spectra of BODIPY 7 in toluene, 





Figure 7.38. Absorbance (A) and fluorescence (B) spectra of BODIPY 4 in toluene, 
tetrahydrofuran and acetonitrile. 
 
  
Figure 7.39. Absorbance (A) and fluorescence (B) spectra of BODIPY 8 in toluene, 
tetrahydrofuran and acetonitrile. 
 
249 
7.3.4 Cyclic voltammetry  
 
Figure 7.40. Cyclic voltammograms of BODIPY 2, 3, 4, 6a, 6b, 7 and 8. 
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3rd 2nd 1st 1st 2nd 
1 
 
2.00a 1.58 -0.58 -1.62a 2.16 
6a 1.69 1.38 -0.57 -1.31 1.95 
6b 1.68 1.38 -0.53 -1.27 1.91 
3 1.78a 1.66a 1.22 -0.72 -1.76a 1.94 
7 
 
1.62a 1.15 -0.64 -1.38a 1.79 
4 1.86a 1.34 -0.77 -1.81a 2.11 
8 1.49 1.22 -0.68 -1.42a 1.90 
         a. peak potential 
         b. Half-wave potential difference between 1st oxidation and 1st reduction 
 
7.3.5 DFT calculations  
To provide insights into the photophysical and electrochemical properties of the BODIPYs, 
DFT calculations are conducted on all the compounds and the results are summarized in Table 7.3, 
Figure 7.41 and 7.42, The installation of electron donating group (-MeO) and electron withdrawing 
group (-CN and –COOBn) to the BODIPYs caused the electron density on the HOMO and 
HOMO-1 shifted to the substituents bearing the electron donating groups, whereas the electron 
density on the LUMO and LUMO+1 shifted to the meso substituent bearing the electron 
withdrawing group. As a result, the overall HOMO-LUMO gap was decreased after introducing 
the push-pull moieties from 2 to 6a and 6b, 3 to 7, and 4 to 8 (Table 7.3, Figure 7.42), which was 
in agreement with the spectroscopic result that the maximum λab and λem was red-shifted after 
installation of push-pull moieties to the BODIPYs. The trend of the HOMO-LUMO gap (2> 6a 




              




Table 7.3. DFT calculated molecular orbital energy levels for the BODIPYs. 
Cpds EHOMO (ev) ELUMO (ev) 
aΔE (ev) 
2 -5.83 -3.25 2.58 
6a -5.32 -2.94 2.37 
6b -5.45 -3.13 2.32 
3 -5.18 -2.78 2.40 
7 -5.13 -2.92 2.21 
4 -5.26 -2.71 2.55 
8 -5.29 -2.71 2.27 
                    aΔE = ELUMO - EHOMO 
 
 
Figure 7.42. Molecular orbital energies of BODIPYs in DFT calculations. The HOMO-LUMO 
gaps are plotted against a secondary axis and are denoted by red triangles. 
7.3.6 Cytotoxicity and uptake in human HEp2 cells 
The concentration-dependent dark and phototoxicity (1.5 J/cm2 light dose) and the time-
dependent cellular uptake of all the BODIPYs were evaluated in HEp2 cells, and the results were 
summarized in Table 7.4, Figure 7.43 and 7.44. These results were obtained in collaboration with 
Ms. Zehua Zhou. All of the BODIPYs showed minimum both dark toxicity (IC50 > 200 μM) and 
phototoxicity (IC50 > 100 μM). All the BODIPYs, with the exception of 2 and 8, were taken up 
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nearly linearly with time. BODIPY 2 and 8 were taken up rapidly in the first 2 h after which slower 
uptake was observed and in the case of 8 a plateau was reached after 8 h. BODIPY 3, 5, 6a, and 7 
exhibited very low uptake in HEp2 cells, which could be due to their poor water solubility. The 
higher cellular uptake of 6b and 8 compared to other compounds probably was due to the 
introduction of –MeO and –CN groups which enhance their water solubility. It’s interesting that 
BODIPY 2 accumulated the most within cells at 24 hours, probably as a result of its lower MW 
and favorable lipophilicity.  
Table 7.4. Dark and phototoxicity and cellular uptake of BODIPYs using human HEp2 cells.  
Cpds Dark toxicity IC50 (μM) Phototoxicity IC50 (μM) Cellular uptake at 24 h (nM/cell) 
2 >200 >100 1.2±0.10 
6a >200 >100 0.14±0.01 
6b >200 >100 0.51±0.01 
3 >200 >100 0.14±0.01 
7 >200 >100 0.12±0.01 
5 >200 >100 0.058±0.028 
8 >200 >100 0.79±0.13 
 
 
Figure 7.43. Concentration dependent dark toxicity (A) and phototoxicity (1.5 J/cm2 light dose) 
(B) of BODIPYs in human HEp 2 cells.  
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Figure 7.44. Time-dependent uptake of BODIPYs 2 (black), 6a (red), 6b (yellow), 3 (green), 5 
(pink), 7 (navy) and 8 (brown) in human HEp2 cells. 
7.4 Conclusion 
A series of push-pull BODIPYs were synthesized in good yields by facile Suzuki and 
Stille-cross coupling reactions from 2,3,5,6,8-penta-chloro-BODIPY. The structures of all the 
compounds were characterized by HRMS, NMR, and X-ray crystallography (except for BODIPY 
3). A systematic comparison was made before and after installation of electron-withdrawing and 
electron-donating group to the BODIPYs to investigate the influence of push-pull effect on their 
spectroscopic and electrochemical properties. Bathochromic shift was observed for both 
absorbance (up to 37 nm) and emission (up to 60 nm) in different solvents after the installation of 
electron donor (-MeO) and acceptor (-CN and –COOBn). This result was in agreement with the 
DFT calculation that the HOMO-LUMO energy was decreased with the installation of push-pull 
moieties. The trend of the HOMO-LUMO energy (2 > 6a and 6b, 3 > 7, 4 > 8) was consistent with 
the HOMO-LUMO trends obtained from cyclic voltammetry. BODIPY 4 bearing thiophene 
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groups at 2 and 6 positions exhibited the longest λmax for absorption (635-653 nm) and emission 
(706-707 nm) and the largest Stokes shift (54-71 nm). The quantum yield was decreased up to 48 
fold after introducing the push-pull moieties and was probably due to ICT between donor and 
acceptor and the internal conversion. All BODIPYs tested showed minimum dark (IC50 > 200 µM) 
and phototoxicity (IC50 > 100 µM) in human HEp2 cells. BODIPY 3, 5, 6a and 7 displayed very 
low cellular uptake and was probably due to their poor water solubility. BODIPY 6b and 8 showed 
higher cellular uptake, which could be attributed to the enhanced water solubility with the –MeO 
and –CN groups. It’s interesting that BODIPY 2 accumulated the most within cells at 24 hours, 
probably as a result of its lower MW. The systematic investigation of these push-pull BODIPYs 
on their spectroscopic and electrochemical properties may provide guidance for the future design 
of new BODIPYs for different uses.  
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